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1 
CHAPTER I 
 
INTRODUCTION 
 
Abstract 
 
Diabetes Mellitus is a complicated disease featured by failure of sugar 
metabolism regulation. This disease affects millions of people worldwide. The 
function of pancreatic islet β cells, which secrete insulin to maintain blood 
glucose homeostasis, is impaired to different extents in diabetic patients. One 
potential cure for diabetes is islet transplantation, yet this procedure is largely 
limited by the lack of transplantable islets. Many researchers therefore attempt to 
generate functional β cells from different sources, especially from human 
embryonic stem cells (hESCs). However, most of the insulin-expressing cells 
generated via various strategies fail to function as efficiently as endogenous 
mature β cells in vivo, suggesting that there are still major gaps in our 
understanding of β cell formation and function. We utilize mouse models to 
understand the molecular pathways that govern the production of functional islet 
cells. Our focus is the interactions between the basic-Helix-Loop-Helix (bHLH) 
transcription factor Neurogenin 3 (Ngn3) and the Myelin transcription factor (Myt) 
family of zinc finger proteins. In this chapter, I summarize our current 
understanding of the pancreas development, and focus on the role of Ngn3 in 
endocrine differentiation and function.  
 2 
Model Organisms for Studying Pancreatic Development 
The pancreas, a heterogeneous organ functioning in both digestive and 
endocrine systems, is unique to vertebrates (Pieler and Chen, 2006; Slack, 
1995). Given the close connection between the pancreas and various diseases, 
such as Diabetes Mellitus and pancreatic cancers, multiple model organisms 
have been used to study its organogenesis, including chicken, zebrafish, frogs, 
mice and rats. All these model organisms share a core molecular mechanism 
governing the pancreatogenesis (Grapin-Botton et al., 2001; Kinkel and Prince, 
2009; Pearl et al., 2009). However, the pancreas in each organism differs in their 
structures and the developmental processes. For example, the dorsal pancreatic 
bud of zebrafish generates only endocrine cells, and it does not need pancreas 
transcription factor 1 (Ptf1a), an essential regulator of rodent pancreatic 
development, to do so (Field et al., 2003). Moreover, Ngn3, which controls the 
endocrine differentiation program in rodents, is not expressed in the developing 
pancreas of zebrafish (Wang et al., 2001). In Xenopus, the gut tube forms after 
the pancreatic buds have appeared and fused, while the mammalian gut 
epithelium forms a tube before pancreatic development, suggesting that different 
signals may be involved in pancreatic bud induction among different organisms 
(Pearl et al., 2009).  
We utilize mice to study pancreatic development in that they share many 
features with humans for diabetes pathogenesis and symptoms. Mice can also 
be easily genetically manipulated to recapitulate human mutations. In this 
chapter, I focus my discussion on mouse models. 
 3 
The Anatomy of the Pancreas  
In mice, the pancreas is composed of multiple cell types (Figure 1.1 A & 
B), including acini that produce digestive enzymes, ducts that deliver digestive 
enzymes into the gut, and endocrine islets of Langerhans that secrete hormones 
to help maintain glucose homeostasis (Slack, 1995). The acini and ducts make 
up the exocrine compartment of the pancreas, contributing to approximately 95% 
of the pancreatic mass. The endocrine islets are globular cell clusters embedded 
in the exocrine pancreas (Murtaugh and Melton, 2003). They consist of 5 major 
cell types, each of which produces a distinct peptide hormone: β cells secrete 
insulin which down-regulates blood glucose levels, α cells make glucagon which 
up-regulate blood glucose levels, δ cells produce somatostatin which help to 
modulate insulin and glucagon secretion (Strowski and Blake, 2008), PP cells 
express pancreatic polypeptide and ε cells make ghrelin (Figure 1.1 B&C). The 
functions of the last two hormones currently remain unclear.  
In adult mouse islets, β cells are the predominant cell type, making up 60-
80% of islet mass, and located in the center of the islets (Edlund, 2002). Other 
islet cell types, which are present in different proportions (α cell: 15-20%; δ & PP 
& ε cells: 1-5%), surround β cells and occupy the periphery of the islets (Figure 
1.1C) (Murtaugh and Melton, 2003). The spatial organization of the islets had 
been suggested to be important for proper islet function (Hopcroft et al., 1985). 
To this end, disrupted islet structure often coincides with diabetic phenotypes in 
mouse mutants, but the underlying mechanism is not clear (Ahlgren et al., 1998; 
Gannon et al., 2000a; Tweedie et al., 2006). In fact, in human islets, there are no 
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apparent spatial separations between different types of endocrine cell 
populations (Cabrera et al., 2006). Thus, islet cyto-architecture might not be 
substantial to islet function in humans. 
 
The Development of the Pancreas 
The organogenesis of the pancreas covers the derivation of multiple cell 
types from different lineages at different developmental stages, and the 
morphogenetic processes that organize these cells into functional organs. In 
mice, the onset of pancreatogenesis is at around E9.0. At this stage, two groups 
of cells evaginate dorsally and ventrally from the pre-patterned endodermal gut 
tube near the prospective stomach and liver endoderm. Later, these two buds 
undergo a process of branching morphogenesis while expanding, fuse at around 
E14 along with gut rotation and differentiate into a fully functional organ right 
before birth (Jensen, 2004) (Figure 1.2 A).  
 5 
 
 
 
 
 
Figure 1.1 The anatomy of the mouse pancreas and islets. (A) 
Twelve-week-old mouse pancreas was stained with mixed antibodies 
against the four major endocrine hormones (insulin, glucagon, 
somatostatin and pancreatic polypeptide). Brown is the result of HRP 
staining, which visualizes the islets. Blue is the result of hematoxylin 
staining, which highlights nuclei. (B) The mouse pancreas is 
composed of islet, acinar and duct cells. Adapted from Gu et al. 2003. 
(C) The composition of mouse islets (Murtaugh and Melton, 2003). 
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Hormone-expressing endocrine cells are the earliest differentiated cells to 
appear in the developing pancreas. From E9.5 to E12.5, while pancreatic buds 
continue to grow into the surrounding mensenchyme, glucagon-expressing (Glu+) 
cells and occasionally a few insulin-expressing (Ins+) cells were found in the 
pancreatic epithelium. This period was generally acknowledged as the “primary 
transition” of the pancreas development (Jensen, 2004). During this phase, the 
Glu+ cells express islet amyloid polypeptide (IAPP) and prohormone 
convertase1/3 (PC1/3) that are not present in adult mature α cells (Wilson et al., 
2002). The Ins+ cells fail to express some mature β cell markers like glucose 
transporter 2 (Glut2) (Pang et al., 1994). Furthermore, while no mature 
endocrine cells are generated in Pdx1-/- (pancreatic and duodenal homeobox 1) 
mice, the primary Glu+ or Ins+ cells are not affected in these mutants, suggesting 
that the early endocrine cells are produced via different pathways in comparison 
with mature islet cells (Offield et al., 1996). Based on this above observation and 
the fact that only a few Glu+ or ins+ cells are produced during the primary 
transition, it has been suggested that the primary endocrine cells appear to be 
immature cells, and may not contribute significantly to adult endocrine mass 
(Herrera, 2000). Between E12.5 and E16.5, a second wave of hormone-
expressing endocrine cells appears, which is known as the “secondary 
transition”. During this phase, the endocrine cell populations, which mainly arise 
from progenitor differentiation, increase dramatically to account for the bulk of 
mature islet cells. After the secondary transition, endocrine cells start to 
aggregate into clusters and proliferate to increase islet mass in the first two 
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weeks of neonatal period (Jensen, 2004; Murtaugh, 2007; Oliver-Krasinski and 
Stoffers, 2008).  
Exocrine cells emerge in the developing pancreas during the secondary 
transition as well. They are strongly proliferating and form a fully functional 
pancreas together with endocrine cells by birth (Jensen, 2004). 
Like any other organs, the production of a functional pancreas requires the 
correct specification and differentiation of multiple cell types in a precise temporal 
and spatial order. Below, I will discuss in detail on the pancreas development at 
the cellular and molecular level. 
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Figure 1.2 The development of the mouse pancreas. (A) At the 
tissue level, the pancreatic buds arise at around E8.5-E9.5 in the 
mouse from two strips of gut endoderm located adjacent to the forming 
liver. At E10.5, the pancreatic primordia evaginate into the surrounding 
mesenchyme. From E12.5 onward, the dorsal and ventral pancreatic 
buds undergo branch morphogenesis, fuse and form nearly fully 
differentiated pancreas before birth at around E18.5. Diagrams are 
adapted from Murtaugh et al., 2007. Blue staining indicates the 
expression of Pdx1 (β-gal staining of Pdx1tTA/+;TetOLacZ pancreata by 
Hale et al., 2005). dp: dorsal pancreas; vp: ventral pancreas; li: liver; 
st: stomach; sp: spleen; cbd: common bile duct; d: duodenum; gl and 
sl: gastric and splenic lobes of the pancreas; as: antral stomach. (B) 
The signaling pathways and transcription factors that are involved in 
the pancreatic development. 
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1. Patterning of the Pancreatic Domains 
Before the formation of visible pancreatic buds in the gut tube, the 
endodermal epithelium is pre-patterned into different progenitor domains by 
expressing different combinations of transcription factors (Grapin-Botton and 
Melton, 2000; Wells and Melton, 1999). A homeodomain transcription factor 
Pdx1 (pancreatic and duodenal homeobox 1) and a bHLH transcription factor 
Ptf1a (pancreas transcription factor 1a) specifically mark the pancreatic 
progenitor domains at the early stages (Burlison et al., 2008; Kawaguchi et al., 
2002; Offield et al., 1996). The initiation of Pdx1 expression in the endoderm 
requires signals from adjacent germ layers at around E7.5 during gut tube 
formation (Wells and Melton, 2000). Subsequently, different mechanisms are 
involved in the specification of dorsal and ventral Pdx1+ pancreatic progenitor 
domains, probably due to their distinct positions in the gut tube.  
Many studies have shown that the dorsal pancreatic progenitor domain is 
induced by relayed interactions between gut endoderm and surrounding 
mesoderm. At around E8.5, the perspective dorsal pancreatic endoderm is in 
contact with the notochord, which sends activin-related signals to suppress Shh 
expression specifically in the dorsal pancreatic endoderm along the A-P axis of 
the gut tube. At this stage, the absence of Shh signaling is permissive for Pdx1 
expression and dorsal pancreatic fate induction (Apelqvist et al., 1997; Hebrok et 
al., 1998; Kim et al., 1997b). It is unclear whether there are inductive signals or 
what the inductive signals that actively promote pancreatic fates are at this stage. 
Later, at around E9.0, as the notochord moves away, endothelial cells of the 
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dorsal aorta interact with pancreatic endoderm, and provide additional signals to 
maintain Pdx1 expression as well as induce Ptf1a expression in the dorsal 
pancreas. Even though isolated aorta endothelial cells can induce Ptf1a 
expression in endoderm explants, it is not clear what the underlying mechanism 
is and whether signals from the blood stream also play roles in pancreatic fate 
induction in vivo (Jacquemin et al., 2006; Lammert et al., 2001; Yoshitomi and 
Zaret, 2004). 
The ventral pancreatic domain is specified through a different mechanism 
(Murtaugh, 2007). At around E9.0, endothelial cells of vitelline veins are closely 
located to the ventral pancreatic endoderm (Lammert et al., 2001). However, 
unlike in dorsal pancreatic domain induction, these endothelial cells are 
unnecessary for ventral Pdx1 maintenance and Ptf1a induction (Yoshitomi and 
Zaret, 2004). It appears that the ventral endodermal cells adopt pancreatic fates 
in a default manner, while FGF signals from cardiac mesoderm could divert these 
endodermal cells to activate the liver differentiation program instead of the 
pancreatic program (Deutsch et al., 2001). Recently, Wandzioch et al. revealed 
that TGFβ signaling might function to restrain the ventral endoderm specification 
until endodermal cells move away from cardiac mesoderm and into a BMP 
signaling domain. Then, the SMAD4-dependent BMP signaling pathway leads to 
ventral pancreatic induction (Wandzioch and Zaret, 2009). 
It remains unclear how pancreatic inducing signals are translated into 
pancreatic gene expression. TGFβ/BMP/FGF signaling pathways may directly 
regulate Pdx1 expression in the gut endoderm. Alternatively, they may function 
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together with intracellular transcription factors to initiate Pdx1 expression. For 
example, Gao et al. recently revealed that Foxa1 and Foxa2, which are 
expressed in the gut endoderm prior to the formation of the pancreas, regulate 
Pdx1 expression via co-occupation of the regulatory domains in the Pdx1 gene. It 
is possible that Foxa1, Foxa2 and other unidentified factors, which can respond 
to the TGFβ/BMP/FGF signaling, work together to inductively initiate Pdx1 
expression and pancreatic bud formation in the gut endoderm, but this 
hypothesis remains to be tested (Gao et al., 2008).  
 
2. Pancreatic Multi-potent Progenitor Cells (MPCs). 
During pancreatic development, the cells that can give rise to all three 
pancreatic lineages (acini, ducts and islets) are defined as the pan-pancreatic 
multi-potent progenitor cells (MPCs) (Burlison et al., 2008; Gu et al., 2002; 
Kawaguchi et al., 2002; Zhou et al., 2007).  Three transcription factors, Pdx1, 
Ptf1a and Sox9 (sex determining region Y-box 9), are highly expressed in the 
early (E9.0-E12.5) pancreatic MPCs. Although deletion of any of these three 
factors in mice results in the lack of mature endocrine and exocrine pancreas, the 
underlying mechanisms are different. MPCs fail to expand when Pdx1 or Sox9 is 
inactivated in mice, suggesting that these two factors are required for 
maintenance of the MPC pool (Offield et al., 1996; Seymour et al., 2007). When 
Ptf1a is disrupted, a portion of otherwise pancreatic MPCs adopts the duodenal 
fates, indicating Ptf1a is essential for the acquisition of pancreatic fates in the gut 
endoderm (Kawaguchi et al., 2002). Nevertheless, these results demonstrate that 
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Pdx1, Ptf1a and Sox9 are required in the MPCs for their further differentiation 
into the mature pancreas. Moreover, Afelik et al. reported that combined ectopic 
expression of Pdx1 and Ptf1a can expand the pancreatic progenitor domains into 
a more posterior region of the gut endoderm in Xenopus, suggesting that these 
factors are also capable of inducing pancreatic fates (Afelik et al., 2006; Jarikji et 
al., 2007). Taken together, these studies demonstrate that Pdx1, Ptf1a and Sox9 
not only mark MPCs in the early pancreatic epithelium, but also regulate 
pancreatic development, in directing cell proliferation and differentiation.  
Interestingly, Pdx1, Ptf1a and Sox9 appear to genetically interact with 
each other, even thought their expression does not depend on each other. 
Wiebe et al. revealed that Ptf1a could bind a highly conserved region within the 
Pdx1 promoter and mediate its expression in early MPCs (Wiebe et al., 2007). It 
would be interesting to compare the downstream gene networks controlled by 
these three transcription factors and elucidate how they cooperatively regulate 
the differentiation and maintenance of early MPCs. 
During the secondary transition (E12.5-E16.5 in mice), massive numbers 
of differentiated exocrine and endocrine cells emerge in the developing 
pancreas. The expression of Pdx1, Ptf1a and Sox9 starts to become restricted to 
specific differentiated cell types. While Pdx1 and Ptf1a are highly maintained in 
differentiated β/ δ and acinar cells, respectively, Sox9 remains exclusive to a 
subset of ductal cells (Burlison et al., 2008; Jensen et al., 2000a; Seymour et al., 
2007). To this end, it is interesting to examine at what stage the 
Pdx1+Ptf1a+Sox9+ triple positive MPCs disappear and whether other MPC 
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populations emerge to act as pancreatic MPCs. Several lines of evidence 
suggest that MPCs do exist at the beginning of the secondary transition (E12.5 in 
mice), even though the number of MPCs is significantly reduced. Gu et al. has 
utilized CreERT-mediated recombination techniques to trace the Pdx1+ cells at 
different developmental stages by giving the mouse embryos tamoxifen (TM) at 
different time points (CreERT is active only in the presence of TM). They found 
that while Pdx1+ cells can give rise to all three pancreatic lineages before and at 
around E12.5, they mainly contribute to acinar and islet cells after E12.5 (Gu et 
al., 2002). Moreover, Zhou et al. recently reported that MPCs reside in specific 
domains in the developing pancreas during the secondary transition, and are 
characterized by their co-expression of Pdx1, Ptf1a, cMycHigh and Cpa1 
(Carboxypeptidase A1). They showed that Cpa1+ cells, which locate in the tips of 
the pancreatic branches, can give rise to all three pancreatic lineages until E14.0 
in mice (Zhou et al., 2007).  These data suggest that MPCs do exist during the 
secondary transition, but their numbers decline quickly after E12.5. 
It has been highly debated whether MPCs, particularly those that can give 
rise to endocrine islet cells, exist in the adult pancreas over the past decade. Dor 
et al. showed that new β cells arise primarily from the replication of pre-existing β 
cells, rather than neogenesis from MPCs or endocrine precursors, during normal 
life and after pancreatectomy in mice (Dor et al., 2004). This study suggests that 
neogenesis does not play a significant role in adult β cell replenishment under 
normal conditions. Nevertheless, Inada et al. recently revealed that CAII+ 
(Carbonic Anhydrase II) ductal cells in the adult pancreas can serve as 
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progenitors for both endocrine and exocrine pancreas after Partial Ductal 
Ligation (PDL), suggesting that MPCs/facultative stem cells may be present in 
the adult pancreas (Inada et al., 2008). However, the identity of these adult 
MPCs/stem cells is still obscure. It is unclear whether they are de-differentiated 
CAII+ ductal cells or putative MPCs/stem cells maintained in the duct lining, and 
whether they express the same markers as embryonic MPCs, such as high 
levels of Pdx1, Ptf1a and Sox9. Furthermore, progenitor cells, which can give 
rise to all islet cell types, have also been shown to exist in the adult mouse 
pancreas, and can be activated to increase the β cell mass after PDL (Xu et al., 
2008). Together, these studies suggest that MPCs/precursor cells/facultative 
stem cells are likely present in the adult pancreas and can be activated after 
severe/specific injuries. 
 
3. The Maintenance of Pancreatic MPCs 
Except for intracellular transcription factors, active Notch and FGF 
signaling are also essential for the maintenance of the MPC pool in the early 
pancreatic epithelium (before E12.5 in mice), 
Both Notch receptors (Notch1, Notch2) and ligands (Delta-like-1, 
Jagged1) are expressed in the developing pancreatic epithelium (Lammert et al., 
2000). Deletion of Delta-like-1 (Dll1), Recombining binding protein suppressor of 
hairless (RBPjk) or Notch target Hairy and enhancer of split 1 (Hes1) in mice all 
results in depletion of the MPC pool due to premature differentiation of endocrine 
cells (Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000b). However, 
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mice without both Notch1 and Notch2 develop normal pancreata, suggesting that 
Dll1, RBPjk and Hes1 possess Notch receptor-independent functions, or there 
are other unidentified Notch receptors expressed in the pancreas (Nakhai et al., 
2008). Moreover, over-expression of constitutively activated Notch1 intracellular 
domain (NICD) significantly impairs both endocrine and exocrine development, in 
that most of the MPCs remain in the progenitor state and fail to differentiate (Hald 
et al., 2003; Murtaugh et al., 2003). Thus, the Notch signaling pathway appears 
to actively maintain MPCs in the progenitor state to ensure their proper 
expansion.  
FGF receptors (FgfR1 and FgfR2) are also expressed in the early 
pancreatic epithelium (Hart et al., 2003; Hart et al., 2000). Fgf10, produced by the 
mesenchymal cells surrounding the pancreatic epithelium, is required to maintain 
the proliferative capacity of MPCs during early pancreatic development (Bhushan 
et al., 2001). Ectopic expression of Fgf10 significantly increases the proliferation 
of MPCs while abrogating cell differentiation by maintaining active Notch 
signaling in early pancreatic epithelium (Hart et al., 2003; Norgaard et al., 2003).  
After E12.5, the MPC pool is significantly diminished. While active Notch 
signaling is still able to retain MPCs in undifferentiated states, the expression of 
both FgfR2 and Fgf10 become undetectable in the pancreatic epithelium and 
mesenchyme during the secondary transition (Bhushan et al., 2001; Hart et al., 
2003; Murtaugh et al., 2003). In adults, the identity of MPCs is still under active 
investigation. It is unknown whether Notch and FGF signaling pathways also play 
essential roles in the maintenance/induction of putative adult MPCs.  
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4. Specification of the Endocrine Pancreas 
It has been suggested that Notch-mediated lateral inhibition helps to 
select the scattered subset of pancreatic epithelial cells destined for endocrine 
fates, which is the same mechanism used to choose the subset of neuroepithelial 
cells destined for neurons in the developing nervous system (Skipper and Lewis, 
2000). 
 The current view of lateral inhibition is largely based on the studies of 
neurogenesis in Drosophila Melanogaster and vertebrates. At the beginning, all 
neural progenitors are equivalent in terms of their expression levels of Notch 
receptors, Notch ligands (like Dll1) and proneural basic-Helix-Loop-Helix (bHLH) 
transcription factors (like Ngn3). The proneural bHLH transcription factors, which 
are repressed by Notch targets (like Hes1), not only stimulate the expression of 
Notch ligands (Dll1), but also drive the cells to differentiate towards specific cell 
fates. Due to some stochastic variations, some neural progenitor cells express 
higher levels of Notch ligands (Dll1), and more efficiently activate Notch signaling 
within their neighboring cells. The latter cells, which receive more Notch signals, 
therefore express higher levels of Notch target Hes1, which leads to lower 
expression levels of proneural factors and Notch ligands (Dll1) in these latter 
cells. As a result, the former cells are less affected by Notch signaling and further 
up regulate their proneural factor and Notch ligand levels. The latter cells receive 
even more Notch signaling and further down regulate their proneural factor and 
Notch ligand levels. Eventually, the former cells accumulate enough levels of 
proneural factors and undergo differentiation. The latter cells maintain high levels 
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of Notch activity and remain in the progenitor state (Beatus and Lendahl, 1998; 
Kageyama et al., 2008).  
In the context of the developing pancreas, Notch target Hes1 and ligand 
Dll1 are highly expressed in the early pancreatic epithelium (Jensen et al., 2000b; 
Lammert et al., 2000). Endocrine progenitors, which are marked by the bHLH 
transcription factor Ngn3, emerge from the pancreatic epithelium in a scattered 
fashion just like the emergence of neurons from neuroepithelium (Lammert et al., 
2000; Murtaugh, 2007). Thus, it is highly possible that Notch-mediated lateral 
inhibition controls the selection of endocrine progenitors. Several lines of 
evidence support this hypothesis. For instance, deletion of Hes1, Dll1 and RBPjk, 
as well as over-expression of Ngn3 in the pancreas all result in precocious 
differentiation of endocrine cells at the expenses of exocrine pancreatic tissues 
(Apelqvist et al., 1999; Schwitzgebel et al., 2000).  
However, several observations need to be clarified. First, no direct 
evidence has been provided to show that lowering or increasing Ngn3 levels 
affects Notch ligand levels in vivo (Heremans et al., 2002; Treff et al., 2006). 
Second, lateral inhibition predicts that Ngn3+ cells inhibit their neighbors from up-
regulating Ngn3 levels. However, high-resolution immunohistochemistry results 
show that Ngn3+ cells are sometimes located next to each other (Jensen, 2004), 
suggesting that mechanism(s) other than classic lateral inhibition, may operate in 
the pancreas.  
Recently, studies in the nervous system revealed that Hes1, proneural 
factors (Ngn2) and Notch ligands are expressed in an oscillatory manner, 
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suggesting that the classic lateral inhibition model needs modification (Kageyama 
et al., 2008). Therefore, the role of Notch signaling in helping to select endocrine 
progenitors from the MPC pool remains to be investigated in the pancreas. 
Besides Notch, other signaling pathways also appear to regulate 
endocrine specification. Follistatin, an activin antagonist, is capable of reversing 
the relative proportion of endocrine versus exocrine pancreas in cultured rat 
pancreatic buds, suggesting that activin signals can promote endocrine 
differentiation (Miralles et al., 1998). Supporting this notion, a reduction of Type II 
activin receptor levels results in islet hypoplasia (Kim et al., 2000; Yamaoka et 
al., 1998). Ectopic expression of Smad7, which is a potent inhibitor of all TGFβ 
signaling, causes decreased endocrine cell numbers, especially β cells (Smart et 
al., 2006). However, contrary to these data, expression of a constitutively active 
form of Type II activin receptor can also induce islet hypoplasia (Yamaoka et al., 
1998). Smad2+/- pancreas, which should have reduced levels of activin and other 
TGFβ signaling, has increased numbers of endocrine cells (Smart et al., 2006). 
At this moment, it is still unclear how TGFβ signaling affects the specification of 
the endocrine lineage. Moreover, retinoic acid signaling has also been suggested 
to promote the generation of endocrine progenitor cells, but the underlying 
mechanism is currently unclear (Ostrom et al., 2008). 
 
After/at the same time of endocrine progenitor selection, the cells that do 
not enter the endocrine lineage differentiate into either ductal or acinar cells. 
However, it does not necessarily mean that there are bi-potential exocrine 
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progenitors. Gu et al. showed that Pdx1+ cells after E12.5 only give rise to islet 
and acinar cells, but not ductal cells, suggesting that ductal and acinar fates are 
not bundled together (Gu et al., 2002). Actually, it is not clear whether a single 
MPC is capable of contributing to all the three lineages of the pancreas. In other 
words, it is possible that the seemingly equivalent Pdx1+Ptf1a+Sox9+ progenitor 
cells are indeed heterogeneous populations, with some cells only capable of 
differentiating into two or single cell types. Fishman et al. had tried to address 
this question and found that a single pancreatic progenitor cell at E11.5 could 
give rise to both CPA1+ acinar cells and insulin+ β cells by a retroviral “tagging” 
method (Fishman and Melton, 2002). However, they, unfortunately, didn’t 
examine any pancreatic duct markers. Furthermore, their method hits cells in a 
blind manner. Differentiated cells could have also been labeled. Recently, Zhou 
et al. examined the clones derived from single CPA1+ cells in the pancreas, and 
revealed that individual E11.5-E12.5 CPA1+ cells are mostly (74%) tri-potent. The 
remaining single CPA1+ cells give rise to either a mixture of two cell types or 
acinar cells. This result suggests that single CPA1+ MPC between E11.5-E12.5 is 
capable of contributing to all three pancreatic lineages, yet the CPA1+ MPC 
population still remains a certain degree of heterogeneity.  
 
5. Islet Cell Type Specification. 
In the developing pancreas, the five major endocrine cell types, which are 
all derived from Ngn3+ endocrine progenitors, emerge asynchronously. It is not 
clear how these different cell types are specified from common progenitors at 
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different stages. Johansson et al. showed that Ngn3+ endocrine progenitors pass 
through a series of competence states, during each of which the progenitors are 
competent to produce a subset of endocrine cell types. Specifically, they 
generated transgenic mice expressing an inducible-Ngn3 protein under the Pdx1 
promoter, and crossed this transgene into Ngn3 null mice. Therefore, the 
production of endocrine cells can only be obtained when the transgenic Ngn3 is 
activated. They found that activation of Ngn3 at different developing stages 
resulted in the production of different subtypes of endocrine cells, a result that is 
confirmed by temporally controlled lineage tracing with Ngn3CreERT knock in mice 
(Johansson et al., 2007). Only after E11.5, Pdx1+ progenitors become competent 
to differentiate into insulin+ β cells upon Ngn3 activation. The competence to 
make β cells increases thereafter, whereas the competence to generate 
glucagon+ α cells begins at E8.5 and dramatically declines after E14.5. These 
data suggest that the Pdx1+ pancreatic epithelium changes its competency to 
make different types of endocrine cells as the development progresses prior to 
Ngn3 activation. Thus, unknown factors that are intrinsic to Pdx1+ progenitors 
must control the specification of endocrine cell types. The identification of these 
factors might greatly facilitate our understanding of endocrine cell type 
specification as well as therapy-oriented β cell generation.  
After the initial specification step, multiple transcription factors, most of 
which depend on Ngn3 for activation, emerge to promote and maintain the 
differentiation of various endocrine cell types. For instance, Paired box gene 4 
(Pax4) and Aristaless-related homeobox (Arx), which promote β and α cell fates 
 21 
respectively, mutually repress the expression of each other to ensure the 
production of functional endocrine cells expressing single hormones (Collombat 
et al., 2005; Collombat et al., 2003; Sosa-Pineda, 2004; Sosa-Pineda et al., 
1997; Wang et al., 2004). It is noteworthy that neither Pax4 nor Arx appears to be 
the factor that provides the Ngn3+ progenitors the competence to become β or α 
cells, since ectopic expression of either gene in early pancreatic progenitors can 
eliminate the production of the other cell type (Collombat et al., 2007; Collombat 
et al., 2009). 
 
The Essential Role of Ngn3 in Endocrine Differentiation 
The bHLH transcription factor Neurogenin 3 (Ngn3) is essential for 
endocrine differentiation in mice. Ngn3 was first discovered in a study searching 
for bHLH transcription factors that are important for mammalian neuronal 
determination in a neural crest stem cell derived immortalized cell line (Sommer 
et al., 1996). Together with Ngn1 and Ngn2, Ngn3 belongs to a family of atonal-
related bHLH transcription factors. Only Ngn3 is highly expressed in the 
developing pancreas (Lee et al., 2003; Yoshida et al., 2004).  
 
1. Ngn3 is both Necessary and Sufficient for Endocrine Differentiation 
In the mouse pancreas, the cells expressing detectable levels of Ngn3 by 
immunohistochemistry (IHC) first appear at around E9.0. The number increases 
gradually thereafter, reaches a peak at around E15.5, and then declines 
(Murtaugh, 2007). After birth, Ngn3+ cells are rarely detected by regular IHC 
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under normal conditions. However, Real time-PCR shows that isolated adult 
islets express significant levels of Ngn3 transcripts (Dror et al., 2007; Gu et al., 
2002). Recently, we show that low levels of Ngn3 are maintained in adult islet 
cells, and can be detected with a Guinea Pig anti Ngn3 antibody following a 
specific protocol (Wang et al., 2009). While high levels of Ngn3 during 
pancreatogenesis promote endocrine differentiation, low levels of Ngn3 are 
important for islet cells to maintain their proper functions in adults. More 
interestingly, in a single pancreatic cell, Ngn3 is only transiently expressed. 
Within about 6-12 hours, Ngn3+ cells differentiate into hormone+ cells, and down-
regulate Ngn3 to low levels (Miyatsuka et al., 2009).  
The essential role of Ngn3 in pancreatic endocrine differentiation has been 
demonstrated in many studies. Gradwohl et al. showed that Ngn3 null mutant 
mice, which have a relatively normal exocrine pancreas, fail to develop any 
endocrine cells, suggesting that Ngn3 is required for endocrine differentiation 
(Gradwohl et al., 2000). Besides, Ngn3 is sufficient to initiate endocrine 
differentiation. Several groups have shown that over-expression of Ngn3 under 
the Pdx1 promoter in transgenic mice can induce the appearance of premature 
endocrine cells in the pancreas or ectopically in the antral stomach (Apelqvist et 
al., 1999; Schwitzgebel et al., 2000). These studies not only establish Ngn3 as a 
core regulator of endocrine differentiation, but also highlight the importance of 
understanding the regulation of the spatiotemporal expression of Ngn3 and the 
transcription network that is controlled by Ngn3. 
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2. Ngn3 Controls the Endocrine Differentiation Program 
Ngn3 controls a network of factors, especially transcription factors that are 
important for endocrine differentiation/function (Gasa et al., 2004; Gu et al., 2004; 
Juhl et al., 2008; Miyatsuka et al., 2009; Petri et al., 2006; White et al., 2008). 
Based on their function and position in the network, the factors downstream of 
Ngn3 can be divided into two major groups (Figure 1.3). 
The first group of factors responds to Ngn3 activation rapidly. These 
genes, including Insulinoma-associated 1 (IA1), NK2 homeobox 2 (Nkx2.2), Pax4 
and Neurogenic differentiation gene (NeuroD), are direct downstream targets of 
Ngn3 (Breslin et al., 2007; Huang et al., 2000; Mellitzer et al., 2006; Smith et al., 
2003; Watada et al., 2003). They not only share common features, but also 
possess some distinct characteristics.  
In terms of the expression pattern, IA-1/Nkx2.2/Pax4/NeuroD start to 
appear in the pancreatic epithelium at around E9.5, the same time Ngn3+ 
endocrine progenitors emerge. Later, they are all maintained in differentiated 
endocrine cells until adulthood (Collombat et al., 2009; Gierl et al., 2006; Naya et 
al., 1997; Sussel et al., 1998; Theis et al., 2004; Wang et al., 2004). It had been 
shown that IA-1 and Nkx2.2 are present in a portion of Ngn3+ cells during 
development, suggesting that they may play essential roles in endocrine 
progenitors (Gierl et al., 2006; Schwitzgebel et al., 2000). Although it remains to 
be determined as to whether Pax4 and NeuroD are expressed in Ngn3+ 
endocrine progenitors, lineage-tracing experiment revealed that Pax4+ cells could 
contribute to all endocrine cell lineages (Greenwood et al., 2007; Wang et al., 
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2008a). Therefore, IA-1/Nkx2.2/Pax4/NeuroD may all play important roles in 
endocrine progenitors.  
In fact, targeted gene disruption experiments revealed that these four 
factors affect different aspects of endocrine differentiation despite their similar 
expression patterns. 
• IA-1 null mice accumulate undifferentiated endocrine precursors that do not 
express any hormones and have reduced endocrine mass, indicating that IA-
1 drives the endocrine progenitors towards a more committed differentiation 
state downstream of Ngn3 (Gierl et al., 2006).  
• Nkx2.2 null mice expand their ghrelin-expressing ε cell population at the 
expense of β, α and PP cells (Prado et al., 2004; Sussel et al., 1998). 
• Pax4 null mice have dramatically reduced β and δ cell numbers and 
coordinately increased α and ε cell numbers (Prado et al., 2004; Sosa-Pineda 
et al., 1997). It is possible that these ε cells represent a type of 
undifferentiated endocrine precursors, but the hypothesis remains to be 
determined.  
• NeuroD null mice show no obvious developmental defects by E14.5 in the 
pancreas. After E14.5, the numbers of each islet cell types are significantly 
reduced due to increased apoptosis. Thus, NeuroD seems to be essential for 
the survival of endocrine cells (Naya et al., 1997).  
The capabilities of IA-1/Nkx2.2/Pax4/NeuroD to induce endocrine 
differentiation are also unequal. Ectopic over-expression of NeuroD in pancreatic 
progenitors can induce endocrine differentiation, a feature shared by Ngn3 
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(Schwitzgebel et al., 2000). IA-1 alone cannot induce Ngn3 target genes in adult 
human duct cells, but can enhance Ngn3’s ability to induce its own targets 
(Mellitzer et al., 2006). Pax4 ectopic expression in early pancreatic progenitors or 
Glucagon+ α cells can re-specify these cells towards a β cell fate (Collombat et 
al., 2009). Currently, it is not clear whether Nkx2.2 are also able to enhance 
endocrine differentiation on its own or in cooperation with Ngn3. 
Overall, transcription factors in the first group respond to Ngn3 activation 
rapidly, and probably function in Ngn3+ cells to promote the endocrine 
progenitors towards a more committed state. Beside the four factors discussed 
above, several other transcription factors may also belong to this group, such as 
transcription factor V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
B (MafB) and Paired box protein 6 (Pax6), which are critical for endocrine 
differentiation (Artner et al., 2007; Artner et al., 2006; Ashery-Padan et al., 2004; 
Sander et al., 1997; St-Onge et al., 1997). It is not clear whether Ngn3 directly 
regulates the expression of these two genes, but MafB and Pax6 are expressed 
in a subset of Ngn3+ progenitors. Their expression levels appear to increase 
rapidly after Ngn3 activation (Artner et al., 2006; Heremans et al., 2002; Jensen 
et al., 2000a). 
The second group of factors downstream of Ngn3 responds to Ngn3 
activation slowly. They define the functional identities of mature endocrine cells, 
and are controlled by the factors in the first group. Transcription factors such as 
V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), Pdx1 and 
NK6 homeobox protein 1 (Nkx6.1), hormone secretion related factors like 
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Glucose transporter 2 (Glut2), and peptide hormones like insulin are included in 
this group. These factors help to define the mature β cell identity, and often 
emerge late after Ngn3 activation (Heremans et al., 2002). For instance, it has 
been shown that as insulin expressing β cells mature, they become 
MafA+Glut2+Insulin+, and express high levels of Pdx1 and Nkx6.1 (Ahlgren et al., 
1998; Brissova et al., 2002; Dutta et al., 1998; Jensen et al., 2000a; Jensen et 
al., 1996; Nishimura et al., 2006; Pang et al., 1994; Sander et al., 2000).  
Several studies have suggested that the factors of the first group play key 
roles in promoting the expression of the factors in the second group. In IA-1-/-, 
Pax4-/-, Nkx2.2-/- and NeuroD-/- mutant pancreata, the level of Pdx1 is significantly 
down regulated starting from E16.5 until birth, even though initial Pdx1 
expression at E10.5 is not affected (Gierl et al., 2006; Naya et al., 1997; Sussel 
et al., 1998; Wang et al., 2004). More directly, NeuroD could bind to the Pdx1 
promoter and promote its expression (Sharma et al., 1997). The level of Nkx6.1 
is also reduced in IA-1-/-, Pax4-/-, Nkx2.2-/- pancreata around birth (Gierl et al., 
2006; Sussel et al., 1998; Wang et al., 2004). Sander et al. had suggested that 
Nkx6.1 lies downstream of Nkx2.2 during the process of β cell differentiation, in 
that Nkx6.1-/-Nkx2.2-/- double mutant pancreata are indistinguishable from that of 
Nkx2.2-/- mice (Sander et al., 2000). How MafA and Glut2 expression is regulated 
is still not clear. It has been shown that MafB is capable of occupying the 
promoter regions of MafA and Glut2 in vivo and positively regulate their 
expression (Artner et al., 2007). For the insulin gene, NeuroD can specifically 
bind to the E-box of the insulin gene promoter with high affinity (Naya et al., 
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1995). Together, these studies demonstrate that the factors of the second group, 
which terminally determine functional mature endocrine cells, are extensively 
regulated by the factors of the first group. 
Besides, within the second group, different factors cross talk and interact 
with each other to promote endocrine differentiation. MafA and Pdx1 are 
transcriptional targets of each other (Raum et al., 2006; Samaras et al., 2003). 
They may up-regulate their expression levels through a feed-forward mechanism. 
Moreover, MafA, Pdx1 and NeuroD together could synergistically enhance insulin 
gene transcription (Aramata et al., 2005; Zhao et al., 2005).  
In summary, Ngn3 controls a network of factors, which not only relay 
differentiation signals to their downstream targets, but also actively cooperate 
with each other to accomplish the endocrine differentiation program.  
 
3. Ngn3 is Tightly Regulated in the Pancreas 
Ngn3+ cells emerge from a seemingly equivalent epithelial sheet in a 
scattered manner.  Each single pancreatic cell expresses high levels of Ngn3 in a 
short time period. This unique expression pattern implies that at least three 
important issues need to be addressed: 
• How are Ngn3+ cells selected from the pancreatic epithelium?  
• What are the signals or factors that up-regulate Ngn3 levels when cells are 
released from Notch-inhibition?  
• How are Ngn3 levels down-regulated in differentiated hormone expressing 
cells?  
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Figure 1.3. Ngn3 controls the endocrine differentiation program. 
1st: genes in this group are directly downstream of Ngn3, and can 
respond to Ngn3 activation rapidly. They mostly function in Ngn3+ cells 
to help the endocrine progenitors differentiate towards a more 
committed state. 2nd: genes in this group respond to Ngn3 activation 
slowly. The expression of these genes, which defines the functional 
identities of mature endocrine cells, is regulated by factors in the 1st 
group. Cross talk within the 2nd group also contributes to the 
differentiation of endocrine cells.    
 29 
 For the first question, it is clear that (see above) Notch-mediated lateral 
inhibition together with other signaling pathways play essential roles in selecting 
Ngn3+ cells, even though the working details of the mechanism remain to be 
clarified. In this part, the latter two issues will be discussed (Figure 1.4). 
 
3-1. Up-Regulation of Ngn3 Levels in Ngn3+ Endocrine Progenitors 
As previously mentioned, the Notch target Hes1 can directly bind to the 
Ngn3 promoter region and inhibit Ngn3 transcription. However, simple release 
from Hes1 repression is not sufficient to up-regulate Ngn3 levels in endocrine 
progenitors, since a longer Ngn3 promoter sequence than the region containing 
just the Hes1 binding sites is necessary to direct strong and selective Ngn3 
expression in the pancreas (Lee et al., 2001). Thus, additional signals/factors are 
required to enhance Ngn3 expression. 
Intercellular signals, such as TGFβ, GDF11, retinoic acid and activin 
signals from the surrounding pancreatic mesenchyme, can promote the 
generation of Ngn3+ cells and endocrine differentiation (see “Specification of 
endocrine pancreas”). However, it is not clear whether these signaling pathways 
directly regulate Ngn3 expression or if it is through some indirect regulatory 
mechanisms.  
Intracellularly, several transcription factors have been shown to positively 
regulate Ngn3 expression. Lee et al. reported that Forkhead box protein A2 
(Foxa2, Hepatocyte nuclear factor 3β, Hnf3β) and Hepatocyte nuclear factor 1α 
(Hnf1α) could bind to the Ngn3 promoter and probably enhance Ngn3 expression 
 30 
(Lee et al., 2001). However, when Foxa2 was specifically deleted from the 
mouse endoderm (by Foxa3-Cre), endocrine specification was not affected (Lee 
et al., 2005). Hnf1α-/- pancreata showed relatively normal endocrine 
differentiation but with defects in β cell growth and function (Pontoglio et al., 
1998). Thus, these two hepatic nuclear transcription factors are not required for 
Ngn3 level up-regulation. Another hepatic nuclear factor Hnf6 has also been 
revealed to play essential roles in regulating Ngn3 expression. It directly binds to 
the Ngn3 promoter and can stimulate the promoter activity in vitro. More 
importantly, Ngn3 expression is nearly abolished in Hnf6-/- pancreata during 
development, suggesting that Hnf6 is necessary for the up-regulation of Ngn3 
levels (Jacquemin et al., 2000). Currently, it remains to be determined whether 
Foxa2, Hnf1α and Hnf6 individually are sufficient to promote Ngn3 levels to a 
certain threshold that is enough to initiate endocrine differentiation in the absence 
of active Notch signals.  
Besides these hepatic nuclear factors, other transcription factors also 
function to regulate Ngn3 expression levels. Sox9 has been shown to bind the 
human Ngn3 promoter and activate its expression in vitro (Lynn et al., 2007). 
However, Seymour et al. found that the number of Hes1+ cells is significantly 
decreased, whereas the percentage of glucagon+ cells (Glu+) increases in Sox9-/- 
mouse pancreas at around E10.5 (Seymour et al., 2007). Since Ngn3 is a direct 
target of Hes1 and able to actively induce Glu+ cell differentiation, this study 
suggests that Sox9 suppresses Ngn3 expression via up-regulation of Hes1. To 
unravel the discrepancy between these two studies, more detailed examinations 
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need to be performed in vivo to investigate the role of Sox9 on regulating Ngn3 
expression. Moreover, Oliver-Krasinski et al. recently showed that mice 
homozygous for a Pdx1 hypomorphic allele displayed a marked reduction of 
Ngn3 mRNA levels and Ngn3+ cell numbers from E13.5 onwards, suggesting that 
Pdx1 is also involved in promoting Ngn3 levels. This result is further confirmed by 
the observation that Pdx1 can bind to the Ngn3 promoter region and directly 
regulate Ngn3 expression (Oliver-Krasinski et al., 2009). 
In fact, Foxa2, Hnf6, Sox9 and Pdx1 not only regulate Ngn3 expression 
individually, but also function in concert with each other to form a cross-
regulatory network. Pdx1 not only physically interacts and cooperates with Hnf6 
to directly regulate Ngn3 promoter activity, but also occupies the conserved 
regulatory region of the Foxa2 gene within the E13.5 pancreas in vivo (Oliver-
Krasinski et al., 2009). Sox9 also binds to conserved regions upstream of Foxa2 
and Hnf6 genes. Reduction of Sox9 levels in the pancreatic ductal cell line, 
mPAC, results in decreased expression of Foxa2 and Hnf6. Reduced Foxa2 
expression in these cells also lead to a dramatic decrease of Sox9 levels (Lynn 
et al., 2007). These results suggest that a complicated cross-regulatory 
transcription factor network function to regulate Ngn3 expression. 
In addition to the above listed transcription factors that can recognize/bind 
specific DNA sequence, several none-specific histone deacetylases (HDACs), 
which modify histones post-translationally, also regulate the number of Ngn3+ 
endocrine progenitors (Haumaitre et al., 2008). However, it is still unclear how 
this regulation is achieved. 
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In order to search for factors that can potentially regulate or cooperate 
with Ngn3, the global gene expression profile of Ngn3+ endocrine progenitors 
had been investigated by microarray-based analysis (Gu et al., 2004). A zinc-
finger transcription factor Myt1 (Myelin transcription factor 1) was identified in this 
study as a factor specifically enriched in the endocrine pancreas. In this thesis 
work, we will provide evidence to show that Myt1 forms a feed-forward 
expression loop with Ngn3 to promote endocrine differentiation.  
 
Taken together, after Ngn3 gene expression is released from Notch 
inhibition, its expression is tightly up-regulated by both intercellular and 
intracellular signaling pathways.  
 
3-2. Down-Regulation of Ngn3 Levels in Differentiated Endocrine Cells 
In endocrine progenitor cells, Ngn3 levels gradually decline as the cells 
progress towards a more differentiated state. As a result, hormone-expressing 
endocrine cells maintain very low levels of Ngn3 expression (Wang et al., 2009). 
It remains unclear how Ngn3 levels are down regulated in these differentiated 
endocrine cells and whether this down-regulation is required for the normal 
function of endocrine cells. 
Smith et al. showed that while Ngn3 activates the endocrine differentiation 
program, it represses its own expression (Smith et al., 2004). This mechanism 
may contribute to the down-regulation of Ngn3 levels in differentiated cells. 
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However, it seems that Ngn3 cannot directly act as a transcriptional repressor 
(Smith et al., 2004). Whether Ngn3 represses its own promoter by competing 
with other transcription activators or by inducing the expression of other 
repressors, remains to be determined (Smith et al., 2004). Nevertheless, the fact 
that Ngn3 represses its own expression offers a possible explanation for the 
“pulse-like” expression of Ngn3 in the endocrine progenitors. Besides, several 
microRNAs, which can potentially bind to Ngn3 transcripts, are highly expressed 
in the adult and regenerating mouse pancreas, and may silence Ngn3 expression 
post-transcriptionally in differentiated endocrine cells (Joglekar et al., 2007).  
It is currently not clear whether down-regulation of Ngn3 levels is required 
for the proper function of differentiated endocrine cells. To test this idea, we over-
expressed Ngn3 in adult mature β cells (under the Pdx1 promoter) in mice. The 
percentage of adult β cells expressing high levels of Ngn3 is relatively low, and 
varies between individual animals, suggesting that unknown mechanisms 
regulate Ngn3 levels post-translationally in at least a portion of mature adult β 
cells (Wang S. & Gu G., unpublished data). The consequences of maintaining 
high Ngn3 levels in mature β cells remain to be examined. As discussed 
previously, Ngn3 controls a network of factors essential for endocrine 
differentiation. It is possible that up-regulation of Ngn3 expression in 
differentiated cells may drive these cells towards an unstable-progenitor-like 
state, and therefore interfere with their proper function, such as insulin secretion. 
However, thinking from a diabetes therapist’s point of view, these β cells re-
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expressing high levels of Ngn3, may be a good source for repopulating the 
reduced or dysfunctional β cells in human patients with diabetes.  
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Figure 1.4 Ngn3 expression is tightly regulated. Multiple signaling 
pathways and transcription factors are involved in regulating Ngn3 
levels in the pancreas. 
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4. Ngn3 Functions Differently at Different Stages. 
The human genome contains less than 30,000 genes, which is only 
increased by about 30% compared to the genome of C. elegans. However, 
human genes obviously conduct much more sophisticated and complex 
biological/physiological processes than that of nematodes. It appears that many 
genes in humans/mammals are used repeatedly during development and in 
adulthood. For instance, in the mouse pancreas, Pdx1 plays very different roles 
throughout the development. At the beginning of pancreatic development (E9.0 in 
mice), Pdx1 is expressed in all the pancreatic progenitors (MPCs), and required 
for the expansion of the progenitor pool (Offield et al., 1996). During the 
secondary transition (E12.5-E16.5 in mice), Pdx1 is expressed in low levels in 
exocrine cells and endocrine progenitors, and probably is required for the 
differentiation and maintenance of these cells (Hale et al., 2005; Oliver-Krasinski 
et al., 2009). During the late gestation stage and adulthood, Pdx1 expression is 
restricted to β and δ cells, and is necessary for the proliferation/function of β cells 
in mice (Ahlgren et al., 1998; Brissova et al., 2002; Gannon et al., 2008). Based 
on these studies, it is clear that Pdx1 carries out distinct functions in different cell 
types at different developmental stages, probably through regulation of different 
sets of downstream targets. Beside Pdx1, Nkx2.2, Nkx6.1, MafB and NeuroD et 
al. function differently in different contexts as well, but Ngn3 was only considered 
as an endocrine progenitor marker previously (Aramata et al., 2005; Artner et al., 
2007; Artner et al., 2006; Henseleit et al., 2005; Naya et al., 1997; Raum et al., 
2006; Sander et al., 2000; Sussel et al., 1998).  
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Recent studies from our lab suggest that Ngn3 also conducts different 
roles within different developmental contexts. During embryogenesis, Ngn3 is 
highly expressed in endocrine progenitors, and is essential for endocrine 
differentiation. After differentiation, Ngn3 levels are down regulated in the adult 
pancreas. While several groups had claimed that Ngn3 expression was not 
maintained in the adult pancreas, others showed that significant amount of Ngn3 
mRNA could be detected in isolated adult islets (Dror et al., 2007; Gu et al., 
2002; Jensen et al., 2000a; Schwitzgebel et al., 2000). By optimizing the 
immunohistochemistry detecting protocol and utilizing sensitized Ngn3 reporting 
strategies, we recently revealed that Ngn3 mRNA and protein are maintained in 
low levels in most of the adult pancreatic endocrine cells. More importantly, 
specific deletion of Ngn3 in β cells impairs proper endocrine function in adults 
(Wang et al., 2009). Therefore, Ngn3 is required not only for initiating the 
endocrine differentiation program, but also for islet cell maturation and proper 
function.  
It is largely unknown what controls the stage/context-dependent functions 
of transcription factors, such as Ngn3 and Pdx1. Different factors might be 
involved in regulating Ngn3 expression in different developmental contexts. 
Moreover, Ngn3 differentially regulates its downstream target genes at different 
stages (Wang et al., 2009). Thus, some differentially expressed factors may 
restrict Ngn3’s capability to activate specific downstream targets. It is also 
possible that chromatin modification states and promoter accessibility vary in 
different contexts, which causes Ngn3 to possess different activities. 
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The Application of Ngn3 in Diabetes-Related Therapies 
Diabetes Mellitus, a metabolic disorder characterized by the failure to 
maintain glucose homeostasis in the body, has rapidly become a worldwide 
disease in the past decade. It is estimated that approximately 246 million people 
had diabetes worldwide in 2007, and the figure is expected to reach 380 million 
by 2025 (International Diabetes Federation, http://www.idf.org). This alarming 
increase of the diabetes prevalence has urged biological and medical 
researchers to understand the pathogenesis of this disease and to forage for 
possible cures.  
Based on the underlying causes, diabetes can be categorized into 
different types. Type I and type II diabetes are the two major forms, contributing 
to approximately 10% and 90% of all diabetic cases respectively. In type I 
diabetes, β cells, which are the major source of insulin production in the body, 
are attacked and eliminated by the autoimmune system. The loss of insulin then 
causes a lasting increase of blood glucose levels that can lead to long-term 
complications and eventually harm all of the organ and systems (Sordi et al., 
2008). In type II diabetes, β cells fail to compensate for obesity-associated insulin 
resistance. As a result, patients gradually progress from normoglycemia to 
hyperglycemia (Prentki and Nolan, 2006). Even though administration of 
exogenous insulin can relieve the symptoms of both type I and type II diabetes, 
there is no cure for this disease currently.  
Considering that it is the β cell that is impaired/dysfunctional in diabetes, 
replenishing patients with renewable, functional β cells would possibly offer a real 
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cure. There are two major ways to achieve such a goal. One is through 
generating mature β cells in vitro or ex vivo that could correct insulin insufficiency 
when transplanted into patients. The other way would be stimulating β cell 
regeneration in vivo (Bonner-Weir and Weir, 2005). Ngn3 has been implied to 
play essential roles in both of these strategies. 
To generate mature β cells in vitro, many efforts have been put on 
directed-differentiation of various cell types, including hESCs/mESCs  
(human/mouse embryonic stem cells), pancreatic duct cells, hepatic progenitor 
cells, neural progenitor cells, bone marrow-derived stem cells, intrahepatic biliary 
epithelial and gall bladder epithelial cells (Ai et al., 2007; Baetge, 2008; 
Heremans et al., 2002; Hori et al., 2005; Jiang et al., 2007; Jin et al., 2008; 
Phillips et al., 2007; Treff et al., 2006; Yechoor et al., 2009). The idea is to mimic 
endogenous embryonic endocrine differentiation in vitro and therefore generate 
mature β cells. As discussed previously, Ngn3 controls the endocrine 
differentiation program during embryogenesis. Thus, several groups have tested 
its role in directing endocrine differentiation in vitro. Heremans et al. showed that 
adult human pancreatic duct cells could be converted into insulin-expressing 
cells after adeno-virus mediated Ngn3 over-expression (Heremans et al., 2002). 
Inducible expression of Ngn3 in mESCs promotes pancreatic endocrine 
differentiation and insulin expression (Treff et al., 2006). These results suggest 
that Ngn3 can promote endocrine differentiation in vitro. However, the insulin-
expressing cells induced by Ngn3 over-expression do not seem to be mature β 
cells in terms of their poor response to glucose stimulation. This is predictable to 
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some extent, in that Ngn3 initiates the endocrine differentiation program, but is 
not responsible for the specification of different islet cell types even during 
embryogenesis in vivo (Johansson et al., 2007). Other factors that can 
specifically promote β cell genesis remain to be determined for successful 
generation of mature functional β cells in vitro. 
Another interesting way to reverse diabetes would be stimulation of adult β 
cell regeneration in vivo. β cell mass is maintained mainly through self-replication 
of pre-existing β cells in a fairly slow rate (0.5%/6 hour in rodents) (Bonner-Weir, 
2000a; Bonner-Weir, 2000b; Dor et al., 2004). Under physiological and 
pathological stresses such as pregnancy and obesity, the β cell replication rate 
significantly increases to compensate for the rising demand (Lee and Nielsen, 
2009). Several factors have been identified playing important roles in β cell 
replication, including cyclin/CDK, menin, transcription factors (Pax4//Nkx6.1), 
hormones and growth factors (Lee and Nielsen, 2009). Although treatments 
targeting these replication-related factors may markedly help type II diabetic 
patients, type I diabetic patients are hardly able to benefit from these treatments 
since they have lost most of their β cells and endogenously regenerated β cells 
are still under the attack of their immune system.  
Stimulating β cell neogenesis in the adult pancreas is another promising 
way to enhance β cell regeneration. The existence of β cell neogenesis in the 
adult pancreas remains highly controversial. On one hand, Dor. et al. showed 
that new β cell arise solely from replication of existing β cells; on the other hand, 
several studies have shown that ductal cells in the pancreas might contribute to β 
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cell neogenesis (Bonner-Weir et al., 2004; Dor et al., 2004). Until recently, Xu et 
al. revealed that β cell progenitors could be activated in injured adult mouse 
pancreas after Partial Ductal Ligation (PDL) (Ackermann Misfeldt et al., 2008; Xu 
et al., 2008). More importantly, these adult β cell progenitors are located in the 
ductal lining, and depend on Ngn3 to further differentiate into all islet cell types, 
including glucose responsive β cells (Xu et al., 2008). Based on this study, it 
would be intriguing to examine whether induced Ngn3 expression in adult 
pancreatic duct cells can enhance β cell neogenesis in vivo. Furthermore, it had 
been shown that β cells could be produced via the reprogramming of other cell 
types. Zhou, Q et al. reported a strategy that could successfully reprogram adult 
pancreatic exocrine cells into insulin producing cells in vivo, through virus-
mediated forced expression of Pdx1, Ngn3 and MafA (Zhou et al., 2008). This 
strategy successfully restores euglycemia in diabetic animals, but more details 
remain to be explored prior to clinical purposes, such as the life span and mitotic 
features of the induced insulin-expressing cells. Moreover, generating β-like cells 
at the expense of the exocrine pancreas may cause some side effects in the long 
run. Nevertheless, this study suggests that Ngn3 together with other key 
transcription factors can reprogram terminally differentiated exocrine cells into 
insulin-expressing cells in vivo. More intriguingly, Ngn3 was revealed to be 
sufficient for trans-determination of hepatic progenitor cells into islet-like cells in 
vivo (Yechoor et al., 2009). Overall, these studies not only indicate that 
transcription factors like Ngn3 can actively reprogram either differentiated or 
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determined cells into islet cells, but have also brought new directions into the 
diabetic therapy field.  
In summary, important progress has been made regarding how to 
generate mature β cells in vitro and in vivo during the past several decades. 
However, even though very promising, none of the above-discussed strategies 
are able to produce β cells as efficient as endogenously generated β cells, which 
highlights the fact that there is still many unknowns about pancreatic 
development and islet biology. A comprehensive understanding of endocrine islet 
differentiation and function would significantly benefit therapy-oriented 
researches. 
 
The Significance of the Thesis Research 
The connection between the pancreas and various diseases such as 
diabetes, has urged biologists and medical researchers to understand the 
molecular programs that control the formation and homeostasis of the pancreas. 
During the past decade, a network of transcription factors has been identified and 
determined to be essential for pancreatic development and maintenance. More 
importantly, based on this information, various strategies have been developed 
and tested to repopulate β cell populations in vitro or in vivo, with the hope of 
benefiting diabetic patients. However, some important issues remain mysterious. 
The existence of stem-cell-like progenitors in the adult pancreas has been 
a big debate in the field. Only until recently, has solid lineage tracing data been 
acquired to demonstrate that pancreatic or β cell progenitors are present in the 
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adult pancreas. Inada et al. revealed that carbonic anhydrase II+ (CAII+) ductal 
cells act as pancreatic progenitors in adults after severe injury (Inada et al., 
2008). However, it is still unknown whether these adult progenitors exist as a 
special population that resides in adjacent to ductal cells or actually comes from 
de-differentiated ductal cells. If the former situation were true, it would be 
important to examine whether these adult progenitors sit in special niches like 
adult intestine stem cells and what contributes to the pancreatic niches. It would 
be even more intriguing if these adult progenitor cells could be isolated, 
expanded in vitro and differentiated into desired cell types. In another study, Xu 
et al. showed that Ngn3+ β cell progenitors could be activated in the adult mouse 
pancreas after PDL (Ackermann Misfeldt et al., 2008; Xu et al., 2008). Although 
these β cell progenitors are located within the ductal lining, their identity is not 
quite clear. It is also unknown whether they differentiate from adult pancreatic 
progenitors as proposed by Inada et al., or represent a distinct population of adult 
endocrine progenitors with their own niches.  
Another issue of pancreatic development that remains mysterious 
concerns the specification of different islet cell types. Ngn3 is the key regulator of 
endocrine differentiation, but it obviously does not control the islet cell type 
specification, nor do the signals from tissues adjacent to the pancreatic 
epithelium (Johansson et al., 2007). It appears that the pancreatic progenitors 
are pre-patterned for which islet subtypes they are fated to be. However, little is 
known about the signals/factors that control islet subtype specification, which is 
integral for generating mature β cells in vitro or in vivo. 
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Moreover, considering Ngn3’s essential role in endocrine differentiation, 
more needs to be explored regarding its upstream regulators and major 
downstream targets. Several signaling pathways and transcription factors have 
been implicated in regulating Ngn3 levels in endocrine progenitors. But 
individually, none of them is sufficient to induce high Ngn3 activity in vivo. 
Additional factors appear to be required to up regulate Ngn3 levels. Moreover, it 
is substantial to know whether Ngn3 levels in individual endocrine progenitor 
cells are important for endocrine differentiation. These questions will be 
discussed and addressed in the following chapters. Furthermore, the 
mechanisms that down regulate Ngn3 levels in differentiated endocrine cells 
have not been thoroughly examined. It is also unknown how Ngn3 is maintained 
in a low level in differentiated endocrine cells in adults, and whether the same 
signals/factors regulating Ngn3 expression during embryogenesis function in the 
adult pancreas. Careful examination of Ngn3 promoter occupancy at different 
development stages might provide useful information and clues needed to 
address these questions.  
Downstream of Ngn3, there is a complicated network of transcription 
factors that are essential for endocrine differentiation. It remains unclear how 
these different factors cross talk with each other, and what the major targets of 
Ngn3 are. In fact, several groups have tried to isolate Ngn3+ cells via various 
strategies to examine their expression profiles (Gu et al., 2004; Juhl et al., 2008; 
Miyatsuka et al., 2009; White et al., 2008). However, due to the nature of Ngn3’s 
transient expression and long duration of reporter proteins like Enhanced Green 
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Fluorescent Proteins (EGFP), the isolated cells remain a mixed population of 
Ngn3+ cells and differentiated endocrine cells, making it hard to identify direct 
Ngn3 targets or Ngn3 co-factors. Moreover, the generation of mutant mouse 
models (knock out/in, transgenic mice), which are predominantly used within the 
field to examine gene function, is very complicated and time-consuming. This 
greatly slows down the identification of significant factors from the massive 
number of candidate genes that stand out from various screens. Considering the 
convenience of gene manipulation in the chick system, such as siRNA/cDNA 
electroporation, establishment of a platform in chicks to quickly test candidate 
gene function may significantly accelerate the experimental process.  
 
 This thesis research work focuses on understanding how pancreatic 
endocrine differentiation/function is regulated, especially the role of Ngn3 in the 
pancreas. The results from this work will not only help us to understand the basic 
principles of organogenesis, but will also provide valuable information to favor the 
generation of unlimited mature β cells, which is the first essential step towards 
curing the worldwide disease Diabetes Mellitus. 
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CHAPTER II 
 
LOSS OF Myt1 FUNCTION PARTIALLY COMPROMISES ENDOCRINE ISLET 
CELL DIFFERENTIANTION AND PANCREATIC PHYSIOLOGICAL FUNCTION 
IN THE MOUSE 
 
This chapter is published under the same title in Mechanisms of Development, 
Nov-Dec, 2007 (Wang et al., 2007). 
 
Abstract 
 
 Myelin transcription factor 1 (Myt1) was identified as a factor that is 
specifically enriched in the endocrine cell lineage. Ectopic gene expression and 
dominant-negative-based loss-of-function studies suggest that Myt1 may 
regulate endocrine differentiation and function in the pancreas. Here, we 
analyzed the expression pattern of Myt1, as well as the effects of Myt1 gene 
disruption to further understand how Myt1 functions in the mouse pancreas. Myt1 
is expressed in both Ngn3+ endocrine progenitors during embryogenesis and 
differentiated endocrine islet cells in adulthood. Myt1-/- animals die postnatally 
due to non-pancreatic related defects. The endocrine compartment of the Myt1-/- 
pancreas contains abnormal endocrine cells that co-express multiple hormones, 
while maintains relatively normal numbers of endocrine cells.  Furthermore, 
pancreatic-specific Myt1 mutant mice, which are viable and fertile, displayed 
similar pancreatic phenotypes as Myt1-/- mice during development. Male mice 
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that have lost Myt1 in their pancreatic cells display poor glucose tolerance, 
attenuated insulin secretion and reduced Glut2 expression. Taken together, 
these findings demonstrate that Myt1 is important for proper endocrine 
differentiation and islet function in the mouse pancreas. 
 
 
Introduction  
 In the pancreas, endocrine islets, whose malfunction is associated with 
Diabetes Mellitus, are generated from Ngn3+ endocrine progenitors in a multi-
step process. Genetic and functional studies have identified several signaling 
pathways and transcriptional factors that are essential for pancreatic endocrine 
differentiation, but a global analysis of regulatory signals/factors in the endocrine 
pancreas is still missing (Murtaugh, 2007; Oliver-Krasinski and Stoffers, 2008). 
Previously, Gu et al. compared the gene expression profiles of Ngn3+ endocrine 
progenitor cell pool with Ngn3- cell pool of the developing mouse pancreas by 
microarray-based analyses. Myt1 (Myelin transcription factor 1) was discovered 
as a candidate gene that is highly expressed in endocrine progenitors (Gu et al., 
2004).  
 Myt1 encodes a C2HC type zinc finger transcription factor that is 
conserved in vertebrates (Bellefroid et al., 1996; Jiang et al., 1996; Matsushita et 
al., 2002). It has two paralogs, Myt1L and Myt3. Proteins encoded by these three 
genes share high similarity in terms of their protein sequences and structures 
(Figure 2.1) (Jiang et al., 1996; Kim and Hudson, 1992; Matsushita et al., 2002; 
Yee and Yu, 1998).  
 48 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Myt family members share high similarities. The protein 
structures of Myt family members were shown. Genome location and 
protein length were indicated on the right. Percentages of amino acid 
similarities of various regions of Myt1L and Myt3 to Myt1 were shown. 
The Myt1 locus produces two proteins (Myt1a and Myt1b) that differ in 
their N-termini. The first 103 aa residues (light cherry rectangle) of 
Myt1a are not shared with Myt1b (light brown rectangle, 152 residues). 
Orange boxes: zinc fingers; Yellow box: putative transactivation domain; 
Green bars: the exons that were deleted to generate null alleles in the 
following chapters; Chr: chromosome. 
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Myt1 gives rise to two transcripts (Myt1a and Myt1b), differing only in their 
5’ regions by utilizing alternative transcription start sites (Kim and Hudson, 1992; 
Matsushita et al., 2002). Myt1b is the predominantly expressed form in almost all 
of the tissues examined (Matsushita et al., 2002). In Xenopus, xMyt1 (the 
homolog of Myt1 in Xenopus) is expressed in the neural plate during 
neurogenesis, and possibly cooperates with xNgnr1 (the homolog of Ngn3 in 
Xenopus) to promote neuronal differentiation (Bellefroid et al., 1996; Quan et al., 
2004). In rodents, Myt1 is highly expressed in the nervous system (brain, spinal 
cord, neural crest, sensory organs and peripheral ganglia) and the endocrine 
pancreas (Kim et al., 1997a; Matsushita et al., 2002). It remains unclear 
whether/how Myt1 functions in any in vivo systems. 
In tissue cultures, Myt1 modulates the proliferation and differentiation of 
myelin-forming oligodendrocytes (Armstrong et al., 1995; Nielsen et al., 2004).  
Since Myt1 can interact with SIN3 homolog B (Sin3B), a chromatin modifier that 
serves as scaffolds tethering histone deacetylases (HDACs) activity (Romm et 
al., 2005), it was proposed that Myt1 might regulate its target genes by 
modulating the chromatin structure (Romm et al., 2005). However, no direct 
study has been performed to address this possibility. 
 In the mouse/chicken pancreas, both Myt1a and Myt1b are expressed in 
the pancreatic epithelium during embryogenesis, with Myt1b being the 
predominantly expressed form (Matsushita et al., 2002). A dominant negative 
Myt1 without the putative transactivation domain can impair endocrine 
differentiation in the mouse pancreas (Gu et al., 2004). Mis-expression of Myt1b 
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in the chicken hindgut endoderm results in the ectopic expression of glucagon 
and stomatostatin (Gu et al., 2004). Myt1 is also able to partially antagonize 
Notch activity to facilitate endocrine differentiation in the chicken pancreas 
(Ahnfelt-Ronne et al., 2007). These data suggest that Myt1 may play important 
roles during pancreatic endocrine differentiation. 
In this chapter, the protein expression pattern of Myt1 was carefully 
examined in the mouse pancreas. Furthermore, Myt1 global and pancreatic 
specific knock out mutant mice were generated and characterized. Myt1-/- 
pancreata contain abnormal islet cells that co-express multiple hormones. 
Pancreatic specific Myt1 knock out male mice display impaired glucose clearing 
ability, reduced Glut2 expression and attenuated glucose induced insulin 
secretion (GSIS). These findings demonstrate that Myt1 is important for proper 
pancreatic endocrine differentiation and islet function in mice. Interestingly, the 
expression of Myt1L and Myt3, which are not expressed in the wild type 
pancreas, is induced upon Myt1 deletion, suggesting that Myt1L and Myt3 may 
compensate for the loss of Myt1 function in mice.  
 
Materials and Methods 
 
1. Mouse strains and care 
 Mouse husbandry and genotyping were performed following 
standard protocols (M/03/363 and M/03/354) approved by the Vanderbilt Medical 
Center Institutional Animal Care and Use Committee (IACUC). For embryonic 
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staging, vaginal plug appearance was counted as embryonic day 0.5 (E0.5). For 
routine mouse embryo production, the ICR mouse strain was utilized (Charles 
River Laboratories, Inc. Wilmington, MA). For initial knockout mice production, 
C57BL/6 strain was used (Charles River Laboratories, Inc. Wilmington, MA). 
Subsequent strain maintenance and crosses utilized CD1 mice. Flpe (used to 
delete the selection marker in the targeted allele), Pdx1-Cre and Sox2-Cre mice 
were previously reported (Dymecki, 1996; Gu et al., 2002; Hayashi et al., 2002). 
Genotyping followed published methods with minor modification. Briefly, mouse 
tissue from ear puncture were collected and boiled in 40mM NaOH for 30 
minutes. Equal volume of 0.1mM Tris (pH: 4.0) was then added for neutralization. 
1µl of the lysate was used for PCR-based genotyping. 
 
2. Generation of Myt antibodies 
         To produce Myt1 antibodies, an open reading frame encoding Myt1 amino 
acid residues 109–298 (as numbered in mKIAA0835) was fused with that 
encoding a maltose binding protein (New England Biolabs, Beverly, MA). The 
fusion protein was purified and used as an antigen. The antibody production in 
rabbits was performed by Strategic Bio-solution (Newark, DE). The specificity of 
the antibodies was verified by the lack of positive signals in Myt1-/- mouse 
tissues, which produces Myt1L and Myt3. Production of Myt1L and Myt3 
antibodies followed the similar design, except that amino acid residues 215-424 
(as numbered in AAC53457) for Myt1L and 63-302 (as numbered in mKIAA0535) 
for Myt3 were used.   
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3. In situ hybridization and immunohistochemistry/immunofluorescence (IHC/IF) 
 In situ hybridization and IHC/IF followed established protocols. Briefly, 
mouse tissues were fixed in 4% paraformaldehyde overnight at 4°C or 4h at 
room temperature. For in situ hybridization, tissues were prepared as 6µm 
paraffin sections. All cRNA probes were made by using cDNA clones as 
templates. The Myt1 cDNA (#LDN 147) was a gift from L. Hudson (Kim et al., 
1997a). This cDNA clone was digested with XhoI and transcribed with T7 RNA 
polymerase. The Myt1L (#6844118) and Myt3 (#5366688) cDNA clones were 
purchased from Open Biosystem (Huntsville, AL). These cDNA clones were 
digested with Sal-I or AvrII and transcribed with T3 or T7 RNA polymerase for 
cRNA probe production, respectively. For IHC/IF, either frozen or paraffin 
sections were utilized. Primary antibodies used: guinea pig anti-insulin, goat anti-
C peptide (recognizing the same cells as anti-insulin antibodies), and guinea pig 
anti-glucagon are from Dako, Carpinteria, CA; Rabbit anti-glucagon, rabbit anti-
SS, goat anti-SS, guinea pig anti-PP are from Invitrogen, Carlsbad, CA; Rabbit 
anti-Glut2 is from Chemicon, Temetula, CA; Rabbit anti-MafA and MafB are gifts 
from R. Stein (Matsuoka et al., 2004); Goat anti-Pdx1 is a gift from C.V. Wright; 
Mouse anti-Ngn3 is from Hybridoma Bank, Iowa (F25A1B3); Guinea pig anti-
Ngn3 is a gift from M. Sander (Seymour et al., 2007). Secondary antibodies 
used: FITC-conjugated donkey anti-rabbit IgG, Cy3-conjugated donkey anti-
rabbit IgG, Cy3-conjugated donkey anti-mouse IgG, Cy3-conjugated donkey anti-
guinea pig IgG and Cy3-conjugated donkey anti-goat IgG are from Jackson 
Immunoresearch, West Grove, PA; Cy5-conjugated donkey anti-rabbit IgG and 
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Cy5-conjugated donkey anti-guinea pig IgG are from Chemicon, Temetula, CA. 
For all antibodies, a 1:500–1:2000 dilution was used, depending on the amount 
of tissue on each slide. 
 
4. Generation of Myt1-/- animals 
 The targeting vector pGKNeo-DTA was a gift from A. P. McMahon (Zhang 
et al., 2001). This vector contains a pBluescript KSII backbone, a diphtheria toxin 
A subunit (DTA) sequence as a negative selection marker, and a FRT-flanked 
pGKneo gene as a positive selection marker. A genomic fragment flanking the 
third exon of Myt1a was PCR amplified, sequenced, and cloned into the FseI site 
of the vector. The primers used were: forward: 5’-aggccggccaaagattaaagtttagag-
3’ and reverse: 5’-aggccggccctaccatgccccagcttaat-3’. The template was BAC 
#519N6 in library RPCI22, purchased from Children’s Hospital of Oakland, 
Oakland, CA (Warming et al., 2005). Another 3.5kb genomic DNA fragment 3’ of 
the deleted region was PCR-amplified, sequenced and cloned between the Sal-
I–PmeI sites of the vector. The primers used were: forward: 5’-
agtttaaacgaaattagggctgggcctgt-3’ and reverse: 5’-
agtcgacgcagttttaaaatcaccctcag-3’. Finally, a 8.2kb genomic fragment 5’ of the 
deleted region, derived through BAC-based recombineering, was ligated into the 
NotI–AscI sites to complete the targeting vector construction. The oligos used for 
BAC recombineering were: 5’-
ggcgcgccctcgagtgctgagactacaggtatgcaccaccatgctctgctaaggatagaatccctccagagag
tgagtagcttcatgtagggttatcccgcggccgc-3’ and its complimentary strand. Oligos used 
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to amplify the 5’ probe were: forward: 5’-atattaggaatattaaaacttgt-3’ and reverse: 
5’ ggtcacaatgatgggcactaac-3’. Oligos used to amplify the 3’ probe: forward: 5’-
ctacataaaccttcaaggtc-3’ and reverse: 5’-gaattcaattcccagcaaccaca-3’.  
Targeted ES cells were utilized to derive chimera mice following standard 
procedure. After mouse line establishment, Flpe mice were used to delete the 
FRT-flanked pGK-Neo selection cassette, deriving the Myt1fl allele (Dymecki, 
1996). Oligos for PCR genotyping: Pr1: 5’-agatccttccagggtggagaagc-3’; Pr2: 5’-
gtctgtccagaacctattccaga-3’; Pr3: 5’-cagacttccattcccacagtt-3’. Expected DNA 
fragment lengths for the wild type, the floxed Myt1fl, and the deleted Myt1- alleles 
are 490, 380 and 340bp, respectively. Oligos for assessing the stability of mutant 
Myt1 messages: 5’-gagctatctagtcctaaacctga-3’ and 5’-ttgggaggatctcctgtctgcaa- 
3’. Expected length of wild-type fragment: 608bp, mutant fragment: 517bp. After 
RT-PCR, the intensities of the bands were quantified by using BIOQUANT true-
color windows system (R &M Biometrics, Nashville, TN). Gene targeting was 
performed by using TL1 ES cells. Three correctly targeted clones were identified 
from 219 colonies screened. Blastocyst microinjections were performed by the 
Vanderbilt Transgenic/ES Cell Shared Resource, following standard procedures. 
 
5. Intraperitoneal glucose tolerance test (IPGTT) and insulin secretion assay 
 IPGTT followed published procedure (Lammert et al., 2003). Briefly, after 
overnight fasting (~16h), mice were injected intraperitoneally with glucose at 2 
gram per kg body weight. Blood glucose levels were monitored by a compact 
glucose analyzer (BD/Medtronic MiniMed Blood Glucose Monitor) at different 
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time points after glucose administration.  
For insulin secretion assay, blood samples were taken before or 30 min 
after glucose injection from the mouse saphenous vein. Serum insulin levels 
were assayed using Elisa Assay Kit from Linco following manufacturer-
recommended protocol (St. Charles, MO).  
 
6. Islet isolation and glucose stimulated insulin secretion assay (GSIS) 
 Pancreatic islet isolation was achieved by collagenase perfusion (Gu et 
al., 2004). Batches of 10–15 similar sized hand-picked islets were incubated in 
RPMI 1640-10% fetal calf serum at 37°C for overnight. These islets were washed 
and incubated in 1 ml Krebs-Ringer Hepes-buffered saline in 2.8 mM glucose at 
37°C for 30 min and then transferred to 1 ml Krebs-Ringer Hepes-buffered saline 
in 20 mM glucose for another 30 min. Supernatants were collected for GSIS. 
Islets were extracted for total insulin assay. Insulin secretion was calculated as 
percent of insulin released within the 30 min glucose stimulation. All assays 
utilized triplicate samples.  
 
7. Confocal microscopy and statistical analysis 
 All fluorescent images in the figures were taken by confocal microscopy. 
Typically, optical sections with 0.4–0.6µm intervals were taken. A single or a 
projection of two adjacent optical sections was used for a high quality image. All 
confocal parameters were kept consistent throughout our experiments. For 
quantification, we utilized BIOQUANT true-color windows system (R & M 
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Biometrics, Nashville, TN). This system measures both cell number and 
fluorescence intensities (Zhang et al., 1997). The hormone amount quantified 
using this approach matched well with our Elisa-based total insulin or glucagon 
assay data from E18.5 embryonic pancreata. For Myt1 staining, 10–15µm frozen 
sections were used. For Glut2 expression or co-hormone expression analyses, 
4–8µm paraffin sections were used. For the quantification of co-hormone 
expressing cells at E15.5 and E18.5, adjacent 10 µm frozen sections were 
separated onto groups of three slides, with one staining for glucagon/insulin, one 
for insulin/PP and one for PP/SS. Co-stained cells were counted on optical 
sections at 6µm apart. Two optical sections from each tissue section were 
counted. All tissue sections from each E15.5 pancreas were analyzed. A third of 
the tissue sections from each E18.5 pancreas were counted. For quantification in 
adults, each pancreas was cut into 25–30 small pieces and embedded into a 
single paraffin block. One of every four 4µm sections was collected, with sets of 
three being mounted onto groups of three slides for glucagon/insulin, insulin/PP, 
and SS/PP staining respectively. Slides were then counterstained with DAPI and 
co-stained cells were scored using a Carl Zeiss Axioplan 2 fluorescence 
microscope. At least 25 sections were scored for each hormone combination in 
each pancreas. Statistical analyses utilized standard Student’s t-test. A p-value 
of 0.05 or less was considered significant. All quantification data were presented 
as (mean+standard deviation).  
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Results 
 
Myt1 is expressed in endocrine progenitors and differentiated islet cells 
Previous mRNA-based studies showed that Myt1 is specifically expressed 
in the endocrine pancreas during pancreatic development in mice (Gu et al., 
2004). To determine which endocrine cell types express Myt1, specific antibodies 
for Myt1 was developed (see “Materials and methods”).  
During embryogenesis, robust Myt1 expression could be detected in the 
developing mouse pancreas starting from E9.0, corresponding with the initiation 
of pancreatic development (Figure 2.2 A1). At E9.0, most Myt1+ cells expressed 
Pdx1 (Figure 2.2 A1&B1), suggesting their pancreatic origins. Later, Myt1 was 
detected in all of the four major endocrine cell types (α, β, δ and PP cells), but 
not in the exocrine pancreas (Figure 2.2 A3-A4, B3-B4, C1-C1 & D1-D2). 
Specifically, Myt1 was expressed in all insulin+ (ins+) cells at E10.5 (Figure 2.2 
A2). Then, the percent of ins+ cells expressing Myt1 decreased with age (E13.5: 
91.4+7.6% of ins+ cells are Myt1+; E18.5: 94.3+2.9% of ins+ cells are Myt1+; 12-
weeks: 58.6+6.7% of ins+ cells are Myt1+, n=3). The percentage of glucagon 
(glu), somatostatin (ss) and pancreatic polypeptide (PP)-expressing cells that co-
express Myt1 remained relatively constant from E10.5 to 12 weeks of age (95% 
of glu+/ss+/PP+ cells are Myt1+). These data suggest that mature β cells are a 
heterogeneous population, whereas the other types of endocrine cells are 
relatively uniform. 
Since Myt1 is specifically enriched in the Ngn3+ cell pool, the expression 
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of Myt1 in Ngn3+ endocrine progenitors was also examined (Gradwohl et al., 
2000; Gu et al., 2004; Jensen et al., 2000a; Murtaugh, 2007; Schwitzgebel et al., 
2000). Two antibodies for Ngn3, a monoclonal mouse anti-Ngn3 antibody and a 
guinea pig anti-Ngn3 antibody (Seymour et al., 2007), were utilized to examine 
whether Myt1 is expressed in Ngn3+ cells. Both antibodies revealed that Myt1 
expression partially overlapped with that of Ngn3 (Figure 2.3), suggesting that a 
portion of Myt1+ cells is endocrine progenitors at different stages (E10.5, E13.5, 
and E15.5). It seems that Myt1 expression is activated in Ngn3+ endocrine 
progenitors, and maintained in these same cells after differentiation when Ngn3 
expression is down regulated. This result was further supported by the findings 
that Myt1 expression overlapped with the expression of Isl1, MafB, Pax6 and 
MafA, which label endocrine progenitors under different commitment states or 
mature islet cell types (Figure 2.4) (see Chapter 1). 
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Figure 2.2 Myt1 is expressed in hormone-expressing endocrine cells 
in the pancreas. (A1-A4) Most ins+ cells expressed Myt1 from E10.5 to 
12 wks (12 weeks of age). Blue: Pdx1; Green: insulin; Red: Myt1. In A1, 
the pancreatic region was circled by white broken lines. Inset represented 
an E8.5 pancreatic epithelium stained for Myt1, insulin and Pdx1. (B1-B4) 
Glu+ cells maintained Myt1 expression from E9 to 12wks. Blue Pdx1; 
Green: glucagon; Red: Myt1. The white arrow in B2 and green arrow in 
B4 pointed to examples of Glu+Myt1- cells. (C1-2 &D1-2) Most ss+ and 
PP+ cells were Myt1+. Red: Myt1; Green: PP or ss. Green arrows in C2 
and D2 pointed to PP+Myt1- and ss+Myt1- cells, respectively. Scale bars: 
20μm.  
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Figure 2.3 Myt1 expression overlaps with that of Ngn3. E10.5, 
E13.5 and E15.5 pancreatic tissues were co-labeled with Myt1 and 
Ngn3 antibodies. Images in the middle column were merges of the left 
and right images. Yellow arrow: Myt1+Ngn3+ double positive cells; 
Green arrow: Ngn3+Myt1- cells; Green arrowhead: cells with low 
levels of Ngn3. Scale bars: 20µm. 
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Figure 2.4 Myt1 is co-expressed with several endocrine markers. 
Results from two stages, E13.5 and E15.5, were shown. Red: Myt1; Green: 
Isl1, MafA, MafB, and Nkx6.1. For each co-staining result, three panels 
were shown. The top and bottom panels were single staining and the 
middle panels were merged images. Yellow arrows: co-stained cells. Red or 
green arrows: cells stained only for Myt1 or other specified transcription 
factors respectively. Sacle bars: 20µm. 
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Myt1 is the only paralog expressed in the embryonic mouse pancreas 
The presence of Myt1 paralogs Myt1L and Myt3 in the mouse pancreas 
was examined. During embryonic development, Myt1L and Myt3 were detected 
in neural or glial cells within the mesenchymal tissues that surround the gut 
epithelium (Figure 2.5). However, they were not detected in the developing 
mouse pancreas by in situ hybridization at E13.5, E14.5 and E15.5 (Figure 2.5) 
(Kim et al., 1997a). Moreover, specific antibodies for Myt1L and Myt3 were 
generated to examine their expression pattern. Neither Myt1L nor Myt3 was 
detected in the developing mouse pancreas (Figure 2.11 I-L). These results 
suggest that Myt1 is the only Myt family member expressed in the developing 
pancreas, and likely involved in pancreatic development.  
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Figure 2.5. Myt1 is the only Myt family member expressed in the 
developing pancreas. (A) Myt1 was detected in the E14.5 pancreas 
by in situ hybridization. (B & C) Myt1L and Myt3 transcripts were not 
found in the E14.5 pancreas. (D & E) Myt3 was expressed in cells 
surrounding the duodenal epithelium at E13.5. Red broken lines 
circled the pancreatic regions. Black broken lines mark the duodenal 
epithelium. Scale bars: 20µm. 
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Myt1 inactivation compromises pancreatic endocrine differentiation  
To directly examine the role of Myt1 in the mouse pancreas, a conditional 
Myt1 knockout allele (Myt1fl) was derived. The 91-base-pair exon common to 
both Myt1 transcripts (#3 exon of Myt1a or #9 exon in Myt1b) was flanked with 
tandem LoxP sites to simultaneously inactivate Myt1a and Myt1b by Cre-
mediated recombination (Figure 2.1 & Fig. 2.6). The frame-shift introduced by the 
deletion in the mutant allele produced truncated Myt1a or Myt1b peptides, which 
have no similarity to any known proteins, or contain a single zinc finger, 
respectively. 
Sox2-Cre animals were used to delete the floxed exon and generate the 
loss-of-function Myt1 allele (Myt1-) in the germ line (Hayashi et al., 2002). Myt1-/- 
animals displayed no visible abnormality yet died immediately after birth. The 
diaphragms of Myt1-/- mice were not properly innervated, which may result in the 
death after birth (Figure 2.7). Because these diaphragm-related defects could be 
readily scored, we used them to determine whether the Myt1- allele has dominant 
negative effects. If the mutant Myt1 products had dominant negative effects, we 
would expect to observe abnormal diaphragm innervations or reduced viability in 
heterozygous animals. In fact, Myt1+/- diaphragms were innervated normally. To 
date, 156 wild type and 329 heterozygous but no homozygous adult animals 
were obtained. This is consistent with the Mendelian ratio, suggesting that the 
Myt1- allele does not behave in a dominant negative manner. Moreover, Myt1 
mRNA levels in wild type, Myt1+/- and Myt1-/- pancreata were analyzed by in situ 
hybridization and semi-quantitative RT-PCR. The cRNA probe, derived from the 
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full-length Myt1 cDNA (see Materials and Methods), recognized both wild type 
and mutant Myt1 mRNA. The mRNA level of the Myt1- allele was reduced by 
more than 4 folds comparing with that of the wild type Myt1 allele (Figure 2.6 D, 
E, and F), making the Myt1- allele unlikely to be a dominant negative allele.  
The expression of endocrine hormones (insulin, glucagon, ss and pp) in 
the Myt1-/- pancreas was examined at E10.5, E13.5, E15.5, and E18.5. There 
was no significant difference in the expression levels of these hormones between 
wild type and Myt1-/- pancreata, as assayed by the number of hormone+ cells 
(Figure 2.8 A1-A2), and the relative fluorescence intensity within each hormone-
expressing cell (Figure 2.8 A3-A4). The number of Ngn3+ endocrine progenitors, 
as well as the Ngn3 expression level within individual cells, did not vary as well in 
wild type, Myt1+/-and Myt1-/- pancreata at E10.5, E13.5, and E15.5 (data not 
shown). 
However, Myt1-/- pancreata contained a substantial number of endocrine 
cells co-expressing insulin and PP, or SS and PP, at all stages (Figure 2.8 B–E). 
Other hormone co-expression combinations were not found at significant 
numbers (Figure 2.8 F&G). Specifically, while less than 1.5% of PP+ cells 
expressed detectable insulin in wild type and Myt1+/- pancreata, 11.6+2.4% 
(mean + standard deviation) of PP+ cells co-expressed insulin in Myt1-/- 
pancreata at E15.5. Moreover, 19.9 + 3.1% of PP+ cells in Myt1-/- pancreata co-
expressed SS, while less than 2% of PP+ cells expressed SS in wild type and 
Myt1+/- pancreata at E15.5 (Figure 2.8 B1-3, C1-3). Similar phenotypes were also 
found at E18.5 (Figure 2.8 D1-3, E1-3). These findings suggest that Myt1 is 
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required for proper endocrine differentiation, or for differentiated cells to maintain 
specific hormone production in the mouse pancreas. 
During pancreatic development, in consistent with previous findings, 
Myt1fl/-;Pdx1-Cre pancreata contained significant numbers of ins+PP+ and PP+ss+ 
cells, in comparison with wild type pancreata at E15.5 and E18.5 (Figure 2.8 
F&G). In adults (12-week of age), the overall islet morphology remained normal 
in Myt1fl/-;Pdx1-Cre pancreata. Yet there was a significant portion of PP+ cells 
expressing either insulin or ss in Myt1fl/-;Pdx1-Cre islets. Specifically, 2.4 + 0.6% 
PP+ cells co-expressed ss in wild type islets, while 10.2 + 5.4% of PP+ cells co-
expressed ss in Myt1fl/-;Pdx1-Cre islets (n = 3, p < 0.01). Similarly, 0.2 + 0.1% of 
PP+ cells co-expressed insulin in wild type islets, whereas 4.1 + 0.6% of PP+ cells 
co-expressed insulin in Myt1fl/-;Pdx1-Cre islets (n = 3, p< 0.01). In addition, a 
significant number of glu+ins+ cells was observed in Myt1fl/-;Pdx1-Cre islets, 
accounting for 2.7 + 0.8% of total glu+ cells and distributing in 8% of islet 
sections. However, only 0.3 + 0.1% of glu+ cells expressed detectable levels of 
insulin in wild type islets, which is consistent with the previous finding that 
glucagon and insulin double positive cells (glu+ins+) can be rarely found in wild 
type pancreata (Guz et al., 1995; Herrera, 2000). 
We also examined the maturity of these double-hormone expressing cells 
in the adult Myt1fl/-;Pdx1-Cre pancreas. As insulin-expressing β cells mature, they 
activate MafA expression while down regulating MafB expression. As a result, 
adult mature β cells are MafA+MafB- (Nishimura et al., 2006). MafA was detected 
in most β cells in wild type islets, but absent in any of these ins+PP+ and glu+ins+  
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Figure 2.6 Generation of Myt1fl and Myt1- alleles. (A) Targeting 
strategy. Targeted fl allele had two LoxP sites flanking exon 3 of Myt1a 
(exon 9 of Myt1b). P1 and P2: DNA Southern blot probes. Pr1, Pr2, and 
Pr3: oligos for genotyping. (B) Southern blots of two targeted ES cell 
clones, 2G12 and 3E8. SpeI (S) digestion and blotting with P1 probe 
produced a wild type band of 14.5kb and a targeted band of 12kb. 
EcoRI (R) digestion and blotting with P2 probe resulted in a wild type 
band of 6kb and a targeted band of 7kb. (C) PCR-based genotyping 
using DNA oligos pr1, pr2, and pr3. Bands marked with ‘‘*’’ were primer 
dimmers. (D and E) Myt1 mRNA was detected by in situ hybridization in 
wild type and Myt1-/- pancreata at E13.5. cRNA was generated from a 
full-length Myt1 cDNA, which also recognized the Myt1 mutant mRNA. 
Red broken lines circled the pancreatic epithelial region. (F) Myt1 
mRNA levels in control and Myt1+/- pancreata, determined by semi-
quantitative RT-PCR. Left lane: RT (reverse transcription) products of 
RNA samples from Myt1+/- pancreata were used as templates. The 
higher and lower bands were the wild type and mutant bands, 
respectively. A comparison of the intensity of these two bands (1:3.1 
ratio as determined by BIOQUNT) revealed the relative abundance of 
the mutant and wild type mRNA. Right lane: a mix of wt and mutant 
DNA products at 1:1 molecular ratio were used as control templates, to 
show the amplification efficiency of these two fragments. Scale bars: 
20μm. 
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Figure 2.7 Diaphragms in Myt1-/- embryos are not properly 
innervated. Whole mount staining by mouse anti-β tubulin antibody. 
Images were light microscopy and confocal images (Z-stack). One 
animal of each genotype, wild type (+/+), heterozygous (+/−), and 
homozygous (−/−) was shown. (A), (B), and (C) represented the 
boxed region of the diaphragm shown in their corresponding color. 
Scale bars: 200µm. 
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Figure 2.8 Myt1-/- pancreata contain abnormal endocrine cells co-
expressing multiple hormones. (A1-4) Individual endocrine hormone 
productions were normal in Myt1−/− pancreata (E15.5 and E18.5). For 
each stage, the relative number of endocrine cells (number of cells/area 
of the pancreas) and the relative hormone expression level (artificial 
level) within each cell were shown. (B1-3 & D1-3) PP and insulin co-
staining were performed on E15.5 and E18.5 wile type, Myt1+/- and 
Myt1-/- pancreata. (C1-3 & E1-3) SS and PP co-staining were 
performed on E15.5 and E18.5 wild type, Myt1+/- and Myt1-/- pancreata. 
Yellow arrows: cells co-expressing two hormones. Yellow arrowhead: 
blood cells, which also show yellow color. Yet they can be distinguished 
from the double hormone expressing cells by their specific appearance. 
Insets in B3 and D3 showed boxed regions within each panel, split as 
green and red channels (green arrows). (F & G) The abundance of 
hormone co-expressing cells. The percentage of PP+SS+ or PP+ins+ 
cells over total PP+ cells, and the percentage of ins+glu+ cells over total 
glu+ cells were indicated in these charts. f/-;Cre refers to Myt1fl/-;Pdx1-
Cre. Ins: insulin. Glu: glucagon, ss: somatostatin, PP: pancreatic 
polypeptide. Scale bars: 20μm. 
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cells in the adult Myt1fl/-;Pdx1-Cre pancreas (Figure 2.9 A&B). Instead, most of 
the abnormal ins+ cells (19/21 ins+PP+ and 26/26 glu+ins+ cells) maintained MafB 
expression (Figure 2.9 B&D). These findings suggest that double-hormone 
positive cells, even though they express insulin, are not mature β cells. 
 
Adult Myt1fl/-;Pdx1-Cre male mice have impaired glucose tolerance and 
insulin secretion abilities 
To investigate whether loss of Myt1 compromises islet function, we 
examined the ability of adult Myt1fl/-;Pdx1-Cre mice to maintain glucose 
homeostasis. Myt1fl/-;Pdx1-Cre and wild type mice showed no difference in their 
fasting glucose levels. Yet intraperitoneal glucose tolerance test (IPGTT), a more 
sensitive assay for general islet function, revealed that Myt1fl/-;Pdx1-Cre male 
mice developed glucose intolerance starting form 6 weeks of age (Figure 2.10 A). 
Consistent with this finding, 10-week old Myt1fl/-;Pdx1-Cre males displayed 
attenuated glucose-induced insulin secretion. Thirty minutes after glucose 
challenge, serum insulin levels increased 100% in wild type male mice, but only 
increased 30% in Myt1fl/-;Pdx1-Cre male mice (Figure 2.10 B), while serum 
glucagon levels altered similarly in these animals. Moreover, Glut2 protein levels 
were significantly reduced in Myt1fl/-;Pdx1-Cre islets compared with that of wild 
type islets (Figure 2.10 C). Therefore, the attenuated insulin secretion and 
reduced Glut2 expression are likely responsible for the glucose intolerance in 
Myt1fl/-;Pdx1-Cre male mice.  
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To further confirm the above finding, glucose-stimulated insulin secretion 
assay (GSIS) was performed on isolated 7-week and 12-week old Myt1fl/-;Pdx1- 
Cre and wild type male islets (Figure 2.10 D). Seven-week-old Myt1fl/-;Pdx1-Cre 
islets displayed no statistically significant reduction in GSIS compare with wild 
type islets, in that Myt1fl/-;Pdx1-Cre males just started to become glucose 
intolerant at this stage. At 12 weeks of age, Myt1fl/-;Pdx1-Cre islets showed 
statistically significant reduction in their ability to secrete insulin under glucose 
stimulation (Figure 2.10 D). Taken together, these data suggest that Myt1 is 
required for the proper function of adult islets. 
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Figure 2.9 Insulin+ cells co-expressing PP or glucagon in adult 
Myt1fl/-;Pdx1-Cre pancreata are not mature β cells. Adult Myt1fl/-; 
Pdx1-Cre islets were co-stained with anti glucagon (glu), insulin (ins), 
PP, MafA and MafB antibodies. (A & C) Insulin and glucagon co-
expressing cells were MafA-MafB+ (yellow arrows). (B & D) Insulin and 
PP co-expressing cells were MafA-MafB+ (yellow arrows). Green arrows 
in all panels: single hormone+ cells (internal controls). Scale bars: 
10µm. 
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Figure 2.10. Adult Myt1fl/-;Pdx1-Cre male mice develop impaired 
glucose tolerance. (A) IPGTT test (Materials and methods). Six to 
nine-week-old Myt1fl/-;Pdx1-Cre male mice and wild typte littermates 
were used in this test. P-values were marked above each data points. 
(B) Glucose-induced insulin release assay (Materials and methods). 
Ten-week-old Myt1fl/-;Pdx1-Cre males and wild type littermates were 
used in this assay. The p-value was calculated based on the 
percentage of serum insulin increase of each animal, before and after 
glucose challenge. (C) Glut2 expression in 3-month-old Myt1fl/-;Pdx1-
Cre and wild type islets. Insulin staining was used to locate the islets. 
C3 and C4: red Glut2 channel in C1 and C2, respectively. White 
arrows: acinar cells that do not express Glut2. Red arrow in C2 and 
C4: blood cells. (D) GSIS in isolated islets from Myt1fl/-;Pdx1-Cre and 
wild type males at 7 and 12 weeks of age. P-values were marked 
above each data set. Scale bars: 20μm. 
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Myt1L and Myt3 are up regulated in the absence of Myt1 
Myt1-/-(or Myt1fl/-;Pdx1-Cre) pancreata with loss of Myt1 function, 
displayed mild endocrine differentiation defects during pancreatic development, 
which is a weaker phenotype than the previous dominant negative based studies 
(Gu et al., 2004). We therefore examined whether the expression of Myt1L and 
Myt3 is induced in the absence of Myt1, which may compensate for the loss of 
Myt1 function. In fact, both Myt1L and Myt3 mRNA were detected in Myt1-/-, but 
not in wild type pancreata at E13.5, E14.5 and E15.5 (Figure 2.11). Interestingly, 
only Myt3 but not Myt1L protein could be detected in Myt1-/- pancreata, 
suggesting that either Myt1L is post-transcriptionally regulated in the pancreas or 
the Myt1L protein level is too low to be detected by our current antibodies. 
Nevertheless, since Myt1, Myt1L and Myt3 share high similarities regarding their 
protein structures, it is highly possible that Myt1L and/or Myt3 activity 
compensate for the loss of Myt1 in the developing pancreas. 
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Figure 2.11. Mty1L and Myt3 are expressed in the absence of 
Myt1. (A-H) Myt1L and Myt3 transcripts were detected by in situ 
hybridization at E13.5 and E15.5. A-D: wild type pancreata; E-H: 
Myt1−/− pancreata. (I-P) Myt1L and Myt3 protein levels were examined 
by immunofluorescent staining at E17.5. I-L: wild type pancreata; M-P: 
Myt1−/− pancreata. K1 & K2: retina tissues of the same embryo were 
collected and stained at the same time. Myt1L was detected in the 
retina. White: nuclei; Green: Myt1, Blue: Myt1L; Red: Myt3. Scale bar: 
20μm.  
 
 
 
 
 
Scale bars = 20 µm. 
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Discussion  
 
The differentiation of endocrine progenitors into mature functional islet 
cells requires many signaling pathways and transcription factors. The zinc finger 
transcription factor Myt1 was previously identified as a factor that is specifically 
enriched and functioned in the endocrine pancreas (Gu et al., 2004). In this 
study, we investigated the roles of Myt1 in the pancreas via loss-of-function 
analyses. Inactivation of Myt1 partially compromises endocrine differentiation and 
islet function in mice, suggesting that Myt1 plays important roles during 
endocrine differentiation and function.  
 
Myt1 is involved in promoting monotypic production of endocrine cell 
types during pancreatic development 
Myt1 is detected in Pdx1+ pancreatic progenitor cells from the beginning of 
pancreatic development. Later, a portion of Ngn3+ endocrine progenitors, as well 
as most of the hormone-expressing endocrine cells, expresses high levels of 
Myt1.  These results suggest that Myt1 may work in Ngn3+ cells to promote 
endocrine differentiation. However, during embryogenesis, neither the number of 
Ngn3+ endocrine progenitors nor the endocrine cell mass is significantly altered 
in Myt1-/- (Myt1fl/-;Pdx1-Cre) pancreata compared with that of wild type controls. 
Instead, significant number of endocrine cell co-expressing insulin and PP 
(ins+PP+) or somatostatin and PP (ss+PP+) were found in the pancreas upon 
Myt1 inactivation, indicating Myt1 might help to maintain the cellular identity of 
 79 
differentiated endocrine cells. Two hypotheses would help to explain the 
appearance of the multi-hormone-expressing cells.  
First, it is possible that a transient PP+ endocrine progenitor pool, which 
can give rise to ins+ β cells or ss+ δ cells in adult islets, exists during endocrine 
differentiation. Ins+PP+ and ss+PP+ cells could be intermediate states of these 
PP+ endocrine progenitors while they undergo differentiation. When Myt1 is 
inactivated, the differentiation process of PP+ progenitors might be slowed down. 
In consistent with this explanation, it had been suggested that at least a portion 
of adult β cells is derived from PP-expressing progenitors (Herrera, 2000). Thus, 
Myt1 may be involved in promoting PP+ progenitors to quickly undergo 
differentiation.  
Another possible explanation is that Myt1 may be required in ins+ β or ss+ 
δ cells to suppress PP expression, or required in PP+ cells to suppress insulin 
and somatostatin expression. Because the total number of PP+ cells is not 
significantly altered between Myt1-/- and wild type pancreata, the latter situation is 
more likely the case.  A temporally controlled lineage tracing of PP+ cells may 
help to clarify these possibilities.  
 
Myt1 is important for maintaining proper islet function  
In the adult pancreas, Myt1 is highly expressed in most of the mature islet 
cells. The glucose intolerance phenotype in the Myt1fl/-;Pdx1-Cre mice was 
consistent with this hypothesis. Two reasons may contribute to these diabetic-
related phenotypes in Myt1fl/-;Pdx1-Cre animals.  
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First, the ins+ cells co-expressing PP or glucagon may interfere with the 
normal function of β cells in the adult Myt1fl/-;Pdx1-Cre pancreas. Our results 
showed that these ins+PP+ and ins+glu+ cells in adult mutant pancreata express 
immature β cell marker MafB, instead of mature β cell marker MafA, suggesting 
they are immature cells and may not function normally. Furthermore, it has been 
suggested that individual β cells of a single islet are actively communicating and 
synchronized with their neighboring cells via gap junctions and intercellular 
signals (Konstantinova et al., 2007). A small number of abnormal performing β 
cells may dominantly hinder β cell communication and cause insulin secretion 
defects and glucose intolerance (Konstantinova et al., 2007). Therefore, even 
though the abnormal insulin expressing cells only represent a small portion of 
total β cells in Myt1fl/-;Pdx1-Cre pancreata, they may significantly interfere with β 
cell function. In addition, while these ins+PP+ cells were derived during 
embryogenesis, ins+glu+ cells were only observed in significant numbers in 
adults. This result suggests that Myt1 may also function to maintain at least the 
proper identity of a portion of β cells during adulthood. 
Another possibility is that Myt1 may actively regulate the expression of 
some factors that are essential for β cell function, such as Glut2. In adult Myt1fl/-; 
Pdx1-Cre pancreata, Glut2 expression is significantly reduced compared with 
controls, suggesting that Myt1 may be required to maintain Glut2 levels in the 
adult pancreas. Alternatively, it is also possible that Glut2 reduction is just a 
consequence but not a cause of hyperglycemia in Myt1fl/-;Pdx1-Cre animals, as 
had been suggested by other groups (Thorens et al., 1990). Other factors, which 
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may potentially work downstream of Myt1 in adult islets, still remain to be 
identified.  
 
Gene compensation between Myt gene family members 
An interesting finding of our studies is the gene compensatory effects 
between three Myt gene family members. When Myt1 was deleted, Myt1L and 
Myt3, which are normally absent in the developing pancreas, were up-regulated. 
The underlying mechanisms of this phenomenon require further investigation. It 
is possible that Myt1 may negatively regulate Myt1L and Myt3 expression in a 
direct or indirect manner in wild type situation. In the absence of Myt1, the 
expression of Myt1L and Myt3 is induced. A detailed examination of Myt1 
downstream targets and Myt1L/Myt3 upstream regulators may shed light on this 
issue.  Nevertheless, whether up-regulation of Myt1L or Myt3 actually 
compensates for the loss of Myt1 function remains unclear. 
 
In summary, we showed that loss of Myt1 partially compromises both the 
endocrine differentiation and islet function in the mouse pancreas. Two paralogs 
of Myt1, Myt1L and Myt3, which are not expressed in the developing pancreas, 
are induced upon Myt1 deletion, and possibly compensate for Myt1’s function. 
Results from this study not only establish the basic role of Myt1 in the pancreas, 
but also encourage us to further investigate how Myt1 regulates endocrine 
differentiation and islet function mechanistically at the molecular level.  
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CHAPTER III 
 
Myt1 AND Ngn3 FORM A FEED-FORWARD EXPRESSION LOOP TO 
PROMOTE ENDOCRINE ISLET CELL DIFFERENTIATION 
 
This paper is published under the same title in Developmental Biology, 2008 
(Wang et al., 2008b).   
 
Abstract    
The bHLH transcription factor Neurogenin 3 (Ngn3), which marks 
pancreatic endocrine progenitors, is essential for endocrine differentiation in the 
pancreas. Our previous studies showed that Myt1 (Myelin transcription factor 1) 
is expressed in a significant portion of Ngn3+ endocrine progenitors during 
pancreatic development, suggesting it may play important roles in these 
endocrine progenitors. Here, we report that Myt1 can induce endocrine 
differentiation through enhancing Ngn3 expression in the developing mouse 
pancreas. Vice Versa, Ngn3 also induces Myt1 expression. Furthermore, a small 
number of cells expressing Myt1 and endocrine hormone glucagon were found in 
Ngn3-/- pancreata, suggesting that Myt1 can also function in an Ngn3-
independent manner. Based on these results, we propose that Myt1 can help 
Ngn3+ endocrine progenitor cells to enter endocrine differentiation pathways by 
forming a feed-forward expression loop with Ngn3 in the developing mouse 
pancreas.  
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Introduction 
The bHLH transcription factor Ngn3 is both necessary and sufficient to 
initiate endocrine differentiation, and Ngn3 expression marks the endocrine 
progenitors (Apelqvist et al., 1997; Gradwohl et al., 2000; Gu et al., 2002). 
Previously, we reported that a significant portion of Ngn3+ endocrine progenitors 
expresses Myt1 (Wang et al., 2007). This result encouraged us to further explore 
how Myt1 functions in endocrine progenitors.  
In Xenopus embryos, xMyt1 (homolog of Myt1 in Xenopus) promotes 
ectopic neuronal differentiation in an xNgnr1 (homolog of Ngn3 in Xenopus) 
dependent fashion during neurogenesis (Bellefroid et al., 1996). Intriguingly, 
while xNgnr1 over-expression alone cannot reverse the inhibitory effects of 
activated Notch signaling on neuronal differentiation, xMyt1 and xNgnr1 together 
can induce ectopic neural differentiation even in the presence of activated Notch 
signaling (Bellefroid et al., 1996). This result suggests that xMyt1 may help to 
modify the competence of xNgnr1+ cells to overcome Notch-mediated lateral 
inhibition and undergo differentiation.  
In chicken studies, Myt1 (specifically Myt1b) can induce the ectopic 
differentiation of glucagon and somatostatin-expressing endocrine cells in the 
hindgut epithelium (Gu et al., 2004). A dominant negative Myt1 (without the 
transactivation domain) significantly impairs the ability of Ngn3 to induce ectopic 
endocrine differentiation (Gu et al., 2004). Moreover, Myt1 is able to partially 
antagonize the repressive effects of activated Notch signaling on Ngn3 function 
(Ahnfelt-Ronne et al., 2007).  
 84 
These data indicate that Myt1 alone can promote the differentiation of 
various progenitor cell types, and probably does so by interacting with Ngn3 
either directly or indirectly. However, the difficulty to precisely control the timing 
and levels of ectopic gene expression, as well as the lack of loss-of-function 
assays in chicken embryos, strongly hinders our ability to understand the function 
of Myt1 in Ngn3+ endocrine progenitors. Mouse models were used here to 
determine the underlying mechanisms regarding Myt1’s ability to drive ectopic 
endocrine differentiation and its relationship with Ngn3.  
We found that over-expression of Myt1b, which is the predominantly 
expressed Myt1 isoform in the mouse pancreas, significantly induces precocious 
endocrine differentiation during embryogenesis. Moreover, the ability of Myt1b to 
induce endocrine differentiation is Ngn3-dependent. Increased Myt1b levels can 
enhance Ngn3 expression. Vise Versa, Ngn3 also induces Myt1 expression. 
Furthermore, glucagon-expressing cells were detected in Ngn3 deficient 
embryonic pancreata, most of which co-express Myt1. These findings suggest 
that Myt1 and Ngn3 form a feed-forward expression loop to promote endocrine 
differentiation in the pancreas.  
 
Materials and Methods 
 
1. Mouse strains and care 
 Mouse production and care follow standard protocols approved by the 
Vanderbilt Medical Center IACUC. For embryonic staging, the noon of vaginal 
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plug appearance was counted as embryonic day 0.5 (E0.5). For routine mouse 
embryo production, the CD1 (ICR) mouse strain was utilized (Charles River 
Laboratories, Inc., Wilmington, MA). For transgenic mouse production, B6/D2 
mice were used (Charles River Laboratories, Inc. Wilmington, MA). Subsequent 
strain maintenance and crosses utilized CD1 mice. The Pdx1tTA/+ mouse strain 
was described previously (Holland et al., 2002). Genotyping followed published 
methods.  
 
2. DNA construct and transgenic animal derivation 
 To over-express Myt1b, a mini-gene containing intron # 6 of the Myt1b 
transcript was constructed using PCR and conventional molecular cloning. The 
final construct included the full Myt1b open reading frame with minimal 5′UTR 
and 3′UTR. TetO-CMV promoter was PCR-amplified from pTRE2 (Clontech, 
Paolo Alto, CA) and inserted in front of the Myt1b minigene. A SV40 PolyA signal 
was then inserted to the 3′ end of the Myt1b minigene to complete the 
construction. A similar approach was utilized for construction of tetO-Ngn3. 
Transgenic animal production followed standard pronuclear injection method. 
Genotyping utilized PCR-based technique. For tetO-Myt1b mouse lines: 5′-
GCGTGTACGGTGGGAGGCCTATAT-3′ and 5′-ACTCTGTAAGCTTCGATGTCT 
GGA-3′. The expected fragment is 360 bp. For tetO-Ngn3 mouse lines: 5′-
GCGTGTACGGTGGGAGGCCTATAT-3′ and 5′-
GGGTGGAATTGGAACTGAGCACT-3′. The expected fragment is 300 bp.  
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3. Immunohistochemistry/immunofluorescence (IHC/IF) 
 Immunofluorescence/immunohistochemistry followed established 
protocols. Tissues were stained either as frozen sections or paraffin sections. For 
frozen sections, dissected tissues were immediately frozen in OCT and then 
sectioned. Sectioned tissues were collected onto Superfrost-plus slides, left at 
room temperature for 30 min, and fixed in 4% paraformaldehyde at room 
temperature for 20 min. Slides were washed in PBS, permealized in 0.2% triton 
X-100, and immunostained. For paraffin sections, tissues were fixed in 4% 
paraformaldehyde overnight at 4 °C or 4 h at room temperature. Dehydration and 
section followed routine procedures. Primary antibodies used were: guinea pig 
anti-glucagon (Dako, Carpinteria, CA), Rabbit anti-MafB, gifts from R. Stein 
(Matsuoka et al., 2004), goat anti-Pdx1, a gift from C. V. Wright, guinea pig anti-
Ngn3, a gift from M. Sander (Seymour et al., 2007), rabbit anti-Ngn3 (Gu et al., 
2002), rabbit anti-Myt1 (Wang et al., 2007), mouse anti-Nkx6.1, mouse anti-Pax6 
(Development Hybridoma Bank, University of Iowa, Iowa, IA) and rabbit anti-
PC1/3 (Chemicon, Temetula, CA). Secondary antibodies used were: FITC-
conjugated donkey anti-rabbit IgG; Cy3-conjugated donkey anti-rabbit IgG, Cy3-
conjugated donkey anti-mouse IgG, Cy3-conjugated donkey anti-guinea pig IgG, 
Cy3-conjugated donkey anti-goat, and Cy5-conjugated donkey anti-rabbit 
(Jackson Immunoresearch, West Grove, PA). All antibodies utilized 1:500–
1:2000 dilutions.  
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4. Microscopy and statistical analysis 
 All fluorescent images were obtained by confocal microscopy. For 
quantification of glucagon expression and Myt1b ectopic expression, samples 
were frozen, sectioned at 15µm intervals, and stained for hormone and 
transcription factor expression. Confocal optical sections were taken at 0.4–
0.6µm intervals on all stained tissues. For Myt1b level estimation in each cell, all 
optical sections for individual nucleus are projected to one picture. The 
fluorescence intensity within each nucleus was then compared using BIOQUANT 
true color windows system (R&M Biometrics, Nashville, TN). For quantification of 
Nkx6.1 and MafB expression, paraffin-sections at 6µm intervals were utilized. In 
this case, only one optical section of each tissue section was counted. Statistical 
analyses utilized standard student t-test. P-values of 0.05 or less were 
considered as significant. All quantification data are presented as the mean ± 
standard error over the mean.  
 
Results 
 
Derivation of transgenic mouse lines that express Myt1b in a tTA-
dependent manner 
To address whether Myt1 is sufficient to induce pancreatic endocrine 
differentiation, well-established inducible Tet-Off system was used to over-
express the predominant Myt1 isoform Myt1b in pancreatic progenitor cells 
(Berens and Hillen, 2003; Gossen et al., 1994). Specifically, transgenic mouse 
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lines that express Myt1b under a TetO-CMV synthetic promoter was generated, 
and termed Myt1tet for simplicity (Figure 3.1 A2). Myt1tet can only be activated in 
the presence of the transactivator tTA when tetracycline or doxycycline (Dox) is 
not provided (Gossen et al., 1994). The advantage of using this approach is that 
it can avoid the possible lethality caused by ectopic Myt1b over-expression in 
pancreatic cells and allow for the derivation of stable mouse lines. A knock in 
mouse line expressing tTA under the Pdx1 promoter (Pdx1tTA/+) was utilized to 
induce Myt1b expression in pancreatic progenitor cells (Figure 3.1A1) (Holland et 
al., 2002). Compound Myt1tet;Pdx1tTA/+ animals were expected to ectopically 
express Myt1b in most, if not all, of the Pdx1+ pancreatic progenitors . 
Seven Myt1tet independent transgenic mouse lines were derived through 
pronuclear injection. As expected, none of these lines ectopically expressed the 
transgene in the absence of tTA proteins. One of these Myt1tet lines, Myt1tet2, 
when combined with Pdx1tTA/+ (Myt1tet2;Pdx1tTA/+, without Dox), produced Myt1 
protein in 20.5±9.5% (n=6) of Pdx1+ cells in E10.5 mouse pancreata, whereas 
only 7.3±0.8% (n=5) of Pdx1+ cells expressed detectable levels of Myt1 in 
Pdx1tTA/+ controls, which showed no difference in comparison with wild type (WT) 
(Figure 3.1 B1-2). Moreover, Myt1 was produced at comparable levels in 
Myt1tet2;Pdx1tTA/+ and Pdx1tTA/+ pancreata on per cell basis, as judged by 
fluorescence intensity within each nuclei during side-by-side 
immunofluorescence staining (Figure 3.1 B1-2 & Materials and Methods). The 
Myt1tet2 line, which showed the highest over-expression efficiency compared with 
the other six lines, was therefore used in all the following experiments. 
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Myt1tet2 was also crossed into a homozygous Pdx1tTA/tTA background, in 
which no functional Pdx1 protein exists, but higher levels of tTA were expected. 
In the Myt1tet2;Pdx1tTA/tTA pancreas, Myt1 was ectopically expressed in most, if 
not all, of the cells in the pancreatic epithelium, suggesting that a higher Myt1 
production can be achieved by increasing tTA levels (Figure 3.1 B3-4).  
In addition, we examined whether the Myt1tet2 transgene could be 
activated at different developmental stages by controlling the availability of Dox. 
Myt1tet2;Pdx1tTA/+ embryos were exposed to Dox (Dox was added into the 
drinking water of pregnant females) starting from E7.5, right before the initiation 
of pancreatic development to repress tTA function. Dox was then withdrawn from 
the embryos to allow for the activation of the Myt1tet2 transgene at E12.5 or 
E18.5. The expression of Myt1 in Myt1tet2;Pdx1tTA/+ and Pdx1tTA/+ control 
pancreata was examined and compared at E15.5 or postnatal day 1 (P1), 
respectively. Other than a few differentiated islet cells expressing higher levels of 
Myt1, there was no significant difference between Myt1tet2;Pdx1tTA/+ and Pdx1tTA/+ 
controls regarding the percentage of Pdx1+ cells that express Myt1. Thus, the low 
efficiency of our over-expression system prevented us from studying the effects 
of Myt1b over-expression in a temporally controlled manner.  
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Figure 3.1 Derivation of transgenic mouse lines that ectopically 
express Myt1b. (A1) The published Pdx1tTA allele (Holland et al., 
2002). tTA was inserted into the Pdx1 locus. This allele therefore 
equaled to a Pdx1- allele. In the absence of Dox (Doxycycline), tTA can 
bind the teto operator sequence, and activate gene transcription. When 
Dox is added into the system, it bind to tTA and prevents tTA from 
behaving as a transactivator. (A2) The structure of the Myt1tet 
transgene. The expression of Myt1b was driven by the CMV promoter, 
which is under the control of the tetO operator sequence. (A3) The 
structure of the Ngn3tet transgene.  (B) Pancreatic Myt1b expression at 
E10.5. Pdx1tTA/+ pancreata (label as tTA/+, B1), which showed identical 
Myt1 expression pattern as WT, and Pdx1tTA/tTA (label as tTA/tTA, B3) 
pancreata were used as controls. The presence of Myt1tet2 (label as 
Myt1b, B2&B4) led to Myt1b ectopic expression in the absence of Dox. 
Pdx1 (green) or glucagon staining (green) were used to mark the 
pancreatic regions. Note that Myt1 antibodies only stain frozen, lightly 
fixed sections, on which the Pdx1 signal appeared diffuse. 
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Myt1b is sufficient to induce endocrine differentiation in pancreatic cells 
Myt1tet2;Pdx1tTA/+ animals were derived via standard genetic crosses in the 
absence of Dox, which allows for the ectopic expression of Myt1b in pancreatic 
progenitors as soon as Pdx1 expression is activated at around E8.5 (Holland et 
al., 2002). Major hormone expression (insulin, glucagon, somatostatin and PP) 
was examined to determine whether Myt1b is sufficient to induce endocrine 
differentiation at early stages (E10.5 and E11.5), when glucagon-expressing cells 
are the dominant endocrine subtypes produced under normal conditions. In 
Myt1tet2;Pdx1tTA/+ pancreata, the number of glucagon+ cells, but not other 
endocrine cell types, was significantly increased compared with that of Pdx1tTA/+ 
pancreata at E11.5 (Figure 3.2 A). This phenotype caused by ectopic Myt1b 
expression is similar to that induced by ectopic Ngn3 over-expression, 
suggesting that additional factors other than Myt1b and Ngn3 are necessary for 
the induction of other endocrine cell types (Schwitzgebel et al., 2000).  
At later stages (E15.5 & E18.5), the number of hormone expressing 
endocrine cells produced in Myt1tet2;Pdx1tTA/+ pancreata was comparable with 
that in Pdx1tTA/+ controls. This is consistent with the finding that ectopic Myt1b 
expression can not be achieved at stages later than E13.5, which makes it 
impossible to determine whether Myt1b is sufficient to induce endocrine 
differentiation at later developmental stages.  
We also examined whether Myt1b can induce endocrine differentiation in 
a Pdx1-independent manner by examining Myt1tet2;Pdx1tTA/tTA  and control 
Pdx1tTA/tTA pancreata. The number of glucagon+ cells increased about 1.8 fold in 
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Myt1tet2;Pdx1tTA/tTA pancreata compared with Pdx1tTA/tTA controls at E11.5 (Figure 
3.2 A, D&E), suggesting that Myt1b is sufficient to induce endocrine 
differentiation in the absence of Pdx1.  
Unlike endodermal cells that ectopically expressing Ngn3, which largely 
differentiated into endocrine cells, only about half of the Myt1+ cells (n=6) in the 
Myt1tet2;Pdx1tTA/tTA pancreas activated glucagon expression (Figure 3.2 B-E) 
(Apelqvist et al., 1999) (Schwitzgebel et al., 2000). By E18.5, glucagon+ cells 
could rarely be detected in Myt1tet2;Pdx1tTA/tTA pancreata. This finding indicates 
that without Pdx1-dependent cell expansion or survival, early glucagon+ cells 
may have died or have trans-differentiated into other cell types, possibly due to 
the lack of paracrine signals produced by Pdx1+ cells or other unknown reasons 
(Jonsson et al., 1994; Offield et al., 1996). 
 
 
Myt1b-induced glucagon-expressing cells express immature α cell markers 
During pancreatic development, the endocrine cells produced from E9.0 to 
E12.5 are mostly glucagon-expressing α cells (Jensen et al., 2000a). It had been 
suggested that these cells might not significantly contribute to the adult islet pool, 
in that their production does not require Pdx1 activity (Herrera, 2000) (Offield et 
al., 1996). Moreover, they express Prohormone Convertase 1/3 (PC1/3), which is 
not maintained in mature adult α cells (Wilson et al., 2002). These early 
glucagon-expressing cells are therefore generally considered as immature α 
cells. 
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Figure 3.2 Ectopic Myt1b expression induces glucagon 
expression. (A) The relative number (mean ± S.E.M.) of glucagon-
expressing cells in E11.5 pancreata (tTA/+: Pdx1tTA/+. Myt1b;tTA/+: 
Myt1tet2;Pdx1tTA/+. tTA/tTA: Pdx1tTA/tTA. Myt1b;tTA/tTA: 
Myt1tet2;Pdx1tTA/tTA). (B–E) Myt1 and glucagon production in 
representative sections of E11.5 pancreata. Scale bars: 20µm. 
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To determine whether Myt1b-induced glucagon-expressing cells are 
mature α cells, the expression of PC1/3 and other known α cell markers, 
including MafB and Nkx6.1, was carefully examined (Artner et al., 2007; 
Henseleit et al., 2005; Wilson et al., 2002). Most, if not all, glucagon-expressing 
cells in the Myt1tet2;Pdx1tTA/tTA or Myt1tet2;Pdx1tTA/+ pancreas expressed PC1/3 
and MafB at E11.5 (Figure 3.3), suggesting that Myt1b over-expression is 
sufficient to activate MafB expression but fails to induce mature α cells. 
Interestingly, there was a 273±160% increase of the number of Nkx6.1+ cells in 
the Myt1tet;Pdx1tTA/tTA pancreas over that of Pdx1tTA/tTA controls (Figure 3.4). 
Nkx6.1/Nkx6.2 were reported to be required for strong Myt1 expression and α 
cell differentiation (Henseleit et al., 2005). Thus, it is highly possible that a 
feedback activation link between Myt1 and Nkx6.1/Nkx6.2 transcription factors 
exists in the developing pancreas. This hypothesis is also consistent with the 
finding that Nkx6.1 expression is maintained in glucagon expressing cells in 
Pdx1−/− pancreata (Pedersen et al., 2005). 
 
Myt1b induces endocrine differentiation through Ngn3 
Ngn3, which is well accepted as a pancreatic endocrine progenitor 
marker, is both necessary and sufficient for endocrine differentiation in the 
mouse pancreas. We examined whether Myt1b induced endocrine differentiation 
is dependent on Ngn3.  
A targeted conditional Ngn3 allele, which has the Ngn3 coding region 
flanked by two LoxP sites to potentially produce an Ngn3 null allele, had been 
generated in the lab (Figure 3.5 A-C). Myt1tet2;Pdx1tTA/tTA;Ngn3−/− embryos were 
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Figure 3.3 Myt1b induced glucagon-expressing cells express 
PC1/3 and MafB. (A) Co-expression of glucagon and PC1/3 in E12.5 
pancreata.  (B) Co-expression of MafB and glucagon in E12.5 
pancreata. tTA/+: Pdx1tTA/+. Myt1b;tTA/+: Myt1tet2;Pdx1tTA/+. tTA/tTA: 
Pdx1tTA/tTA. Myt1b;tTA/tTA: Myt1tet2;Pdx1tTA/tTA. White arrows: blood 
cells. Scales bar: 20µm. 
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Figure 3.4 Myt1b induced glucagon-expressing cells express 
Nkx6.1. tTA/+: Pdx1tTA/+. Myt1b;tTA/+: Myt1tet2;Pdx1tTA/+. tTA/tTA: 
Pdx1tTA/tTA. Myt1b;tTA/tTA: Myt1tet2;Pdx1tTA/tTA. Scales bar: 20 µm. 
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obtained, in which Myt1b was ectopically expressed in the Ngn3 nullizygous 
background. Compared with Myt1tet2;Pdx1tTA/tTA controls, almost no glucagon-
expressing cells were induced by Myt1b in Myt1tet2;Pdx1tTA/tTA;Ngn3−/− pancreata 
(Figure 3.5 D1-2). This result not only provided strong genetic evidence that 
Ngn3 is required for Myt1b-induced endocrine differentiation, but also 
encouraged us to investigate whether Myt1 induces endocrine differentiation by 
activating Ngn3 expression.  
Ngn3 expression was examined in Myt1tet2;Pdx1tTA/tTA, Pdx1tTA/tTA, 
Myt1tet2;Pdx1tTA/+ and Pdx1tTA/+ pancreata. At E10.25, the number of Ngn3+ cells 
in Myt1tet2;Pdx1tTA/+ pancreata increased by 136±22% (n=3) over that of Pdx1tTA/+ 
controls. Enhanced Ngn3 expression was observed in Myt1tet2;Pdx1tTA/tTA 
pancreata as well. At E9.5, Myt1tet2;Pdx1tTA/tTA pancreata contained visibly more 
Ngn3+ cells than Pdx1tTA/tTA controls (Figure 3.5 E1-4). At E10.25, Pdx1tTA/tTA 
pancreata produced no more than two Ngn3+ cells (n=10), yet Myt1tet2;Pdx1tTA/tTA 
pancreata produced an average of 12 Ngn3+ cells per pancreas (n=10). These 
data suggest that Myt1b promotes endocrine differentiation by enhancing Ngn3 
expression, even in the absence of Pdx1.  
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Figure 3.5 Myt1b induces glucagon expression through Ngn3. (A, 
B&C) The production and genotyping strategies of a novel Ngn3 null 
allele (Ngn3−). (A) The structure of the Ngn3 wild type, floxed (Ngn3F) 
and null alleles. A PmeI site was introduced into the 5′ end of the Ngn3 
coding cDNA in the Ngn3F allele. Note that the Ngn3− allele produced 
CreER™, a feature that was not used in this study. The numbers (45, 
722, and 723) and small arrows indicated the position of oligos used for 
PCR-based genotyping. (B) Southern blot identified four targeted ES cell 
clones, producing a 8.1 kb wild type and a 6.4 kb mutant band when 
digested with XbaI + PmeI and blotted with P1 probe. (C) Genotyping 
results with 722+723 and 722+45 primers. (D1-2). Myt1b-induced 
glucagon expression in pancreata with or without Ngn3 at E12.5. Note 
the rare glucagon+ cells (green, white arrowhead) in the Ngn3−/− 
background. Red: Myt1; green: glucagon. (E1-4) Ngn3 production in 
pancreata ectopically expressing Myt1b. Two stages, E9.5 (E1-2) and 
E10.25 (E3-4), were shown. Note the presence of glucagon+Ngn3+ cells 
(white arrows) in pancreata with ectopic Myt1b expression. Red: Ngn3; 
green: glucagon. tTA/tTA: Pdx1tTA/tTA. Myt1b;tTA/tTA: Myt1tet2;Pdx1tTA/tTA. 
Scales bar: 20µm. 
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Ngn3 induces Myt1 expression 
Previous Xenopus studies have suggested that xNgnr1 (homolog of Ngn3) 
positively regulates Myt1 expression (Bellefroid et al., 1996). We therefore 
checked whether Ngn3 could activate Myt1 expression in the mouse pancreas.  
The same strategy was used to ectopically over-expressing Ngn3 in Pdx1+ 
pancreatic progenitor cells (Figure 3.1 A3). Seven Ngn3tet transgenic lines were 
obtained and showed wide spread ectopic Ngn3 expression when combined with 
the Pdx1tTA allele. Consistent with published data, ectopic Ngn3 expression 
induced precocious differentiation of glucagon-expressing cells after E11.5 in 
Ngn3tet;Pdx1tTA/+ pancreata (Schwitzgebel et al., 2000). Moreover, most of the 
Ngn3+ cells in the Ngn3tet;Pdx1tTA/+ pancreas appeared to have delaminated from 
the epithelium, as had been reported in previous findings that Ngn3 could induce 
epithelial-to-mesenchymal transition (Ahnfelt-Ronne et al., 2007; Apelqvist et al., 
1999; Grapin-Botton et al., 2001; Schwitzgebel et al., 2000). One of the 
transgenic lines, Ngn3tet8, that produced Ngn3 protein in a comparable level to 
that of wild type littermates on a per cell basis, was used in the following studies 
(Figure 3.6 A&B).  
In the Ngn3tet8;Pdx1tTA/+ pancreas, where Ngn3 was ectopically expressed 
in most, if not all, of the Pdx1+ pancreatic progenitors at early embryonic stages, 
Myt1 production was dramatically increased (Figure 3.6 C&D). Consistent with 
this observation, we found that Ngn3 can also directly activate Myt1 promoter in 
different cell lines in vitro (Wang et al., 2008b). These results suggest that Ngn3 
induces Myt1 expression in the developing mouse pancreas. 
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Myt1b expression is largely but not totally dependent on Ngn3 
We examined whether endogenous Myt1 expression depends on Ngn3. 
Myt1+ cells were detected at various developmental stages (E10.5, E12.5,  
E13.5, and E15.5) in Ngn3-/- pancreata (Figure 3.7). A portion of these Myt1+cells 
co-expressed glucagon and MafB, indicating they are pancreatic rather than 
neuronal cells. After E15.5, Pdx1+Myt1+ cells could still be detected, even though 
no glucagon+ cells was found in Ngn3-/- pancreata. 
At all stages examined, the number of Myt1+ cells represented less than 
5% of that in WT littermates. Thus, Myt1 expression is largely, but not totally, 
dependent on Ngn3. At present, we do not know whether the emergence of 
these Myt1+ cells depends on the activation of Ngn3 homologs, Ngn1 and Ngn2, 
in the absence of Ngn3 (Sommer et al., 1996). 
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Figure 3.6 Ngn3 induces Myt1 expression. (A, B) Ngn3 expression in 
Pdx1tTA/+ (A, labeled as tTA/+) and Ngn3tet8;Pdx1tTA/+ (B, labeled as 
Ngn3;tTA/+) pancreata at E9.5. White broken lines highlighted the 
pancreatic region. Green: Ngn3; Red: Pdx1. Note the apparent 
thickening of pancreatic epithelium in B. Scales bar: 20 µm. (C, D) Myt1 
and Ngn3 expression in Pdx1tTA/+ (C, labeled as tTA/+) and 
Ngn3tet8;Pdx1tTA/+ (D, labeled as Ngn3;tTA/+) pancreata at E10.5. Red: 
Myt1; Green: Ngn3. Scale bars: 10µm.  
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Figure 3.7 The Ngn3−/− pancreas maintains Myt1 and glucagon 
expression. (A–C, E-G) Myt1 and glucagon expression in  
 Ngn3−/− and WT pancreata, respectively, at E10.5, E12.5 and E13.5. 
(D, H) MafB and glucagon expression in Ngn3−/− and WT pancreata 
at E12.5. White arrows: glucagon+Myt1+ cells in Ngn3−/− pancreata. 
Scales bars: 10μm. 
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Discussion 
It is well established that activated Notch signaling pathway directly 
represses Ngn3 expression in pancreatic progenitors (Chapter 1). However, it is 
less clear how Ngn3 levels are up regulated to allow for endocrine differentiation 
after the pancreatic cells are released from Notch repression. The finding that 
Ngn3 can repress its own transcription makes the situation even more 
complicated (Smith et al., 2004). While this self-inhibitory loop helps to explain 
the transient nature of Ngn3 expression, it prevents the cells from accumulating 
high levels of Ngn3. Additional signals or factors are necessary to increase Ngn3 
levels in endocrine progenitors. Several signaling pathways and transcription 
factors have been revealed to promote Ngn3 expression and activity in the 
pancreas (Chapter 1). 
  Here, we report that Myt1 helps to promote endocrine differentiation by 
forming a feed-forward expression loop with Ngn3. It is likely that a slight 
stochastic difference in Notch activity initiates Myt1 and Ngn3 expression in 
putative endocrine progenitors. These two factors then positively promote each 
other’s expression to ensure robust Ngn3 production and endocrine 
differentiation.  
This model is largely but not completely consistent with previous Xenopus 
studies. In Xenopus, xMyt1 (homolog of Myt1 in Xenopus) and xNgnr1 (homolog 
of Ngn3 in Xenopus) can induce neuronal differentiation individually. However, 
even though xNgnr1 positively regulates xMyt1 expression, the expression of 
xNgnr1 is not noticeably affected by xMyt1 ectopic expression. It seems that 
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xMyt1 works downstream of xNgnr1 to interfere with Notch-mediated repression 
and promote neuronal differentiation in Xenopus (Bellefroid et al., 1996). More 
interestingly, even though over-expression of xNgnr1 under an exogenous 
promoter cannot antagonize the inhibitory effects of activated Notch signaling, 
xMyt1 and xNgnr1 together can overcome Notch-mediated repression on 
neuronal differentiation (Bellefroid et al., 1996). These results suggest that 
xNgnr1 is not the only Notch target required for neuronal differentiation. xMyt1 
may be directly regulated by Notch in an xNgnr1 independent way, which is 
consistent with our finding that Myt1 expression is not totally dependent on Ngn3 
in the mouse pancreas. It would be intriguing to examine whether Myt1 and Ngn3 
together can bypass Notch-mediated inhibition in the mouse pancreas.  
Taken together, these studies suggest that the feed-forward expression 
loop formed by Myt1 and Ngn3 may play essential roles during development. The 
mechanism underlying this feed-forward expression loop is still unclear. It is 
highly possible that Ngn3 directly binds to the Myt1 promoter and increases Myt1 
expression (Wang et al., 2008b). Myt1 may enhance Ngn3 expression in an 
indirect manner in that Myt1b ectopic expression only moderately increases the 
number of Ngn3+ cells. Careful examination of Myt1 and Ngn3 promoters for 
consensus binding sites may be necessary to finally address this question.  
Only a portion of ectopic Myt1+ cells becomes hormone positive cells in 
the developing mouse pancreas. Therefore, Myt1 is not as efficient as Ngn3 in 
promoting endocrine differentiation, since ectopic Ngn3 expression drives most, if 
not all, of pancreatic progenitor cells to an endocrine fate. Combining the fact that 
 106 
endocrine cells with moderate Ngn3 levels often express high levels of Myt1, it is 
highly possible that Myt1 promotes the cells with low levels of Ngn3 to undergo 
endocrine differentiation. It would be interesting to examine whether ectopic 
expression of Myt1 could further promote endocrine differentiation in a 
background with reduced Ngn3 dosage, for example in Ngn3+/- pancreata.  
 
In summary, our studies suggest that Myt1 and Ngn3 form a feed-forward 
expression loop to promote endocrine differentiation. This mechanism may act to 
facilitate the Ngn3-mediated endocrine differentiation during embryogenesis and 
ensure the proper function of islets in adults.  
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CHAPTER IV 
 
REDUCED Ngn3 DOSAGE IMPAIRS ENDOCRINE ISLET DIFFERENTIATION 
AND FUNCTION IN THE PANCREAS  
 
Abstract 
 
  The Basic Helix-loop-Helix transcription factor Neurogenin3 (Ngn3) 
actively initiates the endocrine differentiation program in the mouse pancreas. 
Many signaling pathways and transcription factors are involved in regulating 
Ngn3 levels and activities. However, it remains largely unknown whether the 
level of Ngn3 in endocrine progenitor cells affects endocrine differentiation. To 
directly address this issue, we manipulated Ngn3 expression levels in endocrine 
progenitor cells without altering its expression pattern using heterozygosity and a 
hypomorphic Ngn3 allele. Reduced Ngn3 levels significantly decreased the 
number of endocrine cells generated in the pancreas during embryogenesis, 
resulting in poor glucose tolerance during adulthood. Detailed gene expression 
analysis showed that in the progenitor cells with low Ngn3 levels, a small portion 
of Ngn3-dependent endocrine genes could be activated, but the endocrine 
differentiation program failed to complete. As a result, a significant portion of 
Ngn3+ cells adopted the exocrine fate with reduced Ngn3 dosage. These results 
demonstrate that sufficient levels of Ngn3 are necessary for endocrine 
progenitors to accomplish the endocrine differentiation program and become 
functional hormone-expressing endocrine islet cells.  
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Introduction 
Ngn3, among many other signals/factors, is the core regulator of 
endocrine differentiation. To this end, Ngn3 is both necessary and sufficient for 
initiating endocrine differentiation in pancreatic progenitor cells by controlling the 
expression of many genes that are essential for endocrine differentiation, such as 
Nkx2.2, Pax4, IA-1 and NeuroD (Gierl et al., 2006; Gradwohl et al., 2000; 
Mellitzer et al., 2006; Naya et al., 1997; Oliver-Krasinski and Stoffers, 2008; 
Schwitzgebel et al., 2000; Sosa-Pineda et al., 1997; Sussel et al., 1998; Wang et 
al., 2004; Watada, 2004). Moreover, ectopic expression of Ngn3, alone or 
together with other genes, can convert differentiated pancreatic exocrine cells or 
determined liver cells into insulin-producing cells, indicating the potential 
application of Ngn3 in diabetes therapies (Yechoor et al., 2009; Zhou et al., 
2008). These findings highlight the importance of understanding how Ngn3 
expression is regulated in the pancreas.  
Ngn3+ cells emerge from the seemingly equivalent pancreatic epithelium 
in a scattered fashion (Murtaugh, 2007). Previous studies have suggested that 
Ngn3+ endocrine progenitors are selected by Notch-mediated lateral inhibition. 
Similar to neurogenesis, stochastic events or cell division induced asymmetries 
may cause variations in Notch signaling strength and Ngn3 levels. The latter is 
directly repressed by activated Notch signaling in a portion of pancreatic 
progenitors. Possibly by up-regulating Notch ligand levels, the pancreatic cells 
with slightly higher levels of Ngn3 inhibit their neighbors from up-regulating Ngn3, 
and consequently receive less Notch signaling and further increase their own 
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Ngn3 levels (Beatus and Lendahl, 1998; Skipper and Lewis, 2000). Eventually, 
the cells that accumulated sufficient levels of Ngn3 in a restricted developing time 
window adopt endocrine fates and initiate endocrine differentiation. Even though 
many details of the lateral inhibition model remain to be verified in the developing 
pancreas, it suggests that Ngn3 levels in pancreatic progenitors change 
dynamically. The cells with sufficient Ngn3 proteins may enter the endocrine 
lineage.  
In addition to being repressed by Notch signaling, Ngn3 expression is also 
repressed by itself (Smith et al., 2004). On the other hand, activin and FGF 
signaling from the mesenchyme adjacent to the pancreatic epithelium, and many 
intrinsic transcription factors, such as Myt1, Hnf6, Pdx1, Hnf1a and Foxa2, 
positively regulate Ngn3 expression (Jacquemin et al., 2000; Lee et al., 2001; 
Murtaugh, 2007; Wang et al., 2008b; Watada, 2004). It is therefore intriguing to 
understand whether the level of Ngn3 in endocrine progenitor cells is important 
for endocrine differentiation. 
To directly address this issue, we reduced Ngn3 levels in the mouse 
pancreas by manipulating Ngn3 gene dosage. A lower level of Ngn3 in 
pancreatic cells could activate many Ngn3 downstream targets to low levels, but 
was not sufficient to produce end-stage hormone-expressing endocrine cells. As 
a result, a subset of Ngn3+ cells, probably those expressing very low levels of 
Ngn3, were allocated to exocrine rather than endocrine fates. Animals with 
reduced Ngn3 levels contained less endocrine mass in postnatal life and 
developed glucose intolerance during adulthood. These results suggest that 
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Ngn3 levels are important for pancreatic cells to enter the endocrine lineage and 
differentiate into functional hormone-expressing islet cells.  
 
Materials and Methods 
 
1. Mouse strains and care 
Mouse production and care followed protocols approved by the Vanderbilt 
Medical Center IACUC.  The noon of vaginal plug appearance was counted as 
embryonic day 0.5 (E0.5).  Routine mouse embryo production utilized CD1 mice 
(Charles River Laboratories, Inc.  Wilmington, MA).  The Ngn3F and Ngn3- mouse 
strains were described in Chapter 3. Ngn3TgBAC-Cre is a generous gift from A. 
Leiter (Schonhoff et al., 2004). R26REYFP is a gift from F. Costantini (Srinivas et 
al., 2001). Genotyping followed published methods with minor modification. 
 
2. Immunohistochemistry/immunofluorescence (IHC/IF) 
Immunofluorescence/immunohistochemistry followed established 
protocols. Tissues were stained either as frozen sections or paraffin sections.  
For frozen sections, dissected tissues were immediately frozen in OCT and 
sectioned on the day of staining. Primary antibodies used were: guinea pig anti-
glucagon, guinea pig anti-insulin, guinea pig anti-PP, and rabbit anti-SS (Dako, 
Carpinteria, CA), rabbit anti-MafB, a gift from R. Stein (Matsuoka et al., 2004), 
goat anti-Pdx1, a gift from C. Wright, rabbit anti-Ngn3 (Gu et al., 2002), mouse 
anti-Nkx6.1 (Development Hybridoma Bank, University of Iowa, Iowa, IA), rat 
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anti-BrdU (BU1/75) (ABCam, Cambridge, MA), mouse anti-mouse alpha tubulin 
and Dolichos Biflorus Agglutinin (DBA) (Sigma Aldrich, St Louis, MI).  Secondary 
antibodies used were: Cy3- conjugated donkey anti-rabbit IgG, Cy3-conjugated 
donkey anti-mouse IgG, FITC-conjugated donkey anti-guinea pig IgG, Cy3-
conjugated donkey anti-goat, Cy5- conjugated donkey anti-guinea pig IgG and 
Cy5-conjugated donkey anti-rabbit (Jackson Immunoresearch, West Grove, PA). 
All antibodies utilized 1:500-1:2000 dilutions, depending on the amount of tissue 
on each slide. Antigen retrieval (pH6.0 citrate buffer) was used for recognition of 
Nkx6.1 and MafB (only for paraffin sections). 
 
3. Assays and quantification 
 Intraperitoneal glucose tolerance test (IPGTT), serum insulin assays, and 
Insulin secretion from isolated islets were performed as described in Chapter 2 
(Wang et al., 2007). Western blot utilized α-tubulin as loading control. Twenty or 
10 µg of total protein was loaded for each lane.  
In order to assay islet mass, pancreata of each stage were weighted, fixed 
and prepared as 6µm paraffin sections. One of every 10 sections was collected 
and stained with a mix of antibodies against insulin, glucagon, PP, and SS 
respectively as HRP signals. Slides were counter-stained with hematoxylin. 
Sections were then scanned by Ariol SL-50 (Genetix, Hampshire, UK) for 
quantitative IHC Analysis to calculate the ratio of the stained endocrine areas 
over that of the total pancreas. Islet mass was calculated based on the 
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endocrine/exocrine ratio and the pancreas weight. For each genotype and stage, 
at least four individual pancreata were analyzed.  
In order to examine the mitotic index, animals were injected IP with 
multiple doses of BrdU (at 50mg/Kg body weight). For P1 animals, two doses at 
2-hour interval were injected. For P10 animals, 4 doses at 2-hour interval were 
injected. Pancreata were then collected 2 hours after the last BrdU injection, and 
prepared as paraffin sections to assay for BrdU+ cells, which were visualized by 
immunofluorescence and confocal imaging. Multiple images/sections from each 
pancreas were counted to obtain representative labeling index.  
To count the number of pancreatic cells derived from Ngn3TgBAC-Cre-
expressing progenitors, pancreata were fixed in 4% paraformaldehyde overnight 
(at 4 °C). The pancreata were then prepared as frozen sections and stained with 
antibodies against all hormones (as blue fluorescence) and DBA (as red 
fluorescence). Confocal images were captured for cell counting.  For each 
pancreas, ¼ of all sections were examined.   
All statistical analyses utilized standard student t-test. P-values less than 
0.05 were considered significant. Quantification data were presented as the 
mean ± standard error over the mean. 
 
4. Microscopy 
Confocal microscopy was utilized to visualize fluorescent signals. When 
protein production levels were compared, samples were processed side by side 
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and images were captured using identical confocal parameters. In order to 
estimate the Ngn3 expression level in individual nuclei, Z-sections (1 µm apart) 
were projected onto a single plane for side-by-side comparison.   
 
5. Real time QRT-PCR 
For assays of mRNA levels, whole pancreata were used for RNA 
preparation. Two duplicate cDNA preparations and four QRT-PCR reactions were 
analyzed for each RNA preparation. For each genotype, three independent 
batches of embryos were processed independently. Reverse-transcription PCR 
(RT-PCR) followed standard protocol. cDNA synthesis and RT-PCR were done 
by using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
QRT-PCR was performed using mouse-specific primers (Table1) with iQ SYBR 
Green Supermix on an iCycler Thermal Cycler. The abundance of most 
transcripts was normalized versus the abundance of GAPDH or amylase 
transcripts.  
 
Results 
 
Ngn3 production is reduced in Ngn3+/- and Ngn3F/- pancreata 
In order to investigate whether Ngn3 levels in pancreatic progenitor cells 
are important for them to undergo endocrine differentiation, we reduced Ngn3 
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dosage in the mouse pancreas, with the hope to obtain reduced Ngn3 
production.  
We utilized three Ngn3 alleles, Ngn3+ (wild type allele), Ngn3- and Ngn3F. 
In the Ngn3- allele, the Ngn3 coding region was replaced by a CreERT cDNA. 
This allele does not produce any Ngn3 products and equals to a null allele. In the 
Ngn3F allele, LoxP sites flanked the Ngn3 coding region. A CreERT cDNA lies 
farther 3ʼ (Chapter 3, Figure 3.5 A). Because no DNA element of the Ngn3 locus 
was deleted in the Ngn3F allele, we expected the Ngn3F allele to transcribe floxed 
Ngn3 mRNA in a pattern and level similar to the Ngn3+ allele.  
Ngn3 production in Ngn3+/-, Ngn3F/- and WT (Ngn3+/+) mouse pancreata 
were examined at E14.5, E15.5 and E16.5 by semi-quantitative 
immunofluorescence (IF), western blotting and quantitative real time QT-PCR.  
For IF staining-based assays, pancreata were dissected, processed and imaged 
side by side (Materials and Methods). The average Ngn3 levels, judged by 
fluorescent intensities, in individual Ngn3+ cells were visibly reduced in Ngn3+/- 
and Ngn3F/- pancreata (Figure 4.1 A), as were the number of Ngn3+ cells. 
Noticeably, the Ngn3F/- pancreas had an even lower level of Ngn3 production 
compared with the Ngn3+/- pancreas, suggesting that the Ngn3F allele is a 
hypomorphic allele. This is possibly caused by the insertion of the hair-pinned 
LoxP site in front of the Ngn3 ATG, which may significantly interfere with 
translation initiation. Consistent with this result, western blot and QRT-PCR 
analyses estimated that the total amounts of Ngn3 protein and mRNA in Ngn3+/- 
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and Ngn3F/- pancreata were significantly reduced compared with WT controls at 
E15.5 (Figure 4.1 B&C). We therefore used Ngn3+/- and Ngn3F/- mice to examine 
the effects of reduced Ngn3 levels on endocrine differentiation.  
 
Reduced Ngn3 dosage impairs endocrine islet function  
We first examined whether reduced Ngn3 dosage affects proper endocrine 
islet function. The resting blood glucose levels of the adult Ngn3+/-, Ngn3F/- and 
WT mice did not vary significantly. Yet intraperitoneal glucose tolerance test 
(IPGTT), a more sensitive endocrine functional assay, revealed that both male 
and female Ngn3+/- and Ngn3F/- animals displayed significantly compromised 
glucose-clearance capacities at 4 and 8 weeks of age (Figure 4.2 A).  Despite the 
overt glucose intolerance problem, Ngn3+/- and Ngn3F/- animals did not develop 
frank diabetes (random feeding blood glucose over 300 mg/dl) even at one year 
of age.  
To investigate whether the glucose intolerance in Ngn3+/- and Ngn3F/- 
animals was due to compromised insulin secretion or reduced responses of 
peripheral tissues to insulin, insulin sensitivity and insulin secretion of these 
animals were examined. All three groups of animals (Ngn3+/-, Ngn3F/- and WT 
mice) displayed similar profiles of blood glucose reduction in response to insulin 
administration (Figure 4. 2 B), demonstrating that their insulin sensitivities were 
not altered with reduced Ngn3 dosage. Yet Ngn3+/- and Ngn3F/- animals showed 
reduced serum insulin levels in response to glucose challenge, compared with 
WT control animals (Figure 4.2 C). These data suggest that a high level of Ngn3 
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Figure 4.1 Ngn3 production is reduced in Ngn3+/- and Ngn3F/- 
pancreata. (A) Immunofluorescence detection of Ngn3 at E14.5 and 
E16.5. Shown were Z-stacked images captured at identical confocal 
parameters (methods and materials). Green arrows: Ngn3low cells. White 
arrows: Ngn3high cells. Scale bars: 20µm. (B) Western blot detection of 
Ngn3 protein in E15.5 pancreata. Each sample was loaded into two 
lanes, with different amount of total protein loaded. α-tubulin was used as 
loading controls. Note that Ngn3 protein migrated as two visible bands 
under this condition. (C) Real time RT-PCR detection of Ngn3 mRNA 
levels in E15.5 pancreata. Presented were relative mRNA levels 
normalized against amylase mRNA. “*”: P<0.05. 
 
 117 
 
 
 
 
 
 
Figure 4.2 Reduced Ngn3 dosage impairs endocrine islet 
function.  (A) IPGTT results of one and two-month-old animals (both 
male and female were grouped together). (B) Insulin sensitivity in two-
month-old mice (both male and female mice).  The “Y” axis 
represented the ratio of glucose level at points of assay over that at 
pre-insulin injection. (C) Serum insulin levels before and 30 minutes 
after glucose challenge. Only male mice were utilized here.  “*”: 
P<0.05. +/+: WT; +/-: Ngn3+/-; F/-: Ngn3F/-. 
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is required for proper islet function.  
 
Reduced Ngn3 dosage decreases endocrine islet mass  
We next examined how reduced Ngn3 dosage affects islet function. In the 
adult pancreas, overall islet architecture did not vary in Ngn3+/-, Ngn3F/- and WT 
animals. However, total islet mass, as measured by islet area, was substantially 
reduced at P1 (postnatal day 1) and P28 in Ngn3+/- and Ngn3F/- animals over that 
of the WT controls (Figure 4.3 A-D). This reduced endocrine islet mass may 
contribute to the impaired glucose tolerance in Ngn3+/- and Ngn3F/- animals. 
Furthermore, islets were isolated from 6-week-old Ngn3+/-, Ngn3F/- and WT 
pancreata to examine their insulin secretion capabilities. Ngn3+/- and Ngn3F/- 
islets displayed a trend of increased insulin secretion over that of WT islets in 
response to glucose (Figure 4.3 E). This observation can explain why Ngn3F/- 
animals with reduced islet mass, had similar GTT profiles compared with Ngn3+/- 
animals. The underlying mechanism of this phenomenon is not clear at present. It 
may represent an adaptive behavior of the islets which up-regulate glucose-
induced insulin secretion to compensate for endocrine mass loss, a process that 
occurs prior to phenotypic manifestation of Type 2 Diabetes in human patients. 
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Figure 4.3 Reduced Ngn3 levels decrease pancreatic islet cell 
production. (A-C) Representative images of islets in 4-week-old Ngn3+/-; 
Ngn3f/- and WT pancreata.  Islets (brown) were stained with a 
combination of insulin, glucagon, SS and PP antibodies. Scale bar: 
50µm. (D) Quantification of islet mass at one day (P1) and 4 weeks after 
birth (P28). The islet mass in WT pancreata was artificially set to 100%. 
(E) Insulin secretion in isolated islets of 8-week-old male mice.  The X-
axis represented the % of insulin released from isolated islets within 1 
hour under 20mM glucose stimulation, after pre-incubated in 3.3 mM 
glucose. “*”: P<0.05. +/+: WT; +/-: Ngn3+/-; F/-: Ngn3f/-. 
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Reduced Ngn3 dosage shunts Ngn3+ cells to exocrine fates  
To further elucidate the underlying reasons for decreased endocrine islet 
mass upon Ngn3 dosage reduction, the proliferation and apoptosis rates of 
endocrine cells in Ngn3+/-, Ngn3F/- and WT pancreata were examined at various 
stages. No significant difference was discovered (data not shown). Therefore, it is 
possible that pancreatic progenitor cells with reduced Ngn3 levels cannot enter 
the endocrine lineage, which results in reduced endocrine mass. To test this 
hypothesis, Ngn3TGBAC-Cre transgenic and R26REYFP reporter mice were utilized to 
trace the fates of Ngn3+ cells in both WT and Ngn3+/- backgrounds (Schonhoff et 
al., 2004; Srinivas et al., 2001). The advantage of this approach is that activation 
of the R26REYFP allele can lead to a similar strong level of EYFP expression 
irrespective of cell types. Thus, we could evenly detect all cells that express 
Ngn3 at a level above the threshold for Cre activity.  
The EYFP+ progeny of Ngn3+ cells was monitored at embryonic and 
postnatal stages. At E14.5, most EYFP+ cells in Ngn3TGBAC-Cre;R26REYFP/+ 
pancreata, appeared in clusters of endocrine cells, whereas a substantial number 
of EYFP+ cells was in the exocrine compartment, readily recognized by their 
typical cellular morphology and marker expression in Ngn3+/-;Ngn3TGBAC-
Cre;R26REYFP/+ pancreata (Figure 4.4 A-C). The similar phenomenon was also 
observed at newborn and P10. While about 15% of Ngn3TGBAC-Cre-labeled cells 
became exocrine cells in the WT background, about 45% of Ngn3TGBAC-Cre-
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labeled cells became exocrine cells in the Ngn3+/- background with reduced Ngn3 
production (Figure 4.4 D).  
The fates of Ngn3+ cells in the Ngn3F/- and Ngn3-/- backgrounds were also 
determined. The Ngn3F/-;Ngn3TgBAC-Cre;R26REYFP/+  pancreas contained nearly no 
endocrine cells, due to the deletion of the Ngn3F allele by the Ngn3TgBAC-Cre 
transgene at some time point after sufficient amounts of Cre protein were 
produced. In this case, most of the EYFP+ cells ended up in the exocrine 
pancreas. In the Ngn3-/- background, EYFP+ pancreatic cells are all exocrine 
cells, confirming that Ngn3 is required for endocrine differentiation (Figure 4.4 
C1-C3, D). 
In summary, these data suggest that Ngn3 expression must reach a 
threshold level in order to allocate the cells to endocrine fates. The Ngn3low cells 
may maintain the features of multi-potent progenitors, and can be re-allocated to 
exocrine fates in proper environments.  
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Figure 4.4 Reduced Ngn3 activity shunts more Ngn3+ cells to 
exocrine fates. (A1, B1, and C1)  EYFP expression (white) in E14.5 
Ngn3TgBAC-Cre;R26REYFP/+  pancreata under different genetic 
backgrounds. Whole-mount pictures were showed.  Dotted lines circled 
the pancreatic regions.  (A2-C3) The identities of EYFP+ pancreatic 
cells. A2 and A3, B2 and B3, or C1 and C3 showed images of identical 
pancreata, respectively, with different magnifications. Scale bars: 
50μm.  (D) Percentage of EYFP+ cells that were of islet, acinar or duct 
cells at P0 (n=6). +/+: WT; +/-: Ngn3+/-; F/-: Ngn3F/-. 
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Discussion 
 
Ngn3 is well known for its essential roles in pancreatic endocrine 
differentiation. However, it remains unclear whether Ngn3 levels in individual 
pancreatic cells affect their ability to adopt endocrine fates. Here, we provide 
evidence to show that sufficient Ngn3 levels are necessary for the pancreatic 
progenitors to initiate and fulfill endocrine differentiation. When Ngn3 levels are 
reduced, significant portion of Ngn3+ cells fails to enter the endocrine lineage, but 
becomes exocrine cells.  As a result, animals with reduced Ngn3 dosage contain 
less endocrine islet mass postnatally, and fail to secrete enough insulin and 
maintain glucose homeostasis upon challenge during adulthood. This Ngn3-
level-dependent regulatory mechanism may act to ensure the proper allocation of 
the endocrine and exocrine pancreas. 
 
A threshold level of Ngn3 serves as a checkpoint for entry into endocrine 
lineage. 
When in situ hybridization or various mono- or polyclonal antibodies was 
used to detect Ngn3 expression, Ngn3+ cells were always observed to express 
unequal levels of Ngn3 mRNA/protein as judged by signal intensities. However, it 
is not clear whether these Ngn3low and Ngn3high cells possess similar features 
and eventually adopt same fates. It is possible that Ngn3low and Ngn3high cells 
represent different steps of the Ngn3 protein accumulating process in pancreatic 
cells. In other words, Ngn3low cells may gradually become Ngn3high cells, and 
adopt endocrine fates. Alternatively, Ngn3low cells may not necessarily move 
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towards the Ngn3high state, but instead possess high plasticity to become 
exocrine cells.  
Previous studies suggested that both of these possibilities might exist in 
the pancreas. While Ngn3CreERT line, which can only mark the Ngn3high cells, 
labels mostly endocrine cells in the presence of Cre-reporter, Ngn3TgBAC-Cre based 
lineage tracing showed that a small portion of Ngn3-expressing precursors gives 
rise to exocrine cells under WT situation, when a sensitive Cre reporter R26R 
mouse was used (Schonhoff et al., 2004; Wang et al., 2009). This result 
suggests that a portion of Ngn3low cells marked by the Ngn3TgBAC-Cre line may 
adopt exocrine fates under normal conditions. Here, we directly show that 
Ngn3low cells maintain the progenitor cell plasticity and are able to revert to 
becoming exocrine cells.  The threshold level of Ngn3 seems to serve as the 
checkpoint for initiating endocrine differentiation (Figure 4.5). 
 
Ngn3-level-dependent regulation of Notch mediated lateral inhibition  
Except for initiating the endocrine differentiation program, Ngn3 is also an 
essential component of the Notch-mediated lateral inhibition, which functions to 
select Ngn3+ cells from seemingly equivalent pancreatic progenitors. During 
neurogenesis, Ngn3 positively regulates the level of Notch ligands (for example, 
Dll1) in some cells, to activate Notch signaling in their neighboring cells and 
prevent their neighbors from accumulating Ngn3. If this classic view of lateral 
inhibition fits the context of the pancreas as proposed, we would expect 
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decreased expression of Notch ligands and increased number of Ngn3low cells 
when Ngn3 dosage is reduced. 
In fact, there were more EYFP+ cells in Ngn3+/-;Ngn3TgBAC-Cre;R26REYFP/+ 
pancreata compared with Ngn3TgBAC-Cre;R26REYFP/+ controls at E14.5, when no 
significant difference was observed in proliferation and apoptosis rates between 
these pancreata. Consistent with the classic lateral inhibition, this result suggests 
that more pancreatic cells activate Ngn3 expression, albeit low levels, when 
Ngn3 dosage is reduced. However, reduced Ngn3 dosage did not significantly 
reduce the transcription of major Notch ligands in the pancreas, when EGFP+ 
cells were isolated from E14.5 Ngn3EGFP/+ and Ngn3EGFP/F pancreata by 
Fluorescence-Activated-Cell-Sorting (FACS), and analyzed for their expression of 
Notch ligands (Dll1 and Dll4) by QRT-PCR (Unpublished data, Jingbo Yan and 
Guoqiang Gu). It is possible that Ngn3 utilizes other unknown mechanisms to 
achieve the lateral inhibition. Alternatively, QRT-PCR may not be sensitive 
enough to detect a statistically insignificant variation of expression levels. 
Faithful/sensitive antibodies for Notch ligands may help to solve this problem. 
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Figure 4.5 Certain levels of Ngn3 are important for pancreatic 
cells to enter the endocrine lineage.  X-axis: Ngn3 protein 
levels.  Y-axis: the percentage of Ngn3+ cells with corresponding 
Ngn3 levels. Ngn3+ cells with different Ngn3 levels showed a 
normal distribution (Gaussian Distribution). Dash line: the 
suspected threshold Ngn3 level for endocrine differentiation. The 
cells with an Ngn3 level surpassing this threshold level could 
undergo endocrine differentiation. With reduced Ngn3 dosage in 
Ngn3+/- and Ngn3F/- pancreata, less pancreatic cells could get 
beyond the threshold level, resulting in decreased endocrine 
mass. Blue: WT; Red: Ngn3+/-; Green: Ngn3F/-. 
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Dosage requirement of transcription factors during development 
During development, extrinsic gradients of morphogens (BMP, Wnt, Hh, 
FGF et al.) trigger different developmental events and specify various cell types. 
Intrinsically, many studies suggest that the concentration/level of transcriptional 
factors also affects developmental processes and organ functions. In the 
pancreas, several transcription factors have been shown to function in a dosage 
dependent manner.  
Mice heterozygous for Pdx1 showed severe defects in maintaining their 
glucose homeostasis, which is consistent with the finding that Pdx1 
haploinsufficiency results in maturity-onset diabetes of the young 4 (MODY4) in 
human patients (Macfarlane et al., 2000; Stoffers et al., 1997a; Stoffers et al., 
1998; Stoffers et al., 1997b). More interestingly, Fujitani et al. showed that 
different gene dosage of Pdx1 is required for the formation of endocrine and 
exocrine pancreas, as well as foregut organs, by targeted deletion of a cis-
regulatory region in the Pdx1 promoter (Fujitani et al., 2006). Recently, Oliver-
Krasinski also revealed that mice homozygous for a Pdx1 hypomorphic allele 
displayed a selective reduction in endocrine differentiation. Similarly, reduced 
dosage of Sox9, which marks the multipotent pancreatic progenitors, results in 
decreased endocrine mass (Seymour et al., 2008).  
These studies suggest that the levels of transcription factors within 
individual cells are important for their function. It is possible that higher local 
concentrations of transcription factors in promoter regions can strongly and 
sustainably activate downstream target genes. Moreover, it appears that 
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threshold levels are set up for some transcription factors. When the concentration 
of transcription factors surpasses the threshold level, certain differentiation 
events could be triggered. It currently remains unclear how the threshold level is 
determined. Possibly, many events cooperate intensively to make the decision, 
such as the interaction between transcription factors, chromatins and their 
binding partners, as well as the mobility and duration of transcription factors.  
 
In summary, we provide direct evidence to show that Ngn3 levels are 
important for pancreatic cells to undergo proper endocrine differentiation. This 
mechanism not only helps to ensure the proper balance between different tissue 
types in the pancreas, but also suggests that Ngn3 levels need to be tightly 
controlled for the generation of endocrine cells from various cell sources in vitro 
or in vivo. 
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CHAPTER V 
 
SUSTAINED Ngn3 EXPRESSION IN HORMONE-EXPRESSING ISLET CELLS 
IS REQUIRED FOR ENDOCRINE MATURATION AND FUNCTION 
 
This chapter is published under the same title in PNAS, June 2009 (Wang et al., 
2009). 
 
Abstract 
 
 Ngn3 is both necessary and sufficient to induce endocrine islet cell 
differentiation from embryonic pancreatic progenitors. Since robust Ngn3 
expression has not been detected in hormone-expressing cells, Ngn3 is used as 
an endocrine progenitor marker and regarded as dispensable for the function of 
mature islet cells. Here we used 3 independent lines of Ngn3 knock-in reporter 
mice and mRNA/protein-based assays to examine Ngn3 expression in hormone-
expressing islet cells. Ngn3 mRNA and protein are detected in hormone-
producing cells at both embryonic and adult stages. Significantly, inactivating 
Ngn3 in insulin expressing cells at embryonic stages or in Pdx1 expressing islet 
cells in adults impairs endocrine function, a phenotype that is accompanied by 
reduced expression of several Ngn3 target genes that are essential for islet cell 
differentiation, maturation and function. These findings demonstrate that Ngn3 is 
required not only for initiating endocrine cell differentiation, but also for promoting 
islet cell maturation and maintaining islet function.  
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Introduction 
It is well established that the basic helix–loop–helix transcription factor 
Ngn3 has an essential role in pancreatic endocrine cell differentiation. All such 
endocrine islet cells are derived from Ngn3+ precursors (Gu et al., 2002; 
Schonhoff et al., 2004) and Ngn3 deficiency virtually abolishes islet cell 
differentiation (Gradwohl et al., 2000; Wang et al., 2008b). Moreover, ectopic 
Ngn3 expression converts early endodermal progenitor cells into endocrine islet 
cells (Apelqvist et al., 1999; Grapin-Botton et al., 2001; Johansson et al., 2007; 
Schwitzgebel et al., 2000), and Ngn3 controls the expression of multiple genes 
that influence both endocrine differentiation and function (Gradwohl et al., 2000; 
Petri et al., 2006; White et al., 2008). Because Ngn3 has not been detected in 
differentiated islet cells, its expression in the adult pancreas is proposed as a 
marker for putative endocrine progenitors (Gu et al., 2002; Xu et al., 2008). 
Contradictory findings exist regarding Ngn3 expression in the adult pancreas. 
Several reports have shown Ngn3 expression in WT adult islet cells (Dror et al., 
2007; Gu et al., 2002; Joglekar et al., 2007; Kodama et al., 2005), and this 
expression is enhanced by regenerative conditions (Joglekar et al., 2007; 
Kodama et al., 2005; Xu et al., 2008). Yet these analyses have failed to establish 
whether Ngn3 expression is restricted to only a few putative endocrine progenitor 
cells at a high level, or whether Ngn3 is also present in differentiated islet cells at 
a low level. Nor is it clear how the sustained Ngn3 expression impacts endocrine 
function. Here we have used a combination of knock-in reporter mice, 
immunoassays, and loss-of-gene function studies to show that differentiated 
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hormone-expressing islet cells continue to express Ngn3, and that Ngn3 is 
important for both islet cell production and function. 
 
Materials and Methods 
 
1. Mouse strains and care 
Routine mouse crosses used ICR or CD1 mice (Charles River 
Laboratories). The Ngn3CreERT, TetOLacz, Ins2Cre, and Pdx1CreERT alleles were 
described previously (Gu et al., 2002; Wang et al., 2008b; Yu et al., 2005) 
(Gannon et al., 2000b; Lee et al., 2006). Ngn3EYFP and R26REYFP mice were kind 
gifts from K. Kaestner (University of Pennsylvania School of Medicine, 
Philadelphia) and F. Costantini (Columbia University Medical Center, New York), 
respectively (Lee et al., 2002; Srinivas et al., 2001). All animals used for IPGTT 
assays were maintained on a mixed genetic background, with roughly 50% 
129Sv/Ev + 25% CD1 + 25% CBA/Bl6 composition (estimated from the number 
of intercrosses). Genotyping and TM administration followed published methods 
(Gu et al., 2002; Lee et al., 2006; Wang et al., 2008b; Yu et al., 2005).  
 
2. Immunohistochemistry/Immunofluorescence and Western Blot 
Immunoassays followed established protocols with minor modifications. 
For MafA (1:500 dilution) and Ngn3 antibody (preincubated with Ngn3F/-;Ins2Cre 
adult pancreas, 1:1000 dilution) staining, pancreata were frozen in OCT 
(optimum cutting temperature compound, Sakura Finetek) after dissection. Air-
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dried sections of 10–20 μm thickness were fixed in 4%paraformaldehyde in PBS 
(with 1mMEGTA and 1.5mM MgCl2) for 15–20 min. Sections were permeated in 
0.1% Triton-X100 (in PBS) for 20 min and blocked with antibody solution (0.5% 
BSA + 5% donkey serum + 0.1% Tween-20 in PBS; pH 7.6 –7.8) for 30 min. 
Slides were incubated overnight at 4 °C with primary antibodies. After 4 washes 
with PBS containing 0.1% Tween-20, fluorophore-conjugated secondary 
antibodies were used to visualize signals. Glut2 staining used paraffin sections. 
Guinea pig anti-insulin, goat anti-C-peptide, guinea pig anti-glucagon, guinea pig 
anti-PP, and rabbit anti-SS were obtained from Dako. Rabbit anti-MafA was a gift 
from R. Stein (Vanderbilt University Medical Center, Nashville, TN) (Matsuoka et 
al., 2004) and goat anti-Pdx1 was a gift from C. Wright (Vanderbilt University 
Medical Center, Nashville, TN). Guinea pig anti-Ngn3 was described previously 
(Seymour et al., 2007), rabbit anti-Glut2 was from Alpha Diagnostics, and Rabbit 
anti-EGFP was from Clontech. FITC-conjugated donkey anti-rabbit IgG, Cy3-
conjugated donkey anti-rabbit IgG, Cy3-conjugated donkey anti-mouse IgG, Cy3-
conjugated donkey anti-guinea pig IgG, Cy3-conjugated donkey anti-goat, Cy5-
conjugated donkey anti-rabbit, and Cy5-conjugated donkey anti-guinea pig were 
all from Jackson Immunoresearch. All transcription factor antibodies (except 
Ngn3) were used at a 1:500 dilution. Hormone antibodies were diluted at 1:1,000. 
Secondary antibodies were used at 1:2,000 dilutions. For Western assays, islets 
from 6–8 adult animals of desired genotypes were hand-picked (Wang et al., 
2007) and used for nuclear extract preparation by using NuPer following 
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manufacturerʼs protocol (Pierce). For blot, nuclear extract from ≈50–100 islets 
was loaded into each well (≈5–10μg protein). E16.5 pancreatic nuclear extract 
was prepared as individual samples from each bud. After genotyping, extract 
from 3 buds of identical genotype were pooled and loaded for Western (≈5 μg 
protein per lane). Recombinant Ngn3 protein from whole 293HEK cell lysate was 
used as positive control. Acrylamide gels (18%) were used to resolve the protein 
for blotting.  
 
3. Glucose Tolerance Test, Microscopy, QRT-PCR, and Statistical analysis 
IPGTT followed published procedures (Wang et al., 2007). All fluorescent 
images were obtained by using confocal microscopy. QRT-PCR used the Bio-
Rad I-cycler. For PCR analysis of embryonic tissues, 2 or 3 embryos of the same 
genotype were prepared as a single RNA sample. Four individual RNA samples 
of control and 4 samples of experimental animals were prepared. For adult islets, 
12 controls or 12 experimental pancreata were perfused. Four or five islet pools 
were handpicked from both groups and were used to extract total RNA. For each 
RNA preparation, duplicated reverse transcriptase reactions were used to 
prepare cDNA. Each cDNA was used to assay the abundance of each transcript 
as duplicated PCRs. DNA oligos used are listed in Table 1. Statistical analyses 
used the standard studentʼs 2-tailed t test. A P value of <0.05 was considered 
significant. Data are presented as the mean + SEM.  
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Table 1. Oligos utilized for realtime RT-PCR 
 
 
 
Gene  Sequence 5'-3'  Gene  Sequence 5'-3'  
GAPDH AACTTTGGCATTGTGGAAGG MafA CTCCTCCAAGCGCACGTGGT 
  GGATGCAGGGATGATGTTCT   TTCAGCAAGGAGGAGGTCAT 
amylase TGCAGACACTACTTGTGGCA MafB CAGGGTTTCTGAGCTTCTCC 
  GCAACCATGTTCCTGATTTG   CAGGGTTTCTGAGCTTCTCC 
insulin CAGCAAGCAGGTCATTGTTT NeuroD1 CAGCATCAATGGCAACTTCT 
  GGGACCACAAAGATGCTGTT   GAAGATTGATCCGTGGCTTT 
glucagon ACATCTCGTGCCAGTCACTT Nkx6.1 ACTTGGCAGGACCAGAGAG 
  CGTTGGGTTACACAATGCT   GCGTGCTTCTTTCTCCACTT 
SS CCCAGACTCCGTCAGTTTCT Ngn3 CAGGGTTTCTGAGCTTCTCC 
  ACTTGGCCAGTTCCTGTTTC   GGGAAGGGTAACGACTTGAA 
PP ATGACCCAGGCGACTATGC Myt1 GGGAGCTACAGACCCAATGT 
  TGTATCTGCGGAGCTGAGTT   GAACTTCTCCAGCTCCTTGG 
Glut2 AGCAACTGGGTCTGCAATTT Pax4 AGTGTACCCTCAGCTGCCTT 
  AAGAACACGTAAGGCCCAAG   GGTGTCACTGGAACATCTGC 
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Results 
 
Knock-in reporter mice reveal Ngn3 expression in adult islet cells 
Three independent Ngn3 knock-in mice were used to examine Ngn3 
expression in the adult pancreas (Figure 5.1A-B). The Ngn3tTA line, in which an 
IRES-tTA-PolyA cassette replaced the endogenous Ngn3 coding sequences, 
was generated by our collaborator (Wang et al., 2009). They found that in 
combination with a tTA reporter line TetOLacZ, the pancreata of 9-week-old 
Ngn3tTA;TetOLacZ animals (without Doxycycline) contained large proportions of 
islet cells expressed robust levels of  β-Gal, suggesting Ngn3 expression is 
maintained in adult islet cells (Wang et al., 2009). We obtained the same findings 
by using an Ngn3CreERT allele in which the 5’ 150 base pairs of the Ngn3 coding 
region were replaced by CreERT cDNA (Wang et al., 2008b). CreERT remains 
cytoplasmic and inactive, and unable to recombine LoxP sites in the absence of 
tamoxifen (TM). The conditional R26REYFP (Srinivas et al., 2001) reporter line 
was used to monitor for the presence of CreERT. In R26REYFP/+ mice, enhanced 
yellow fluorescent protein (EYFP) is ubiquitously expressed under Rosa26 
promoter control, but in a strictly Cre-dependent manner. In Ngn3CreERT;R26REYFP 
adult mice, no pancreatic cells expressed EYFP without TM (Johansson et al., 
2007). Seven days after the administration of TM to 7-week-old adult 
Ngn3CreERT;R26REYFP mice, up to 4.5% of the 4 major islet cell types expressed 
EYFP (Figure 5.1 C1-4). 
The above findings led us to examine enhanced green fluorescent protein 
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(EGFP) expression in the pancreata of Ngn3EGFP knock-in mice (Lee et al., 
2002), a line in which EGFP expression was reportedly absent in the adult 
pancreas (Joglekar et al., 2007; Lee et al., 2002). By using confocal microscopy, 
weak yet visible EGFP fluorescence (enriched in nuclei) was seen in a large 
number of islet cells from Ngn3EGFP animals at 2, 4, and 6 months of age. A 
rabbit anti-EGFP antibody further verified the presence of EGFP in a large 
portion of adult islet cells (Figure 5.1 D1-2). Notably, no exocrine cells were 
found to express EGFP (Figure 5.1 D1-2). Not all islet cells exhibited EGFP 
signals. It is not clear whether this lack of EGFP signal in all islet cells is due to 
limited EGFP detection sensitivity or variation in Ngn3 expression between 
different islet cells.  
 
Ngn3 mRNA and protein can be detected in hormone-expressing islet cells.  
The above analyses demonstrate that Ngn3 expression is maintained in 
the adult pancreas, albeit at low levels, and with the caveat that all 3 knock-in 
alleles studied inactivate Ngn3 and thus may exhibit an Ngn3 haploinsufficiency 
phenotype. Additionally, because there could be a time lag between Ngn3 
activation (as represented by CreERT or tTA expression) and the EYFP and β-
Gal production, it is not clear whether Ngn3 expression is restricted to 
differentiated islet cells or putative islet progenitors (which express Ngn3 and 
quickly relocalize to the islets) or both. For this reason, we sought to directly 
examine the expression of Ngn3 in WT adult islet cells by using RT-PCR, protein 
blot, and immunofluorescence (IF) methods in 2-month-old mice. 
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Figure 5.1 Knock-in reporter mice reveal Ngn3 expression in 
adult islet cells. (A&B) Knock-in and reporter alleles. TetOLacZ and 
R26REYFP were reporter alleles of tTA and Cre, respectively. (B) 
Coexpression of endocrine hormones (red) with EYFP in 8-week-old 
R26REYFP;Ngn3CreERT males that received TM at 7 weeks of age. 
Two panels (as a column) for each staining were shown: a merged 
image of EYFP (green), hormone (red), and DAPI (blue) signal, and 
a single channel of EYFP. Arrows indicated EYFP+hormone+ cells. 
(D) EGFP recognized by a rabbit anti-EGFP antibody in the 6-
month-old Ngn3EGFP pancreas. Only EGFP alone and EGFP-DAPI 
merged images were shown. Scale bars: 20µm. 
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Adult islets were isolated and analyzed for Ngn3 transcription. Consistent 
with published findings (Johansson et al., 2007; Kodama et al., 2005), Ngn3 
transcripts were readily detected by RT-PCR in the WT adult islet cells (Figure 
5.2A). When blotted with a guinea pig anti-Ngn3 or a rabbit anti-Ngn3 antibody 
(Gu et al., 2002; Seymour et al., 2007), multiple protein bands were detected in 
islet nuclear extract (Figure 5.2 B). The mobility of the protein closely matched 
that of recombinant Ngn3 produced in HEK293 cells and Ngn3 in E15.5 or E16.5 
WT pancreatic buds (Figure 5.2 C1). Importantly, the putative Ngn3 bands were 
absent in the Ngn3-/-pancreas and substantially reduced in the islets of 
Ngn3F/F;Ins2Cre adults, where Ngn3 should be inactivated in most, if not all, β 
cells (see below). Consequently, preabsorbing the Ngn3 antibodies by using 
Ngn3 produced in HEK293 cells caused a specific block in the detection of the 
Ngn3 signal (Figure 5.2 C2). Interestingly, Ngn3 produced in transfected cells 
resolved into 4 major bands, whereas the putative Ngn3 in isolated islets and in 
embryonic pancreases appeared as 3 species (Figure 5.2 B). Although the 
presence of multiple Ngn3 species suggests the possibility of posttranslational 
modification of Ngn3, neither the basis nor implications of this finding are 
currently known. 
IF-based assays on mildly fixed pancreatic cryosections (see Materials 
and Methods) using a guinea pig anti-Ngn3 antibody showed that a substantial 
number of hormone-expressing cells expressed Ngn3 at E18.5 and in the adult 
pancreas (Figure 5.2 D&F). Notably, 2 types of Ngn3+ cells were found in the 
E18.5 pancreas. A small population of cells (≈2–5% of all endocrine clusters) 
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produced a relatively higher level of Ngn3 based on their brighter IF signals 
(Figure 5.2 D). These cells did not express detectable insulin C-peptide or other 
islet hormones. A majority of cells expressed a low level of Ngn3 and co-
expressed hormones. As expected, the Ngn3-/- pancreas showed no Ngn3 signal 
in any cells, verifying the specificity of the guinea pig anti-Ngn3 antibody (Figure 
5.2 E). Similar to E18.5, large portions of islet cells in adult WT, Ngn3F/F, and 
Ins2Cre pancreata expressed Ngn3 (Figure 5.2 F). In some cells the Ngn3 nuclear 
signal appeared higher than in others, yet we could not find any cells expressing 
Ngn3 at a level as high as that in embryonic endocrine progenitors. We verified 
the Ngn3 signal by inactivating Ngn3 in Ngn3F/F;Ins2Cre animals. This 
arrangement allows β cells to be generated, yet not produce Ngn3. Indeed, the 
number of Ngn3+ islet cells was largely reduced, although some Ngn3+ cells 
remained at the periphery of islets (presumably non-β cells, or β cells escaping 
recombination) (Figure 5.2 G). Because of the light fixation, endocrine hormone 
signals appeared diffuse, and we could not identify the exact islet cell type(s) that 
express Ngn3 by using the guinea pig antibody. We also examined Ngn3 
production in the adult islet cells by using a mouse monoclonal Ngn3 antibody 
(Zahn et al., 2004) and a rabbit anti-Ngn3 antibody (Gu et al., 2002). Both 
antibodies produced high background in lightly fixed postnatal islets, making it 
impossible to discern whether a true Ngn3 signal existed.  
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Figure 5.2 Differentiated islet cells express Ngn3. (A) RT-PCR 
detection of Ngn3 mRNA in 2-month-old WT (+/+) islets and E16.5 
embryonic pancreata. GAPDH expression was used as RT control. (B) 
Western blot detection of Ngn3. Recombinant Ngn3 produced in 
HEK293 cells, WT (+/+), and Ngn3+/− (+/−) E16.5 embryonic pancreata 
were used as positive controls. E16.5 Ngn3−/− (−/−) total pancreata 
and 2-month-old Ngn3F/F;Ins2Cre (F/F; Cre) islets were used to verify 
the specificity of the Ngn3 antibodies. All pancreatic samples except 
the Ngn3F/F lane (F/F, labeled with *) were nuclear extract. Note the 
presence of the nonspecific bands (red arrows), which served as 
internal loading controls of total proteins. The Ngn3 proteins were 
marked with blue arrows. (C1) Western blot of two-month-old islet cells 
with rabbit anti-Ngn3. Nuclear extracts from HEK293 cells transfected 
or nontransfected with Ngn3-producing plasmids and WT E15.5 
pancreatic tissues were used as controls. White arrows pointed to the 
putative Ngn3 protein bands. (C2) Western blot using guinea pig anti-
Ngn3 that was preabsorbed with Ngn3 expressed in HEK293 cells. 
Note the lack of Ngn3 signal in the positive control (HEK293 
expressing Ngn3) and islet cells samples (at the position pointed by 
the arrows). Also note that after prolonged exposure, the lane 
containing the whole E15.5 pancreatic bud lysate produced 
nonspecific signals. The blot used Pdx1 antibody as a loading control. 
(D-G) IF detection of Ngn3 in embryonic (E18.5) and 6-week-old 
pancreata. C-peptide co-staining localized the endocrine compartment. 
Also note that the Ngn3High cells in D2 (arrowheads) did not express 
insulin c-peptide, but some Ngn3low cells did (white arrows). Broken 
lines in E2 showed a duct. Scale bars: 20µm. 
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Ngn3 expression is maintained in all islet cell types  
To understand the potential functional significance of Ngn3 expression in 
hormone+ cells, we determined which islet cell type(s) maintains Ngn3 
expression. We chose EGFP production as a marker for Ngn3 expression. 
Because EGFP has a half-life of ≈26 h in mouse cells (Corish and Tyler-Smith, 
1999), detectable EGFP is unlikely to survive beyond 2 months after birth if 
Ngn3EGFP expression is silenced after birth. EGFP can survive harsh fixation, 
which is required for clear cellular resolution detection of hormones. In 2- and 6-
month-old pancreata, double immuno-IF assays showed that all islet cell types 
maintained Ngn3 expression (Figure 5.3 A), suggesting that Ngn3 may have a 
general role for endocrine cell maintenance, either for survival or function. We 
also examined whether any hormone- (negative) cells expressed Ngn3, which 
may potentially represent adult islet progenitor cells. Only rarely did we find 
EGFP+ cells remain hormone- (≈1% of total EGFP+ cells; Figure 5.3 B). At 
present, we do not know whether these EGFP+hormone- cells are putative 
endocrine progenitors. 
 
Ngn3 plays a functional role in newly born β Cells.  
We next determined whether the expression of Ngn3 in differentiated β 
cells is essential for islet functions. Ngn3 was efficiently inactivated in newly born 
insulin-expressing cells in Ngn3F/F;Ins2Cre animals (Figure 5.2 G) via Cre 
recombination, which we verified to be restricted to insulin-producing β cells 
(Gannon et al., 2000b) (Data not shown). WT, Ins2Cre, and Ngn3F/F animals were 
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Figure 5.3 Ngn3 expression is maintained in all islet cell types. (A) 
Co-expression of EGFP with endocrine hormones in three-month-old 
Ngn3EGFP pancreata. Note that all 4 major islet cell types expressed 
detectable EGFP. White arrows pointed to examples of 
EGFP+hormone+ cells. In the “merge” channel, DAPI signal (blue) was 
included to show the enriched EGFP presence in nuclei. Scale bars: 
20µm. (B) Most EGFP+ cells in Ngn3EGFP adult pancreata expressed 
endocrine hormones. Immunofluorescence (IF) staining in 2-month-old 
Ngn3EGFP pancreata. Red fluorescence was a combination of insulin, 
glucagon, somatostatin and pancreatic polypeptide signals. Note that 
most EGFP+ cells expressed hormone. The white arrow showed an 
EGFP+hormone- cell. Also note the lack of EGFP+ cells outside the 
islet. Scale bar: 20µm. 
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used as controls. The fasting blood glucose levels of these 4 groups of animals 
showed no significant variation at 6 weeks of age (Figure 5.4 A). By 13 weeks 
after birth, male Ngn3F/F;Ins2Cre animals displayed significantly higher fasting 
blood glucose levels than the control groups (Figure 5.4 A), suggesting that loss 
of Ngn3 in β cells compromises islet function. These findings demonstrate that 
Ngn3 expression in insulin-producing β cells affects overall/global glucose 
homeostasis, which was most clearly evident in male animals.  
During our analysis of Ngn3 dosage (Chapter 4) on islet cell 
differentiation, we found that although glucose homeostasis in Ngn3F/F animals 
was normal, Ngn3+/-and Ngn3F/-adult animals displayed significantly impaired 
glucose tolerance. Thus, Ngn3F/- animals provided a sensitized background to 
examine the consequences of Ngn3 deficiency in β cells. Indeed, six-week-old 
Ngn3F/-;Ins2Cre animals, in this case both males and females, displayed 
significantly higher fasting blood glucose levels compared with Ngn3+/-;Ins2Cre 
and Ngn3F/- control animals (Figure 5.3B). These findings further demonstrate 
that Ngn3 expression in β cells contributes to endocrine function. 
We also examined whether Ngn3 deficiency in insulin+ cells affects the 
expression of insulin, Glut2, Myt1, MafA, MafB, NeuroD1, Nkx6.1, Pax4 and 
Pdx1 in E18.5 embryonic pancreata. These genes were chosen because their 
expression depends on Ngn3 and they are known to play important roles in 
endocrine cell differentiation and function. E18.5 embryos were selected to 
examine the primary effect of Ngn3 inactivation before the pancreatic function 
was required for postnatal life, which may feed back to affect gene expression. 
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We first scrutinized possible Ins2Cre toxicity to β cells. E18.5 pancreata of 
Ngn3+/- and Ngn3+/-;Ins2Cre animals were collected for section-based 
immunoassays or quantitative RTPCR (QRT-PCR). IF staining and QRT-PCR 
results showed that the presence of Cre did not significantly affect the 
transcription of the above genes (Figure 5.5 A, B&J), demonstrating the lack of 
overt Cre toxicity on gene expression in β cells at this stage. 
Protein production of the above genes in E18.5 Ngn3F/- and Ngn3F/-
;Ins2Cre pancreata was analyzed. Qualitative evaluation from side-by-side IF 
staining suggested that the levels of insulin, glucagon, Glut2, MafB, Myt1, Nkx6.1 
and Pdx1, on a per-cell basis, were not appreciably affected by loss of Ngn3 in 
insulin-expressing β cells (Figure 5.5 C–H), whereas MafA expression was 
considerably reduced in the Ngn3F/-;Ins2Cre pancreas compared with controls 
(Figure 5.4 C&D). NeuroD1 and Pax4 were not examined because of the lack of 
suitable, well-characterized antibodies. 
QRT-PCR assays showed that Glut2 and MafB mRNA levels were not 
significantly affected by Ngn3 inactivation in β cells. Yet the mRNA levels of 
insulin, MafA, Myt1, NeuroD1, and Pax4, all of which are required for β cell 
differentiation/maturation, in the Ngn3F/-;Ins2Cre pancreas, were significantly 
reduced compared with the Ngn3F/- pancreas (Figure 5.4 E). We could not detect 
Ngn3 mRNA reduction at this stage (Figure 5.4 E), possibly due to the presence 
of a significant number of Ngn3+ progenitor cells whose high Ngn3 expression 
could not be inactivated by Ins2Cre. Because we did not detect significant β cell 
mass variation between Ngn3F/-;Ins2Cre and Ngn3F/- animals (Figure 5.5 I), this 
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reduction in gene expression indicated that the loss of Ngn3 in insulin-producing 
cells delayed the maturation of the β cells (Nishimura et al., 2006). One notable 
finding here is that, although we detected significant reduction in insulin and Myt1 
mRNA levels in the Ngn3F/-;Ins2Cre animals over that of the controls, we did not 
observe any apparent decrease in either insulin or Myt1 protein by using confocal 
microscopy. The underlying reasons for this discrepancy are not known.  
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Figure 5.4 β-cell-specific Ngn3 inactivation impairs endocrine 
function and endocrine gene expression. (A and B) Fasting blood 
glucose levels in males. The genotypes and ages of animals were 
labeled. “P” was calculated between the Ngn3F/F and Ngn3F/F;Ins2Cre 
mice in A and Ngn3F/− and Ngn3F/-;Ins2Cre animals in B. (C and D) 
Insulin, MafA, and Pdx1 expression in E18.5 Ngn3F/- and Ngn3F/-;Ins2Cre 
pancreata. Three single channels and a merged image were presented. 
Note the percentage of islet cells (Pdx1+) expressing MafA (arrows). 
Scale bar: 20µm. (E) QRT-PCR analysis of the expression of several 
genes in Ngn3F/- and Ngn3F/F;Ins2Cre. 
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Figure 5.5 Loss of Ngn3 activity in β cells does not affect the 
expression of most islet-specific genes (all data at E18.5, except in I). 
(A and B) The expression of MafB and Pdx1 was not changed in the 
presence or absence of Ins2Cre. (C–H) The expression of several factors 
(MafB, Pdx1, Glucagon, Nkx6.1, insulin) after Ngn3 inactivation in β cells. 
(I) Islet mass in newly born Ngn3F/- and Ngn3F/-;Ins2Cre mice. (J) QRT-PCR 
results of Ngn3+/- and Ngn3+/- ;Ins2Cre pancreata. Scale bar: 20µm. 
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Sustained Ngn3 expression in young adult islets contributes to endocrine 
maintenance 
  We next examined whether sustained Ngn3 expression in mature islet 
cells contributes to endocrine function/maintenance. We used the TM-inducible 
Cre deleter, Pdx1CreERT (Gu et al., 2002) for this study. One-month-old 
Ngn3F/F;Pdx1CreERT animals were administered with TM. At this stage, Pdx1CreERT 
based recombination was mostly restricted to insulin-expressing β cells (Gu et 
al., 2002). As controls, Ngn3F/F;Pdx1CreERT mice were administered with vehicle, 
and Ngn3F/F animals were administered with TM. Six weeks after TM 
administration, TM-administered male Ngn3F/F;Pdx1CreERT animals showed a 
trend of compromised glucose tolerance capability, although this glucose 
tolerance reduction did not attain statistical significance (Figure  5.6 A). Ten 
weeks after TM administration, TM-administered males, but not females, showed 
a significant decrease in glucose tolerance (Figure 5.6 A). We also tested the 
effect of Ngn3 inactivation in Ngn3F/- animals, in which Ngn3 haploinsufficiency 
renders them more sensitive to a loss of endocrine function. One-month-old 
Ngn3F/-;Pdx1CreERT animals were administered with TM. Four weeks later, TM-
treated male animals displayed a significant (P < 0.01) increase in their fasting 
blood glucose levels compared with control littermates (Figure 5.6 B). The 
differences between the experimental and control groups increased with time, so 
that by 12 weeks after TM injection, hyperglycemia (a blood glucose level higher 
than 250 mg/dL) occurred in most of the TM-treated males but rarely in controls 
(Figure 5.6 B). Fasting blood glucose levels of female Ngn3F/-;Pdx1CreERT animals 
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did not significantly vary with or without TM administration (Figure 5.7 A, data at 
“0” min). However, intraperitoneal glucose tolerance testing (IPGTT) showed that 
2 and 3 months after TM administration, TM-treated Ngn3F/F;Pdx1CreERT females 
displayed significantly decreased glucose tolerance compared with control 
animals (Figure 5.7 A). Consistent with this phenotype, post-glucose-challenge-
serum-insulin levels in TM-treated Ngn3F/-;Pdx1CreERT males were significantly 
reduced 12 weeks after treatment compared with control animals (Figure 5.7 B). 
Next we examined whether sustained Ngn3 expression in the adult β cells 
regulates cell division and cell survival. Ten days after TM administration, both 
mitotic and cell-death indices remained similar in islets of Ngn3F/F and 
Ngn3F/F;Pdx1CreERT animals (Figure 5.7 D-F). These data suggest that Ngn3 in 
mature islet cells regulates β cell function, but not cell division or cell death. 
Finally, we investigated whether Ngn3 regulates the same set of genes in 
adult β cells as in newly born insulin+ cells (see above). Ten days after TM 
administration in 1-month-old Ngn3F/F;Pdx1CreERT animals, a time at which the 
animals still showed normal glucose homeostasis, gene expression in the islets 
was examined by QRT-PCR and IF. As expected, QRT-PCR showed that Ngn3 
mRNA in TM-treated Ngn3F/F;Pdx1CreERT islets was substantially reduced (Figure 
5.8 A). The mRNA level of insulin, Glut2, and MafA, but not of MafB, Myt1, 
NeuroD1, Nkx6.1, Pax4, and Pdx1, was significantly down regulated (Figure 5.8 
A). Accordingly, MafA and Glut2 protein levels in the TM-treated islets were 
significantly reduced (Figure 5.8 B&C). To our surprise, insulin IF staining did not 
appear reduced, despite a >3-fold reduction in insulin mRNA levels (Figure 5.8 B 
 151 
&C). Because we could not detect statistically significant variation in insulin 
secretion in isolated islets of TM-treated and control Ngn3F/F;Pdx1CreERT animals 
10 days after TM administration, we do not know the underlying reason for the 
discrepancy. Notwithstanding, these combined studies suggest that sustained 
Ngn3 expression in adult islet cells is required to maintain a high level expression 
of some endocrine genes, which are necessary for proper endocrine function. 
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Figure 5.6 Ngn3 inactivation in adult islet cells compromises 
endocrine function. (A) IPGTT assays after Ngn3 inactivation in 
Ngn3F/F;Pdx1CreERT female animals. (B) Fasting blood glucose levels in 
male Ngn3F/−;Pdx1CreERT animals 4 and 12 weeks after Ngn3 inactivation. 
Each dot represented one animal. Control animals received corn oil 
vehicle instead of TM.  
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Figure 5.7 Loss of Ngn3 in mature islet cells compromises endocrine 
function, but does not affect cell division or cell death. (A) Female 
Ngn3F/-;Pdx1CreERT animals were administered with TM or corn oil at 1 
month of age. Intraperitoneal glucose tolerance testing (IPGTT) was 
performed 4, 8, and 12 weeks after TM administration (n=8). (B) Serum 
insulin assays were performed 12 weeks after TM administration on 
Ngn3F/-;Pdx1CreERT female animals. Serum was collected before and 30 
min after glucose challenge. *, P<0.05, calculated based on the ratio of 
insulin increase in each individual animal between the 2 groups (+oil and 
+TM). (C) Glucose-induced insulin secretion (GSIS) in isolated islets ten 
days after TM administration in Ngn3F/F;Pdx1CreERT animals male animals. 
Data were presented as % of insulin release in one hour of glucose 
stimulation at 20 mM. (D) Quantification of mitotic index (n=3) of Ngn3F/F 
and Ngn3F/F;Pdx1CreERT animals administered with TM (by BrdU labeling). 
(E1-2) BrdU labeling in Ngn3F/F (E1) or Ngn3F/F;Pdx1CreERT (E2) animals 
administered with TM. Green arrows pointed to BrdU+ cells. (F1-2) Assay 
for apoptotic cell death. F1 and F2 used the same pancreatic tissues as in 
E1 and E2, respectively. Inset in F1 showed a dying cell (green arrow), 
positive for DNA fragmentation (stained brown). Scale bar: 10µm. 
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Figure 5.8 Ngn3 inactivation in mature islet cells compromises 
insulin, Glut2 and MafA expression. Gene expression 10 days after 
TM administration in Ngn3F/F;Pdx1CreERT males was shown. (A) QRT-
PCR analysis of gene expression in handpicked islets. (B and C) IF 
staining of Glut2 and MafA. For each tissue section, a single channel 
(white) was presented to highlight the relative intensity of Glut2 (B) or 
MafA (C) signals, respectively. A merged image was also presented to 
show the position of the stained islets (recognized by insulin signals). 
Scale bar: 20µm. 
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Discussion 
 
During endocrine islet-cell differentiation, robust Ngn3 expression was 
only detected transiently in hormone- endocrine progenitor cells (Xu et al., 2008). 
Thus, Ngn3 expression has been proposed as an exclusive marker for islet 
progenitors in both embryonic and adult pancreata (Gu et al., 2002; Jensen et al., 
2000a; Schwitzgebel et al., 2000). Although Ngn3 mRNA expression in adult 
pancreata has been documented consistently (Dror et al., 2007; Gu et al., 2002; 
Joglekar et al., 2007; Kodama et al., 2005), the presence of Ngn3 protein in adult  
pancreata was only recently reported in a pancreatic duct ligation regeneration 
model (Xu et al., 2008). These data have led to the hypothesis that 
posttranscriptional regulation plays a role in controlling Ngn3 activity (Joglekar et 
al., 2007; Villasenor et al., 2008), and only under specific conditions could Ngn3 
be produced to facilitate neogenesis in the adult pancreas (Xu et al., 2008). 
Here we present several independent lines of evidence to show that Ngn3 
is both transcribed and translated in a large portion of hormone-expressing islet 
cells at both embryonic and adult stages under normal physiological conditions. 
We show that Ngn3 inactivation in β cells of newly born or adult mice results in 
down-regulation of the expression of several genes required for endocrine 
differentiation and function. The genes whose expression was most severely 
affected by Ngn3 inactivation were insulin and MafA, 2 genes that are associated 
with β cell maturation. In contrast, the expression of NeuroD1 and Nkx6.1 was 
reduced only by smaller degrees, which suggests that, unlike in embryonic 
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progenitors where the expression of Nkx6.1 and NeuroD1 depends on Ngn3 
activity (Gradwohl et al., 2000), expression of these factors is less dependent on 
Ngn3 in β cells.  
It is presently unclear how Ngn3 contributes to endocrine function after 
endocrine differentiation. Although our data clearly demonstrate the presence of 
Ngn3 transcript and protein in the adult mouse pancreas, the level of the protein 
is much lower than in endocrine progenitor cells at embryonic stages. It is likely 
that a transient, high Ngn3 expression modifies the chromatin structure to allow 
cells to gain autonomy along the endocrine differentiation pathway (Apelqvist et 
al., 1999; Jensen et al., 2000b). A sustained low level of Ngn3, after full 
endocrine differentiation, allows cells to maintain their chromatin structure that 
favors the expression of genes required for islet cell function. By far, the 
expression of many endocrine-specific genes has been shown to depend on 
Ngn3 (Petri et al., 2006; White et al., 2008). However, the absence of a highly 
specific and high-affinity Ngn3 antibody has prevented the comprehensive study 
of how Ngn3 interacts with it transcriptional target DNA sequences to regulate 
gene activity. To fully understand how Ngn3 regulates gene expression and islet 
cell function will likely require a comprehensive microarray-based expression 
analysis of sorted β cells, generation of high quality Ngn3 antibodies, and 
subsequent Ngn3-DNA promoter binding assays. 
Overall, our findings reveal a previously unsuspected role for Ngn3 in islet 
cell maturation and functional maintenance after initial endocrine differentiation. 
These results highlight the inherent deficiency when Ngn3 expression is used as 
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an endocrine progenitor marker without examining whether the specific Ngn3+ 
cells are mature endocrine islet cells (Gu et al., 2002; Xu et al., 2008). However, 
the detection of Ngn3 expression in mature islet cells does not prevent the 
utilization of Ngn3 expression as a marker for neogenesis in the adult pancreas, 
due to low Ngn3 levels in the hormone-expressing cells. By separating Ngn3high 
and Ngn3low cells in the adult pancreas, it is possible to distinguish putative 
endocrine progenitor cells from differentiated islet cells (Xu et al., 2008). Finally, 
our findings raise the possibility that Ngn3 over expression in mature islet cells 
could be used to boost endocrine islet function in diabetic conditions.  
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Since the endocrine islet malfunction is highly associated with diabetes in 
humans, the differentiation/function of pancreatic islet cells has been an intense 
focus of study over the past half of century (Murtaugh and Melton, 2003; Oliver-
Krasinski and Stoffers, 2008; Slack, 1995). The goal of these studies is to 
facilitate the production of functional mature endocrine cells in vitro or in vivo for 
transplantation or regeneration-based diabetes therapies respectively. Aided by 
ever improving technologies, these studies have revealed much about the 
endocrine islet differentiation, and made islet cell production in vitro or in vivo a 
possibility (Baetge, 2008; Bonner-Weir and Weir, 2005; Kroon et al., 2008; 
Murtaugh, 2007; Oliver-Krasinski and Stoffers, 2008; Yechoor et al., 2009; Zhou 
et al., 2008). 
All pancreatic cells are derived from endodermal cells that are located in 
the gut epithelium. To differentiate into mature endocrine islet cells, these 
endodermal cells have to make multiple decisions. They need to go through 
stages of pancreatic progenitors, endocrine progenitors, hormone-expressing 
endocrine cells, and finally become functional mature endocrine cells, such as β 
cells that can secrete insulin in respond to stimuli (Oliver-Krasinski and Stoffers, 
2008). A transcriptional network controls different phases of this multi-step 
process. For instance, Pdx1, Ptf1a and Sox9 are required for the establishment 
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of multipotent pancreatic progenitors (Burlison et al., 2008; Gu et al., 2002; 
Kawaguchi et al., 2002; Offield et al., 1996; Seymour et al., 2007). Ngn3 is 
essential for endocrine differentiation (Gradwohl et al., 2000; Gu et al., 2002; 
Schwitzgebel et al., 2000). Pax4, Nkx2.2, Arx1 et al. are important for the 
specification/differentiation of different endocrine islet cell types (Naya et al., 
1997; Oliver-Krasinski and Stoffers, 2008; Sosa-Pineda, 2004; Sussel et al., 
1998). MafA, Nkx6.1, Glut2 and Pdx1 are necessary for the maturation and 
maintenance of insulin-expressing β cells (Ahlgren et al., 1998; Gannon et al., 
2008; Guillam et al., 1997; Henseleit et al., 2005; Jensen et al., 2000a; Matsuoka 
et al., 2004; Nishimura et al., 2006; Zhang et al., 2005).  
We are particularly interested in understanding how the identity of 
endocrine progenitors is established and regulated during pancreatic 
development, specifically, the endocrine progenitors expressing Ngn3. Our 
comprehensive studies showed that the interactions between Myt1 and Ngn3 
promote the endocrine differentiation. Specifically, Myt1 and Ngn3 can enhance 
each other’s expression and form a feed-forward expression loop to promote 
endocrine differentiation from endodermal progenitor cells in mice (Chapter 3 of 
this thesis work). Centering on this conclusion, we also investigated whether 
Myt1 is required for endocrine differentiation and islet function by loss-of-function 
analyses. In Myt1-/- mutant pancreata, significant numbers of endocrine cells co-
express multiple hormones during embryogenesis. Myt1fl/-;Pdx1-Cre animals that 
have lost Myt1 conditionally in the pancreas, although viable, develop glucose 
intolerance from 6 weeks of age. Thus, Myt1 is important for proper endocrine 
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differentiation and islet function in mice. Interestingly, Myt1 paralogs, Myt1L and 
Myt3, which are not expressed in the WT developing pancreas, are induced in 
the absence of Myt1, suggesting that these two genes may compensate for the 
loss of Myt1 function (Chapter 2 of this thesis work). Furthermore, we examined 
the importance of maintaining proper Ngn3 levels within endocrine progenitor 
cells, and found that reduced Ngn3 dosage shunts more Ngn3+ cells to adopt 
exocrine fates, which in turn results in reduced endocrine mass by birth and 
impaired islet function in adults (Chapter 4 of this thesis work). Additionally, we 
revealed a very interesting but previously unsuspected role of Ngn3 in islet cell 
maturation and functional maintenance (Chapter 5 of this thesis work). Taken 
together, these studies not only have answered some basic biological questions, 
but also provide important information to improve the generation of mature 
endocrine cells in vitro, for example, β cells, which may greatly favor diabetes 
therapies.  
 
Future directions 
 
 The work outlined in this thesis aimed to understand how endocrine 
progenitors are established and regulated in the mouse pancreas, with the 
anticipation to benefit diabetes therapies in the future. Specifically, two 
transcription factors, Ngn3 and Myt1, were investigated by various approaches. 
However, we are just beginning to understand how Myt1 and Ngn3 function and 
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how they are regulated in the pancreas. Several important questions remain to 
be answered (Figure 6.4). 
 
Is the Myt gene family required for endocrine differentiation and function? 
Our studies suggest that Myt1 is important for endocrine differentiation 
and islet function in the pancreas. However, this study is hampered by the 
unusual compensation between the Myt family members, that is the two paralogs 
of Myt1, Myt1L and Myt3. They are not normally expressed in the developing 
mouse pancreas, but induced when Myt1 is inactivated. Therefore, potential 
functions of Myt1 could be compensated by Myt1L and Myt3 in the mouse 
pancreas.   
We have now generated both Myt1L and Myt3 conditional alleles (Figure 
6.1).  Subsequent crosses of these alleles with Sox2-Cre animals led to the 
production of Myt1L- and Myt3- alleles. As expected, immunofluorescence-based 
assays showed that both Myt1L- and Myt3- cells produced no functional proteins 
(Figure 6.2). These alleles will allow us to examine the consequences of 
inactivating all three Myt factors during pancreatic development and adulthood.   
Our preliminary studies from several triple null mutants (Myt1-/-;Myt1-/-
;Myt3-/-) showed that although inactivation of Myt factors did not affect the 
number of endocrine islet cells produced in the developing pancreas, it 
compromised the expression of endocrine hormones and other well-established 
endocrine transcription factors (Figure 6.3). These results suggest that Myt 
factors may regulate endocrine cell maturation and function in the pancreas.  
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Figure 6.1 Myt1L and Myt3 gene-targeting strategies. (A1) Derivation 
of Myt1LF and Myt1L- alleles. Targeted Flox allele had two LoxP sites 
flanking exon 12 and 13 of Myt1L. In this case, the intron 12 was deleted 
in order to shorten the distance between the LoxP sites, which facilitated 
ready recombination. P5’: DNA southern blot probe. Pr1, Pr2 and Pr3: 
oligos for genotyping. (A2) Southern blots of the targeted ES cell clone. 
Bgl II digestion and blotting with P5’ probe produced a wild-type band of 
14kb and a targeted band of 12kb. (A3) PCR-based genotyping using 
DNA oligos pr1, pr2 and pr3. (B1) Derivation of Myt3F and Myt3- alleles. 
Targeted Fl allele had two LoxP sites flanking exon 11 and 12 of Myt3. P5’ 
and P3’: DNA southern blot probes. P1, P2 and P3: oligos for genotyping. 
(B2) Southern blots of 3 targeted ES cell clones. XbaI digestion and 
blotting with P5’ probe produced a WT band of 6.8kb and a targeted band 
of 4.1kb. ApaLI digestion and blotting with P3’ probe resulted in a WT 
band of 11.2kb and a targeted band of 9.6kb. (B3) PCR-based genotyping 
using DNA oligos p1, p2 and p3. 
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Myt 
 
 
 
Figure 6.2 No Myt1, Myt1L and Myt3 protein was produced in 
Myttriple-/- embryos. WT and Myttriple-/- neural retina and brain 
tissues were stained with Myt1 (A), Myt1L (B) and Myt3 (C) 
antibodies. Blue: DAPI for nuclei. White arrows: Myt1+, Myt1L+ or 
Myt3+ cells. Scale bar: 20µm. 
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Figure 6.3 Loss of Myt gene family members attenuates hormone 
production in the mouse pancreas. (A) E17.5 WT and Myttriple-/- 
pancreata were stained with antibodies against for major endocrine 
hormones. Scale bar: 20µm. (B) Quantification of the number of each 
endocrine cell type at E17.5 (materials and methods in Chapter 3). The 
percentage of stained area for each endocrine cell type over total 
endocrine areas was calculated (n=2). (C) The mRNA levels of various 
genes in E17.5 control and Myttriple-/- pancreata (n=3, material and 
methods in Chapter 5). Controls: Myt1+/-;Myt1L+/-;Myt3+/- , 
Myt1+/+;Myt1L+/+;Myt3+/-  and Myt1+/-;Myt1L+/-;Myt3-/- (n=3). “*”: Significant 
difference, P<0.01 by student t-test. Ins: insulin; Glu: glucagon; SS: 
somatostatin; PP: pancreatic polypeptide.  
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Future studies are needed to examine how losing Myt activity affects islet cell 
gene expression and endocrine function in a systematic fashion. 
 
How do Myt factors regulate endocrine differentiation/function in the 
pancreas? 
It is possible that Myt factors can directly bind to the promoters of 
hormone genes and activate their transcription. Alternatively, Myt factors may 
regulate hormone expression via regulating other transcription factors. The 
expression levels of some candidate genes, such as Pdx1, IA-1 and NeuroD, 
could be examined in Myttriple-/- (Myt1-/-;Myt1L-/-;Myt3-/-) pancreata to further 
explore this hypothesis.  
It is also worth investigating whether the observed endocrine cells with 
reduced hormone production during embryogenesis can persist into adulthood, 
and contribute to adult islet function. Due to the immediate death of Myttriple-/- 
embryos after birth, pancreatic specific or β cell-specific Myt null animals are 
needed to address this question. If Myt factors could regulate hormone 
expression, we would expect the conditional null animals to develop diabetic 
phenotypes, such as impaired glucose tolerance, attenuated insulin secretion 
and GSIS (glucose stimulated insulin secretion), in their juvenile or adult lives. 
Additionally, Myt1 can modulate the proliferation of oligodendrocyte lineage cells 
(Nielsen et al., 2004). It is possible that endocrine cells fail to proliferate 
efficiently in the absence of Myt genes in the first two weeks after birth, when 
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endocrine cells normally undergo extensive proliferation, or under conditions with 
increased insulin demands, i.e. during pregnancy or in obesity. 
Furthermore, Myt genes may function differently in newly differentiated 
endocrine cells and adult mature islet cells. It is also intriguing to understand the 
role of Myt genes specifically in adult islets by deleting Myt genes in adult mice 
using CreERT-mediated recombination.  
 
How do Myt factors function in the pancreas at the molecular level? 
In order to understand how Myt factors function in the pancreas at the 
molecular level, it is important to explore the genes that act downstream of Myt 
and the factors that can cooperate with Myt to regulate gene transcription. 
The downstream targets of Myt factors are largely unknown. Considering 
the compensatory regulation between Myt genes, it is possible that Myt1 
negatively regulates the expression of Myt1L and Myt3 under normal conditions, 
either directly or indirectly. Therefore, when Myt1 is inactivated, the expression 
Myt1L and Myt3 is induced. 
At present, Sin3B, which is a well-studied chromatin modifier that can 
regulate gene transcription by recruiting HDACs, is the only reported direct 
binding partner of Myt1 or Myt1L (Romm et al., 2005). It has been shown that 
Myt1-Sin3B (or Myt1L-Sin3B) complexes immunoprecipitated from transfected 
mammalian cells included HDAC1 and HDAC2. Moreover, Myt1 or Myt1L could 
bind with both the Sin3B long isoform (Sin3BLF), which contains the HDAC-
binding domain, and the Sin3B short isoform (Sin3BSF) without the HDAC-binding 
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domain (Romm et al., 2005). Thus, Myt1 or Myt1L may mediate transcription 
repression or activation by forming complexes with different Sin3B isoforms, 
which could either recruit or preclude HDAC binding. In fact, Myt1 appears to 
function as a transcriptional activator during pancreatic endocrine differentiation 
in chickens (Wang et al., 2008b). It is highly possible that Sin3BSF is the 
predominant isoform expressed in the chicken/mouse pancreas, and can 
cooperate with Myt1/Myt1L to activate downstream target genes.  
 
How does Myt1-Ngn3 gene cascade function in the endocrine progenitors? 
Myt1 and Ngn3 form a feed-forward expression loop to promote endocrine 
differentiation during pancreatogenesis (Chapter 3). However, the underlying 
mechanisms are still unclear (Figure 6.4).  
Ngn3 appears to be capable of activating Myt1 transcription directly, in 
that Ngn3 significantly enhances Myt1 promoter activity in cultured cell lines in 
vitro (Wang et al., 2008b). Yet, Myt1 doesn’t appear to be sufficient to directly 
activate Ngn3 expression. The number of Ngn3+ cells only moderately increased 
when Myt1 is ectopically expressed. It is possible that Myt1 indirectly enhances 
Ngn3 expression in endocrine progenitor cells through enhancing the expression 
of Hnf6, Foxa2 and other unknown factors, which can positively regulate Ngn3 
expression. 
In addition of enhancing each other’s expression levels, Myt1 and Ngn3 
may also cooperate to promote endocrine differentiation. In the chicken gut 
epithelium, the endocrine differentiation induced by ectopic Ngn3 expression 
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under an exogenous promoter can be repressed by constitutively activated Notch 
signaling, suggesting that Ngn3 is not the only Notch target required for 
endocrine differentiation. Additional factors, whose expression is inhibited by 
activated Notch, are also necessary for the cells to escape Notch repression. 
Myt1 may be one of these factors, in that ectopic expression of Myt1 (xMyt1 in 
Xenopus) together with Ngn3 (xNgnr1 in Xenopus), but not individually, can 
overcome the repressive effects of activated Notch signaling on differentiation in 
both Xenopus and chicken studies (Ahnfelt-Ronne et al., 2007; Bellefroid et al., 
1996). Myt1 and Ngn3 may also work together to antagonize the activated Notch 
signaling in the developing mouse pancreas. A rescue experiment, in which Myt1 
and Ngn3 are ectopically expressed in pancreatic cells with constitutively 
activated Notch signaling, may help to test this hypothesis. 
 
Does Myt1-Ngn3 gene cascade function in a similar fashion in 
differentiated islet cells? 
 In the pancreas, Myt1 is highly expressed in most of the differentiated 
endocrine islet cells (Chapter 2). We revealed that Ngn3 is maintained in most of 
the differentiated islet cells as well, albeit in a low level, compared with 
embryonic Ngn3+ endocrine progenitors (Chapter 5). It is possible that Myt1 and 
Ngn3 also interact with each other in differentiated islet cells (Figure 6.4). 
When Ngn3 is inactivated specifically in the insulin-expressing β cells, the 
expression of Myt1 is significantly reduced, suggesting that Ngn3 is important for 
the maintenance of Myt1 expression in β cells (Chapter 5). However, it is 
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unknown whether Ngn3 is sufficient to promote Myt1 expression, and further 
enhance islet function in islet cells. We had tried to ectopically express Ngn3 in 
adult β cells (Ngn3teto8;Pdx1tTA/+, add Dox from E7-P28). Only a small percentage 
of β cells can achieve high levels of Ngn3. It is possible that Ngn3 levels are kept 
low in differentiated β cells by some unknown mechanisms. It would be important 
to understand whether increasing the level of Ngn3 in differentiated islet cells can 
enhance islet function, and whether it is through the enhancement of Myt1 
expression. 
On the other hand, it remains to be clarified whether Myt factors are 
required for maintaining Ngn3 levels in differentiated islet cells. Examination of 
pancreatic specific or β cell specific Myt triple null mutants may help to address 
this question. 
Furthermore, enlightened by the embryonic endocrine differentiation, in 
which activated Notch signaling negatively regulates Ngn3 expression, we 
suspect that the Notch signaling pathway may also play important roles in 
differentiated islet cells. Fujikura et al. revealed that loss of Rbp-j (the key 
mediator of the Notch signaling pathway) specifically in β cells did not affect β 
cell number and function, suggesting that the Notch/Rbp-j signaling may not be 
required for maintaining β cell function or mass (Fujikura et al., 2006). Moreover, 
Murtaugh et al. showed that the constitutive activation of Notch signaling 
pathway in adult β cells did not perturb mature β cell function two weeks after the 
Notch activation (Murtaugh et al., 2003). Contrary to these studies, Notch 
receptors, ligands and targets are expressed in the adult mouse and human 
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islets, and function to suppress apoptosis in cultured mouse/human islets (Dror 
et al., 2007). Ectopic expression of the Notch signaling pathway in insulin-
expressing β cells for a longer period, probably from embryonic stages to 
adulthood, may help to address this question, and further understand 
whether/how the Notch signaling pathway interacts with the Myt1-Ngn3 gene 
cascade. 
 
How does Ngn3 control the endocrine differentiation program? 
Ngn3 controls the expression of a network of factors that are essential for 
endocrine differentiation. According to their response to Ngn3 activation, the 
factors downstream of Ngn3 can be divided into two major groups. The factors in 
the first group are mostly direct targets of Ngn3, and respond to Ngn3 activation 
quickly, such as Nkx2.2, Pax4, NeuroD and IA-1. The factors in the second group 
respond to Ngn3 activation slowly, such as insulin, MafA and Glut2. They help to 
determine the mature states of endocrine cells, and are mostly under the control 
of the factors in the first group. Many lines of evidence suggest that there are 
complicated interactions and crosstalks between these factors downstream of 
Ngn3. However, general views of this network, as well as many key points, 
remain to be explored.  
It is largely unknown how different endocrine islet cell types are specified 
in the pancreas. Previous studies showed that the specification of islet cell types 
is not dependent on Ngn3 (Johansson et al., 2007). It appears that the 
competence of pancreatic progenitors to generate different islet cell types 
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changes over time cell-autonomously, but what factors control this competence 
changing process are still not clear. We observed that the percentage of 
Myt1+Ngn3+ double positive cells over Myt1+ and/or Ngn3+ cells changes in 
consistent with the percentage of insulin+ cells over total endocrine cells at 
various stages during pancreatic development (Yuhan Hao and Guoqiang Gu, 
unpublished data). It is possible that these Myt1+Ngn3+ double positive cells are 
destined to become insulin expressing β cells. Moreover, Myt1 may be 
competent to drive Ngn3+ endocrine progenitors towards the β cell fate. Ectopic 
expression of Myt1 in Ngn3+ cells may help to address this question.  
Furthermore, Ngn3 alone or in combination with other transcription factors, 
is capable of reprogramming differentiated/determined cells into insulin-
expressing endocrine cells (Yechoor et al., 2009; Zhou et al., 2008). Pancreatic β 
cell neogenesis after PDL is dependent on Ngn3 (Xu et al., 2008). However, it 
remains unknown whether Ngn3 controls the endocrine neogenesis in the adult 
pancreas in a similar manner as during embryogenesis. It is possible that 
Ngn3high cells induced in the adult pancreas by virus mediated over-expression or 
injuries have similar properties and follow the same multi-step differentiation 
process as embryonic endocrine progenitors, as suggested by Xu et al. (Xu et 
al., 2008). Alternatively, induced Ngn3high cells in the adult pancreas may 
possess different properties and go through different differentiation process. To 
distinguish between these two hypotheses, it is important to identify the origin of 
the induced Ngn3high cells, compare their differentiation potentials with embryonic 
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endocrine progenitors, and examine the downstream transcriptional networks 
activated in these Ngn3high cells.  
 
 
Concluding Remarks 
 
 This work demonstrated that two transcription factors, Myt1 and Ngn3, 
form a feed-forward expression loop to promote endocrine differentiation in the 
pancreas (Figure 6.4). Centering on this conclusion, we further revealed that 
Myt1 is important for the proper endocrine differentiation and islet function in the 
pancreas by loss-of-function analyses. Moreover, we provided direct evidence to 
show that proper levels of Ngn3 within endocrine progenitor cells are essential 
for endocrine differentiation. Reduced Ngn3 levels significantly impair endocrine 
differentiation and endocrine/exocrine allocation. Additionally, we revealed that 
sustained Ngn3 expression in hormone-expressing islet cells is required for 
endocrine maturation and function. These studies not only provide important 
information regarding the regulation of endocrine differentiation/function, but also 
open up new directions to improve islet function under diabetic conditions.  
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Figure 6.4 Myt1 and Ngn3 form a feed forward expression loop to 
drive endocrine differentiation in the mouse pancreas 
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